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Abstract 
Jui-Hua Hsieh: Cheminformatics Approaches to Structure Based Virtual Screening: 
Methodology Development and Applications 
(Under the direction of Dr. Alexander Tropsha) 
 
Structure-based virtual screening (VS) using 3D structures of protein targets has 
become a popular in silico drug discovery approach. The success of VS relies on the quality 
of underlying scoring functions. Despite of the success of structure-based VS in several 
reported cases, target-dependent VS performance and poor binding affinity predictions are 
well-known drawbacks in structure-based scoring functions. The goal of my dissertation is to 
use cheminformatics approaches to address above problems of the existing structure-based 
scoring methods.  
In Aim 1, cheminformatics practices are applied to those problems which 
conventional structure-based scoring functions find difficult (anti-bacterial leads efflux study) 
or fail to address (AmpC β-lactamase study). Predictive binary classification QSAR models 
can be constructed to classify complex efflux properties (low vs. high) and to differentiate 
AmpC β-lactamase binders from binding decoys (i.e., the false positives generated by scoring 
functions). The above models are applied to virtual screening and many computational hits 
are experimentally confirmed.  
In Aim 2, novel statistical binding and pose scoring functions (or pose filter in Aim 3) 
are developed, to accurately predict protein-ligand binding affinity and to discriminate 
native-like poses of ligands from pose decoys respectively. In my approach, the protein-
ligand interface is represented at the atomic level resolution and transformed via a special
iii 
 
computational geometry approach called Delaunay tessellation to a collection of atom 
quadruplet motifs. And individual atom members of the motifs are characterized by 
conceptual Density Functional Theory (DFT)-based atomic properties. The binding scoring 
function shows acceptable prediction accuracy towards Community Structure-Activity 
Resources (CSAR) data sets with diverse protein families. 
In Aim 3, a two-step scoring protocol for target-specific virtual screening is 
developed and validated using the challenging Directory of Useful Decoys (DUD) data sets. 
In the first step our target-specific pose (-scoring) filter developed in Aim 2 is used to filter 
out/penalize putative pose decoys for every compound. Then in the second step the 
remaining putative native-like poses are scored with MedusaScore, which is a conventional 
force-field-based scoring function. This novel screening protocol can consistently improve 
MedusaScore VS performance, suggesting it possible applications to practical 
pharmaceutically relevant targets. 
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Chapter 1 Introduction: 
Drug discovery is an expensive and time-consuming process, starting from target 
protein establishment to FDA approval. According to the statistics in pharmaceutical industry 
during the 1990s, it took an average of 14 years and cost around $800 million to bring a new 
drug into the market.1 In addition to inevitably lengthy and expensive clinical phases where 
roughly nine in ten compounds is forced to discontinue,2 the attrition rate in discovery stage 
is also similarly high. This demands more efficient methods to identify new chemical entities 
(NCE) to maintain a profitable pharmaceutical company. Mostly, the high-throughput 
screening (HTS) approach is applied to identify initial chemical hits from a large compound 
collection in the early stage of drug discovery process.3 However, HTS approach is also a 
costly campaign, involving automated robotic screening systems, large quantities of 
resources and time-consuming assay set-ups, which only large pharmaceutical companies or 
few highly specialized labs can afford4. Thus, to complement the experimental HTS approach 
in the hope of speeding up the discovery rate in hit-identification phase, computational 
methods, for example, virtual screening (i.e., searching libraries in silico and selecting only a 
limited number of molecules for testing), are suggested and applied in order to identify hits 
with higher reliability yet less effort.5-7  Moreover, computational methods can also be 
applied in the lead-optimization phase,8 where dozens of compounds need to be 
synthesized/tested to achieve desired ADME-Tox properties and sufficient binding affinity 
for the target protein. Modeling based on a set of tested compounds can help predict the 
potency of unknown compounds in order to prioritize the synthesis. To date, numerous 
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computational methods have been extensively applied in the drug discovery process with 
varying degree of success. This chapter will provide an overview of these technologies and 
some well-known limitations as well as the outline of this dissertation. 
1.1 Cheminformatics in Drug Discovery 
The term cheminformatics is firstly introduced in literature by Brown.9 Despite 
various extensions,10 broadly speaking, cheminformatics can be defined as: the application of 
informatics methods to solve chemical problems. Traditionally, the subjects in 
cheminformatics are mainly associated with small molecules despite the fact that 
macromolecules such as proteins and DNAs are also considered as chemicals. The research 
in understanding the relationship between macromolecules and ligands (mostly small 
molecules) is usually discussed intensively in the realm of structure-based drug design 
(Chapter 1.2).  
 The scientific roots of cheminformatics in drug discovery11, 12 can be traced back to 
the pioneering work conducted by Hansch and Fujita who quantitatively explain the property 
of a series of structurally related small molecules based on their steric, electrostatic, and 
hydrophobic effects.13 This is the so-called quantitative structural-activity analysis (QSAR) 
or quantitative structural-property analysis (QSPR). The basic approach to the issue of 
predicting properties can be simplified to this equation: P = f(C), where the molecular 
property P is expressed as the mathematical function of molecular structure C.  The implicit 
assumption of this equation is that compounds with similar structures should have similar 
property profiles. To date, the general QSAR modeling procedure can be summarized as 
follows: data preparation, data analysis, and model validation.14 The resulting models can be 
used to explain the relationship between the molecular property and the chemical features in 
  
3 
 
molecules, helping to design new molecules, or identify molecules with desired property 
through searching chemical databases (i.e., database mining).  
Starting from the data preparation, a high-quality data set with reliable property 
measurements is the prerequisite to constructing predictive models. After the curation of data 
set,15 which means the information of small molecules are extracted and converted to 
electronic formats, small molecules can be further represented by a set of parameters called 
molecular descriptors. Descriptors can be generally divided into 1D, 2D, or 3D descriptors, 
depending on the dimensionality of molecular representation where they are calculated. For 
example, the molecular mass descriptor or count-of-hydrogen-donor descriptor is considered 
as 1D descriptor; the topological indices descriptors which are widely applied in 2D-QSAR 
modeling take account of atom connectivity derived from the 2D chemical graphs; the 
molecular surface descriptors are 3D descriptors, whose values are dependent on the 
experimental/predicted active 3D conformation. Moreover, if the geometry of target protein 
(receptor) is available, the enthalpy contributions, which are calculated based on the 
interactions between protein and small molecules, can be treated as descriptors in receptor-
dependent (RD) 3D-QSAR modeling. Zhang et al. in our laboratory employs a different 
approach to incorporating the protein-ligand chemical geometrical knowledge into descriptor 
calculation. The descriptors are coined as ENTess descriptors,16 which are obtained by using 
Pauling electronegativity (EN) as atomic property and Delaunay Tessellation (Tess) to 
characterize the protein-ligand interface. The ENTess descriptors have been successfully 
applied in constructing quantitative structure-binding affinity relationship (QSBAR) models 
for 264 x-ray characterized protein-ligand complexes with known binding affinity. The 
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extension of ENTess descriptors – PL/MCT-tess descriptors – will be discussed in this 
dissertation (Chapter 3).  
After completing the stage of data preparation, the next stage deals with the selection 
of techniques which optimize the correlation between desired property (dependent variable, 
Y) and molecular descriptors (independent variables, Xs) during model training. These 
optimization techniques can be generally divided into linear or non-linear, depending on 
whether the equation that is applied to explain the relationship between Y and Xs, is a linear 
combination of parameters or not. The most extensively applied linear method in QSAR 
studies is Partial Least Squares (PLS), which extends the traditional multiple linear 
regression (MLR) method when the number of independent variables (descriptors) is much 
larger than the number of data instances, a common situation in modern QSAR. However, as 
the increasing availability of experimental data resources, more and more compounds with 
diverse scaffolds are incorporated into QSAR modeling, the assumption that the variance of 
independent variables linearly corresponds to the variance of dependent variables is not 
always true.  Instead, non-linear models may be constructed using machine learning 
algorithms such as k nearest neighbors (kNN). The kNN method is firstly introduced to 
QSAR world in 2000,17 where a particular compound’s property is predicted by its k nearest 
neighbors defined in a subset of descriptor space (resultants from the variable selection 
optimization).  
Furthermore, sometimes researchers care more about whether unknown compounds 
have certain property or not (e.g., active or inactive) or if they can classify unknown 
compounds into groups (e.g., high affinity, medium affinity, or low affinity). By contrast, the 
classification algorithms are employed to construct binary or multi-class classification QSAR 
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models. The support vector machine (SVM) and random forest (RF) are among the most 
popular classification techniques. For example, the SVM algorithm searches for the optimal 
hyperplane that separates the two classes in the descriptor/feature space by maximizing the 
distance (called margin) between the classes' closest points. If the data is not linear separable 
in the descriptor space, the kernel trick is applied to project the data into higher dimensional 
feature space where the linear separation may exist.  
Applying rigorous model validations after and during the model construction is 
important and necessary to afford predictive QSAR models.18, 19 The five-fold external cross 
validation technique or at least a set of randomly removed compounds preserved solely for 
validation should be conducted. For five-fold external validation, the modeling set is divided, 
by random selection, into five nearly equal subsets. Each subset will be used solely as 
external set for the models built from the remainder. On the other hand, during the model 
construction, as emphasized in the previous study,20 training-set-only modeling is insufficient 
to achieve models with validated predictive power when using the leave-one-out (LOO) 
procedure, which each compound is excluded once for validation while remainders are 
applied for training. Thus, additional internal test sets are needed to construct predicted 
QSAR models.20 Moreover, the Y-randomization validation test should be conducted, where 
the performance of mock models constructed with randomly shuffled independent Y variable 
(response) is compared to that of the ‘real’ models under the same modeling protocol. All of 
the validated models performed significantly better than the randomized models are eligible 
for external prediction. When predicting the external set, the consensus prediction technique, 
which is carried out by averaging the predicted activity values resulting from all eligible 
models, usually has better prediction accuracy comparing with by using the result from a 
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single, “best” model. This could be resulted from the prediction error of compounds from one 
model cancelled by the correct predictions from the other model if the errors do not correlate. 
Furthermore, the compound should be predicted only when it is similar to the training set 
molecules (i.e., those within model applicability domain).18 
Naming by the dimensionality of descriptors applied for model building, two types of 
QSAR methods, 2D-QSAR and 3D-QSAR are regularly compared to each other in many 
aspects such as the model performance and the ease of descriptor interpretation. Compared to 
2D-QSAR models, 3D-QSAR models are more easily interpretable due to its visualizablity, 
making it simpler to suggest compounds for synthesis. The most popular commercial 3D-
QSAR methods include Catalyst21 and Phase22. However, a recent study comparing these two 
programs demonstrates that the prediction accuracy of external validation set is less 
acceptable (the squared correlation coefficient, R2, less than 0.5), informing the further 
development of 3D-QSAR methodology is necessary.23 By contrast, our laboratory has been 
working on developing predicted 2D-QSAR workflow. Using predictive QSAR models as a 
virtual screening tool in hit discovery, many success stories are published.24-26 Herein, the 
QSAR binary classification modeling approaches are applied in several presented projects 
such as AmpC β-lactamase and Gram-negative efflux property (Chapter 2). And an 
extension of ENTess descriptors, P/L MCT-tess descriptors, is applied in QSBAR model 
building and structure-based virtual screening (Chapter 3 & Chapter 4).  
1.2 Structure-based Drug Design 
Structure-based drug design/discovery (SBDD) is defined as the use of 3D target 
protein structural information in the development of biologically active molecules (e.g., 
drugs or drug candidates).27 By understanding the interactions between the target protein and 
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molecules, chemists could rationally design and optimize the lead molecules compared with 
time-consuming systematic modifications of molecular structures by cycles of trial-and-error. 
The 3D protein structural information can come from X-ray crystallography, NMR 
spectroscopy, cryo-electron microscopy, and homology modeling, where 3D protein 
structural model is constructed based on its amino acid sequence and a related homologous 
protein structure determined by experiments (e.g., x-ray crystallography). The popularity of 
SBDD has substantially increased in recent years since the first seminal paper was published 
in 1982 by Kuntz’s group.28 This mainly results from the remarkable technical advances in 
determining target protein structures and protein/ligand complexes, multiplying structural 
resources related to therapeutically relevant target proteins. The solved 3D structures may be 
deposited in Protein Data Bank (PDB)29, where researchers can freely search and download 
structures. The exponential increase of deposited PDB structures since 1980s (from 70 to 
64,357 as of April 2010) also raises the quality issue of the applied structures in SBDD. 
Scrutinizing the congruence between the experimental electron density map and the fitted 
protein model gradually becomes a common and necessary procedure before any further 
SBDD calculations. Thus, various subdivided libraries of PDB are curated for such purpose. 
For example, PDBBind database30, 31 is curated by culling from high-quality protein-ligand 
complexes with experimentally measured binding affinity data. Nevertheless, SBDD 
approaches have been becoming indispensable tools in the early stage of drug discovery 
process.  
The SBDD approaches are usually divided into two classes: docking and de novo 
design. In this dissertation, only the respect of docking is discussed. Docking is defined as 
the prediction of compound conformations and orientations (i.e., pose) within the target 
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protein binding site. This process involves several steps: a) search algorithms explore the 
possible binding regions for each compound within the target protein binding site and 
generate multiple poses; b) scoring functions are applied to calculate a score for each pose, 
which is represented the degree of complementarity to the binding site, or the predicted 
binding affinity; c) the best ranking pose is commonly selected to represent the binding of 
that particular compound (i.e., binding mode).  
Since the pioneering docking program DOCK28, 32 published in 1980s, a series of 
other programs, such as FlexX,33 GOLD,34 and AutoDock35, have emerged.  Each of them 
varies in the respect of pose generation algorithms, the applied scoring functions, and the 
degree of protein/ligand flexibility taken into account. At present, all docking programs allow 
compounds to dock flexibly, either by exploring the translational and orientational degrees of 
freedom of pre-generated conformers (e.g., Fred36), or by generating the poses on-the-fly 
(e.g., AutoDock). However, explicit protein flexibility (i.e., the movement of protein 
backbone/side-chain) is still not regarded as a norm in docking considering the size and 
possible degrees of freedom of macromolecule.  
The SBDD approaches have been successfully applied in several cases. There are two 
prominent drug discovery projects: the structure-based design of neuraminidase inhibitors37 
contributes the birth of first anti-influenza virus drug – Relenza, and the development of HIV 
protease inhibitors used as anti-AIDS drugs.37, 38 Moreover, Aggrastat, a fibrinogen receptor 
(GP IIb/IIIa) antagonist launched in 1998, is cited as first marked drug whose discovery 
highly influenced by virtual screening.39 While these success stories accompany the burgeon 
of docking programs, the SBDD practitioners are eager to know if the state-of-the-art 
docking programs can really help them when dealing with novel targets. Since 2000, a 
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plethora of studies comparing the performance of different docking programs have been 
published.40-46 The 2006 GSK paper by Warren et al.47 concludes the current achieved status 
in docking by conducting an extensive retrospective study using ligand/decoy sets with 
experimentally determined binding affinities against a wide range of pharmaceutically 
relevant protein targets. In total, they evaluate 10 docking programs and 37 scoring functions 
and summarize the performance of those docking programs on three tasks: a) search 
algorithms in docking can generate poses which are closed to the experimentally determined 
binding mode (native pose) yet less successful in predicting the correct binding mode of 
ligands; b) docking/scoring can identify ligands among a set of pharmaceutically relevant 
decoys in virtual screening campaigns but the performance is highly target-dependent; c) in 
terms of lead optimization, none of the docking programs or scoring functions can make a 
useful prediction of ligand binding affinity. All of these retrospective studies demonstrate 
that significant improvements are needed for current scoring functions (or scoring schemes in 
virtual screening).  
In general, scoring functions can be classified into three types27: a) force-field based 
scoring functions rely on explicitly computed electrostatic and van der Waals interaction 
energies (i.e., enthalpic effects) between the ligand and the protein based on a molecular 
force field. For example, G-score48 which is based on the Tripos force field48 and AutoDock 
3.05 score based on the AMBER force field49; b) empirical scoring functions are defined as 
the sum of individual uncorrelated energy terms whose coefficients are optimized from 
regression analysis by fitting the experimental data such as binding energies/affinities. 
Several non-enthalpic contributions can be included such as deformation and hydrophobic 
terms in XSCORE50 and the ligand rotor term in ChemScore;51 c) knowledge-based scoring 
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functions are designed based on various statistical parameters derived from x-ray crystal 
structures that could reflect the interactions between a ligand and its receptor depending on 
their molecular environment.  Simple distance-dependent pair potentials and non-polar 
surface-dependent singlet-potential are used in DrugScore.52 They could implicitly capture 
the binding effects that are difficult to model in force field based scoring functions. Moreover, 
consensus scoring schemes53-56, which various data fusion approaches are used to combine 
information from multiple scoring results in the hope of compensating the errors inherent in 
each single score, are also widely employed. However, a paper published in 2005 
demonstrates that consensus only works when each of the individual scoring functions has 
relatively high performance and the scoring characteristics of each individual scoring 
function are quite different.56 
A popular strategy to improve the force-field scoring functions is to consider the 
entropic and solvation effects that are ignored in most of the current force-field scoring 
functions. The well-known methods are: MM-GB/SA,57 Linear Interaction Energy (LIE),58 
and Free Energy Perturbation (FEP).59  However, due to computationally intensive 
calculations, the application of these methods is constrained for target-specific lead 
optimization. Moreover, a recent study demonstrates that the prediction accuracy of binding 
affinity of static x-ray structures is less acceptable60, no wonder the same poor prediction 
accuracy is observed when conducting cross-docking calculations where protein induced-fit 
effects are encountered. The result suggests that, for other than some computationally 
intensive approaches recently being developed for target-specific lead optimization in 
structure-based drug design,58, 59 the improvement of current scoring functions for generic 
high-throughput molecular docking is also needed. 
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Recently, a hybrid (empirical + knowledge-based) scoring function incorporating the 
cheminformatics concepts into conventional structure-based scoring functions is developed 
in our laboratory.16  The scoring function is quantitative structure-binding affinity 
relationship (QSBAR) models constructed by 264 x-ray protein-ligand complexes with 
known binding affinity using ENTess descriptors. The ENTess descriptors are generated 
based on the tetrahedra resulting from Delaunay tessellation (Tess), characterizing the 
protein-ligand interface by means of Pauling electronegativity (EN) values. The output of 
ENTess scoring function can be directly related to absolute binding affinities and could 
implicitly take into account binding effects that are difficult to specify, combining the merit 
of both empirical and knowledge-based scoring function. However, the performance of 
ENTess scoring function in practical virtual screening is limited. One of the possible reasons 
could be the limitation in applicability domain of ENTess models. In Chapter 3, we report 
the study managing to improve the ENTess scoring function. . 
Regarding the issue of virtual screening in hit identification stage that multi-purpose 
scoring functions cannot perform consistently across diverse targets, a popular alternatives is 
to address the problem by including knowledge of a single specific protein target or a family 
of targets during docking/scoring. For instance, some studies have demonstrated that target-
specific customized scoring functions61, 62 are effective methods for improving the 
discrimination between true ligands and binding decoys in VS for the aimed target. On the 
other hand, because the awareness of the scoring problem may originate current scoring 
functions are solely optimized by existing ligand data, scoring function developers manage to 
include decoy compounds (or poses) during scoring function optimization.63-69 In Chapter 4, 
we report the target-specific cheminformatics-based pose (-scoring) filter trained to 
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discriminate native-like poses of ligands vs. pose decoys. The pose filter, along with 
MedusaScore (a force field-based scoring function), is combined to develop a novel two-step 
protocol for target-specific virtual screening with the aim to improve the hit enrichment in 
structure-based virtual screening.  
1.3  Summary 
This dissertation will describe the contributions to the field of SBDD by incorporating 
cheminformatics concepts into structure-based scoring methods. Firstly, cheminformatics 
practices are applied to those problematic cases which conventional structure-based scoring 
functions find difficult (anti-bacterial leads efflux study) or even fail to address (AmpC β-
lactamase study). Secondly, novel pose and binding structure-based scoring functions and a 
two-step scoring protocol are developed by employing cheminformatics approaches to 
improve protein-ligand binding affinity prediction and structure-based virtual screening 
respectively.  
Chapter 2 discusses two case studies demonstrating that cheminformatics approaches 
can complement structure-based drug discovery/drug design and identify promising hits by 
virtually screening molecular libraries.   
The first case study is prediction of efflux properties (low vs. high) for Gram-negative 
bacteria, by the binary classification QSAR approach with pharmacophore fingerprint 
descriptors. Bacterial efflux properties are difficult to model by structure-based methods due 
to the structural complexity of the efflux pump. However, I successfully construct QSAR 
models which show high prediction accuracy in both internal and external validation. After 
applying the models to virtual screening, many compounds predicted as low-efflux were 
experimentally confirmed as such.  
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The second case study is differentiation of AmpC β-lactamase binders vs. binding 
decoys using the binary classification QSAR approach. The binding decoys are false 
positives mispredicted by conventional structure-based scoring functions. To differentiate 
them, I successfully construct predictive QSAR models based on rigorous internal and 
external validations. Applying the models to predict false positives and false negatives from 
high throughput screening, the models discard false positives and can rescue false negatives.  
Chapter 3 explains the development of binding scoring function, which is a 
collection of QSBAR models. Compared with the previous ENTess scoring function, the new 
binding scoring function is constructed with an increased number of protein-ligand 
complexes and novel protein-ligand interfacial descriptors incorporating conceptual DFT 
atomic properties. Upon the application of global applicability domain, this new binding 
scoring function shows acceptable prediction accuracy (the squared correlation coefficient: 
0.57) towards the Community Structure-Activity Resources (CSAR) data set.    
Chapter 4 describes the development of the target-specific pose (-scoring) filter with 
the aim to improve the hit enrichment in structure based virtual screening. The pose filter is 
developed for each target by building binary classification models that can discriminate 
native-like poses of ligands vs. pose decoys. Furthermore, a two-step scoring protocol for 
target-specific virtual screening is developed. In the first step our pose filter is used to filter 
out/penalize putative pose decoys for every compound, and in the second step the remaining 
putative native-like poses are scored with MedusaScore, which is a conventional force-field-
based scoring function. 
Chapter 5 presents conclusions and future studies.
   
Chapter 2 Cheminformatics Approaches Complement Structure-based Virtual Screening: 
2.1a Classification of Gram Negative Bacteria Efflux Properties of Antibacterial Leads Using 
Pharmacophore Fingerprint-based SVM QSAR Modeling and Application to Virtual Screening 
2.1a.1  Introduction 
Bacterial multidrug resistance (MDR) is frequently reported in clinics, underlining 
the need for developing new antibiotics. Unfortunately, a majority of recently approved 
antibiotics and developing compounds still lack activities against Gram-negative bacteria 
despite the fact that they cover a number of novel, well-conserved bacterial targets to 
overcome the resistance by target modification and enzymatic drug inactivation.  It is widely 
recognized that this intrinsic resistance largely results from the constitutive expression of 
multi-drug efflux pumps. Unlike other bacterial efflux pumps only selectively extruding 
specific drugs, efflux pumps involved in MDR can pump out a number of antibiotics with 
diverse structures and unrelated functions, rendering simultaneous bacterial resistance. The 
efflux issue is especially serious for Gram-negative bacteria due to combined effects of 
efflux pumps to actively expelling antibiotics (efflux) and the unique Gram-negative 
bacteria’s outer membrane to reducing antibiotics uptake (influx)70 (Figure 2.1a.1), 
providing an effective barrier against both hydrophilic and hydrophobic antibiotics.71  
There are a total of five families of efflux pumps associated with MDR:72 the ATP binding 
cassette (ABC) superfamily, the major facilitator superfamily (MF), the multidrug and toxic-
compound extrusion (MATE) family, the small multidrug resistance (SMR) family, and the 
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resistance nodulation division (RND) family. Among them, members in the RND family are 
the most significant efflux determinants of intrinsic and acquired resistance in Gram-negative 
bacteria. Efflux pumps in RND family are organized into three-component structures 
transversing both inner and outer membranes, allowing diverse antibiotic substrates to 
directly expel out from the cytoplasm and periplasm (Figure2.1a.1). Recent x-ray structures 
of efflux pumps co-crystallized with several ligands simultaneously in an extremely large 
cavity confirms the diverse substrate specificity of efflux pumps.73 
The inhibition of efflux pumps has been suggested as a viable approach to overcome 
MDR.   Common strategies for efflux inhibition include a) development of efflux pump 
inhibitors (EPI) in combination with available antibiotics to increase antibacterial potency; b) 
design of anti-bacterial lead compounds which can elude efflux pumps.  The latter approach 
is potentially more practical compared to the former one, where EPIs can only be effective 
when the complimentary antibiotic substrates share the same binding site (i.e., competitive 
inhibition). One of the goals of this study is to help medicinal chemists to identify anti-
bacterial lead compounds that can elude the efflux pumps using in silico models. 
Computer-aided drug design, including both structure-based and ligand-based drug 
design, has demonstrated its contribution in drug discovery.37  Despite the availability of x-
ray crystal structures of each component of E. coli efflux pump,74-76 the complexity of efflux 
pump stoichiometry and the extra-large substrate binding site make structure-based approach 
less plausible. On the other hand, modeling of efflux properties is also challenging using 
ligand-based approach since efflux is a dynamic process of compounds going through 
cellular trans-membrane channels instead of binding to a static target. Published ligand-based 
studies mostly fall into the realm of explanatory models with fairly small data sets (<45 
  
16 
 
compounds).77, 78 Herein, in silico quantitative structure-activity relationship (QSAR) models 
are built to classify Gram-negative bacteria efflux properties (low vs. high) with five-fold 
external cross validation (CV) average accuracy as high as 79%. The predictive models are 
built and validated using GlaxoSmithKline (GSK) in-house pharamacophore fingerprint (pFP) 
descriptors and support vector machine (SVM) algorithm on a GSK proprietary K. 
pneumoniae efflux data set (~400 compounds). The models are subsequently applied in 
virtual high throughput screening and 60 out of 75 available potent computational hits are 
confirmed as low-efflux by bioassays, achieving high accuracy of 80%. The predictive 
models can also further be used to prioritize synthesis of GSK anti-bacterial series. These 
encouraging results provide a good template for further efflux modeling research. 
2.1a.2  Methods 
2.1a.2.1  Data Sets 
The GSK anti-bacterial series are broad-spectrum bacterial topoisomerase IIa inhibitors 
(Figure 2.1a.2), which show a novel mode of inhibition different from clinical 
topoisomerase IIa inhibitors in the quinolone series, providing the hope of against 
topoisomerase IIa - mediated cross-resistance.79  However, the novel GSK anti-bacterial 
series also suffer from the multidrug efflux pump issue especially in Gram-negative 
bacteria.80  Thus, it is desirable to build in silico models to predict efflux properties of GSK 
anti-bacterial series to further improve potencies by reduction of efflux activities. 
  Minimum inhibitory concentration (MIC) assays are used to measure the in vivo 
antibacterial activity (µg/ml) of compounds. The efflux properties of anti-bacterial 
compounds are quantitatively characterized by the efflux index (EI), which is defined by the 
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ratio of the MIC of wide-type bacteria to that of efflux knock out bacteria. The EI values are 
transformed to the logarithmic value (pEI) for modeling purpose (Equation 2.1). 
                                                           (2.1)
  
 
  Each MIC is measured at least twice to ensure data integrity. The experimental 
variability of pEI for each compound is usually around ±1, but could be as high as ±2. 
Therefore, a classification model is better suited for modeling the efflux indices. All 
compounds are classified by a threshold of pEC = 6, i.e. 64-fold difference between wide 
type MIC and efflux knock-out MIC, determined by biological interests. In total, there are 
399 GSK anti-bacterial series annotated as low and high efflux properties against K. 
pneumoniae for modeling, containing 149 low-efflux compounds (37%) and 250 high-efflux 
compounds (63%). The pEI distribution of dataset is shown in Figure 2.1a.3. Compound 
structures are relatively diverse, including, for example, the tricyclic nitrogen series81 and the 
cyclohexane/cyclohexene series.82  
Furthermore, seventeen compounds in a new subseries outside of training set are 
served as an additional external validation set.  The pEI distribution of these 17 compounds is 
shown in Figure 2.1a.4. 
Regarding the library used for virtual screening, a total of 4013 historical GSK 
bacterial topoisomerase IIa inhibitors without K. pneumoniae efflux properties are curated to 
search for low-efflux templates. 
2.1a.2.2  Training, Test, and External Validation Set Selection 
)
MIC
MIC(log)(
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WT
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The overall modeling workflow is shown in Figure 2.1a.5. The double five-fold cross 
validations are applied for modeling, including internal (optimization of model parameters) 
and external cross validations (testing model performance). The data set is randomly split 
into five subsets, where the ratio of low-efflux to high-efflux compounds corresponding to 
that in the modeling set. Each subset is applied independently to validate the models built 
from the remaining subsets by five-fold internal CV using the Support Vector Machines 
(SVM) algorithm. Furthermore, seventeen compounds in a new subseries outside of training 
set are served as an external validation set. The pEI distribution of these 17 compounds is 
shown in Figure 2.1a.4. 
2.1a.2.3  Generation of Pharmacophore Fingerprint (pFP) Descriptors and 
pFP Noise Reduction by pFPBitRank Tool 
The GSK in-house pFP program is applied to generate the pFPs for all compounds. 
The implementation is similar to the one previously reported.83, 84 There are six 
pharmacophore feature types (hydrogen bond donor/acceptor, positive/negative ionizable, 
hydrophobic centroid, and aromatic centroid) and seven inter-pharmacophore distance bins 
(1.0-3.0, 3.0-4.0, 4.0-5.2, 5.2-6.5, 6.5-8.0, 8.0-10.0, 10.0-50.0, unit: Å). The distance bin 
boundaries are statistically determined to produce equal occupancies across a large set of 
GSK drug-like compounds.  The combination of six pharmacophore feature types and seven 
distance bins leads to a total of 19208 pFP bits. 
For each compound, multiple conformers are generated by using Omega 36 (version 
2.2) with default parameters. Pharmacophore features are assigned to atoms and functional 
groups in each conformer, while inter-pharmacophore distances are classified into seven bins. 
Then all three-point phamacophore triangles are enumerated based on the triangle constraint 
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and stored into a bit string to generate per-conformer pFP (Figure 2.1a.6). All per-conformer 
pFPs of one compound at each pFP bit position are further processed by logical OR to 
generate the per-molecule pFP of that compound. As long as a certain three-point 
pharamacophore appears in any conformer, that bit is turned on in the per-molecule pFP. 
These three-point pharmacophore fingerprints are applied as descriptors to capture the 
physiochemical nature of a compound, as the GSK pFP descriptors have been successfully 
applied in both lead optimization and lead identification projects.85-87 
The pFP BitRank tool 85 is applied to increase the signal to noise ratio in pFPs based 
on information from known low-efflux/high-efflux compounds. A score for each bit is 
calculated using Equation 2.2.  Given the pFPs of sets of active (e.g., high-efflux) and 
inactive (e.g., low-efflux) compounds, each bit is scored according to relative prevalence 
amongst actives (a) or inactives (i) 
BitScore(j)  fa1 * fi0 + fa0 * fi1                                                                (2.2) 
 where j is the id of each bit and fxy is the fraction of bits whose value is y (e.g., 0 or 1) 
amongst compounds in class x (e.g., active or inactive). 
To estimate the “noise” bitscore value, the activity labels are shuffled (y-
randomization) and the score for each bit is recalculated.  This procedure is repeated 100 
times and the mean as well as standard deviation are calculated using all bitscore values from 
randomization.  Only the bits with bitscore higher than a certain Z cutoff are retained and 
applied as descriptors in SVM model building.  
Bitscore =  + Zσ y
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Here,  is the average bitscore values from randomization, σ is the standard deviation of 
these bitscore values, and Z is an arbitrary parameter to control the significance level. 
(Further implementation details are not disclosed by GSK.) 
2.1a.2.4  Support Vector Machine Classification Method 
The Support Vector Machines (SVM) algorithm implemented in the open-source 
LibSVM88 package are employed to build binary classification models. The SVM algorithm 
searches for the optimal hyperplane separating the two classes in the descriptor space by 
maximizing the margin between the closest points of the two classes (Equation 2.3), 
∑
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where C is the penalty parameter and 0≥iξ  is the slack parameter. To make the data set 
linearly separable, the data points are projected to a higher dimensional space by Radial 
Basis Kernel (RBF), 
0),exp()()(),( >−−=ΦΦ≡ γγ jiiTij xxXXxxK                              (2.4) 
where γ is the kernel parameter. We employ the Python script (grid.py) provided by LibSVM 
to optimize parameters C and γ during model building with 5-fold cross validation (CV). The 
search range of C and γ are -5 to 15 and -15 to 0 respectively. 
2.1a.2.5  Virtual Screening Using pFP-SVM Models  
All SVM models with eligible CV accuracy are used to predict the test set. When 
applied to the compounds in the test set of each fold CV, compounds are considered as low 
(or high) efflux only when they are predicted as low (or high) efflux consistently by no less 
y
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than 50% of all eligible models. However, in the VS study, a higher threshold (90%) is 
applied to select low-efflux compounds for experimental testing. A higher threshold is 
assumed to have higher confidence in prediction.  
2.1a.3  Results and Discussions 
2.1a.3.1  Relationship between Distribution Coefficient and Efflux Index 
The correlation between the measured logD values (the logarithmic value of 
distribution coefficient) and the pEI values is analyzed based on the hypothesis that 
hydrophobic (i.e., high distribution coefficient) compounds tend to have higher EI values due 
to favorable interactions between hydrophobic compounds and the aromatic binding site of 
efflux pumps.  As shown in Figure 2.1a.7, there is a marginal correlation between these two 
factors, indicating that efflux modeling is more complicated than simple polarity modeling. 
Therefore, extra structural information (e.g., pFP) is needed to build in silico efflux models.  
2.1a.3.2  SVM Binary Classification Models 
The pFP descriptors are calculated for all compounds and the pFP BitRank tool is 
applied (Z-cutoff=0.5) to the efflux modeling data set to reduce the “noise” bits according the 
protocol described in Method 2.1a.2.3. In total, there are 2248 pFP descriptors used in model 
building. Firstly, pFP regression models using partial least squares (PLS) algorithm are 
constructed to correlate pFP bits with the pEI values. However, only models with poor 
prediction accuracy are obtained (data not shown). The poor prediction accuracy might result 
from the large experimental variability (±2) of pEI. Therefore, the binary classification 
models are constructed instead to differentiate low-efflux compounds from high-efflux ones 
using SVM algorithm. Only models with internal CV accuracy higher than 75% are saved for 
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consensus prediction on the test sets. The overall statistics are summarized in Table 2.1a.1. 
The average prediction accuracy for training sets and test sets is as high as 76% and 79% 
respectively. The consensus models from the 1st fold and the 4th fold are applied to the 
additional external validation set and in the virtual screening.  
2.1a.3.3  External Validations 
Seventeen compounds in a new subseries outside of training set are served as an 
additional validation set for predictive models.  Compounds are classified as low (or high) 
efflux only when they are predicted as low (or high) efflux consistently by no less than 50% 
of all eligible models. The prediction results are tabulated in Table 2.1a.2. Almost all low-
efflux compounds (8 out of 12) are predicted correctly and three out of four false positives 
have pEI equal to 6 (i.e., borderline compounds).   
In summary, validation results show that the pFP-SVM models can differentiate 
pharmacophore features of low-efflux compounds from high-efflux compounds and can be 
applied for virtual screening. 
2.1a.3.4  Virtual Screening Using Predictive pFP-SVM Models 
The validated consensus prediction models are employed to virtually screen 4013 
historical GSK bacterial topoisomerase IIa inhibitors to identify low-efflux chemical 
templates against K. pneumoniae.  A higher consensus threshold (90%) is applied to select 
low-efflux compounds for experimental testing.  In total, there are 280 selected compounds, 
each of which is predicted as low-efflux by no less than 90% of eligible models. Out of 280 
compounds, 115 available compounds are experimentally tested. 35% of them are identified 
as low potent against K. Pneumoniae and therefore their efflux properties cannot be 
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determined experimentally. For the remaining compounds (75 compounds), 80% are 
confirmed with low efflux properties.     
2.1a.3.5  Virtual Screening Using LogD value 
Further efforts are spent to investigate the prediction accuracy of using logD value 
alone to fish out the low-efflux compounds from those 75 compounds which could be 
assumed randomly selected from the library. The range of measured logD values of these 75 
potent compounds is from -0.3 to 1.5. The probability of fishing out low-efflux compounds 
based on logD values lying in that range in the modeling set is 0.47 in comparison with the 
prediction accuracy (0.80) by using pFP-SVM models, demonstrating the benefits of QSAR 
modeling of efflux properties.   
2.1a.4  Conclusions 
The pFP-SVM-based efflux classification models are able to differentiate the low-
efflux compounds from high-efflux compounds in the GSK anti-bacterial series and can 
identify the low-efflux compounds in new subseries outside of training set. Over 4000 
historical GSK bacterial topoisomerase inhibitors are screened by the models and subsequent 
experimental validation demonstrates that the models afford high prediction accuracy (80%) 
of identifying low-efflux structures. It suggests that the models could be a plausible tool for 
lead optimization and virtual screening. The encouraging results of pFP-SVM-based efflux 
classification model building, validation, and virtual screening provides a good template for 
further efflux modeling exercises as well as modeling against endpoints with large 
experimental variability.         
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Figure 2.1a.1: Schematic representation of both the inner and outer membrane of Gram
negative bacteria together with the porous layer of peptidoglycan, the main target of beta
lactam antibiotics (in blue).  
Influx and efflux systems are also inserted to show the uptake a
antibiotics. The figure is modified from the Figure (1) in 
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Figure 2.1a.2: The novel GSK antibiotic series target bacterial topoisomerase IIA (DNA 
gyrase and topo IV).  
The inhibition mechanism of GSK bacterial topoisomerase IIA inhibitors is different from 
the one of fluoroquinolones, circumventing the topoisomerase IIa 
 
 
Figure 2.1a.3: The distribution of pEI
Applying pEI, 6, as the threshold, totally, there are 149 low
250 high-efflux compounds (Red).
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Figure 2.1a.4: The distribution of pEI
structure activity relationship (SAR) with single functional group substitution of GSK 
antibiotics series.   
There are nine low-efflux compounds (Green), three borderline compounds (yellow), and 
five high-efflux compounds. 
 
 
 
Figure 2.1a.5: The workflow of efflux model building, validation, and virtual screening.
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Figure 2.1a.6: The pFP descriptor calculation. For each compound, multiple conformers are 
generated, each of which is assigned 
Along with seven distance bins (1.0
unit: Å), the 19208 three-point phamacophore features
constraint and stored into a bit string.
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Figure 2.1a.7: The correlation plot of pEI values (x-axis) and logD values (y-axis).  
There is only marginal correlation between pEI values and logD values (R2 = 0.24). 
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Tables for Chapter 2.1a 
Table 2.1a.1: The statistics of accuracies from internal and external five-fold cross-
validation (CV) by models with internal CV accuracy larger than 75%. 
CV split Average CV 
accuracy (%) 
Test set 
accuracy (%) 
Low efflux 
accuracy (%) 
High efflux 
accuracy (%) 
# of models w/ 
accuracy ≥ 75% 
#1 75 84 71 91 50 
#2 75 80 76 82 17 
#3 76 78 71 84 20 
#4 78 76 65 82 100 
#5 75 77 63 82 6 
 
 
Table 2.1a.2: The confusion matrix of 17 newly synthesized compounds with single 
functional group substitution. 
                      
predicted 
experimental 
Low (pEI <=6) High (pEI > 6) 
Low (pEI <6) 8 1 
Borderline (pEI = 6) 0 3 
High (pEI > 6) 0 5 
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2.1b Differentiation of AmpC β-Lactamase Binders vs. Binding Decoys Using Classification 
k-NN QSAR Modeling and Application of QSAR Classifier to Virtual Screening 
2.1b.1  Introduction 
Due to rapid advances in protein crystallography90, 91, the number of x-ray 
characterized biological targets and their complexes with various low molecular weight 
ligands in the RCSB Protein Data Bank (PDB)29 has been growing rapidly. This growth has 
been concurrent with the development of a vast array of structure-based virtual screening 
approaches 92-101. These methods include two critical components, i.e., docking and scoring. 
It has been shown that multiple binding poses of putative receptor ligands resulting from 
docking include those that are geometrically close to the native (i.e., experimental) ligand 
orientation in the binding site. However, identifying (the most) native-like binding poses 
among many alternatives (i.e., ‘geometrical decoys’) resulting from docking continues to 
present a universal problem to most scoring functions.47, 102, 103 Furthering this problem is a 
demonstrated inability of many scoring functions to discriminate between ligands that are 
known to bind to the target receptor from those known to be non-binders yet predicted to 
bind by a docking/scoring method (so called ‘binding decoys’) 42, 104. 
Many strategies have been proposed to improve scoring functions such as to decrease 
the number of false positives as well as improve the enrichment of true positives42, 105-109. 
Nevertheless, in a recent study, Shoichet and coworkers103, 110 reported docking of over 
200,000 compounds into the active site of AmpC beta-lactamase that produced many binding 
decoys. These compounds were ranked highly by many scoring functions such as DOCK, 
ScreenScore and FlexX etc., but were found to be false positives as a result of experimental 
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validation. Similar results have been observed for several other systems (available from the B. 
Shoichet’s laboratory website, http://shoichetlab.compbio.ucsf.edu/take-away.php). 
From the traditional three-dimensional docking and scoring prospective, the existence 
of binding decoys illustrates the need for developing more robust scoring functions. However, 
the same results could be also approached from a cheminformatics prospective. Thus, the two 
groups, i.e., experimentally confirmed binders and binding decoys represent two classes of 
compounds that could be possibly discriminated by their chemical features, or descriptors. 
The problems of this type (i.e., discriminating binding from non-binding compounds based 
on their chemical structure descriptors only) are rather common in case of ligand based drug 
design approaches such as Quantitative Structure Activity Relationship (QSAR) modeling. In 
fact, the use of binary QSAR modeling towards the problem of discriminating true binders vs. 
decoys may be perhaps even more challenging than the standard binary QSAR modeling. 
Indeed, in this case both classes of compounds are apparently sufficiently similar to each 
other to fit into the same receptor binding site to be indistinguishable by well-defined and 
validated scoring functions. Thus, being able to discriminate binders vs. (similar) decoys 
should be a difficult exercise. On the other hand the successful structural models could 
potentially inform protein structure based scoring functions about specific functional groups 
that are primarily responsible for the discriminatory power of the QSAR models but most 
likely are not adequately scored by the traditional scoring functions. Furthermore structural 
models could be potentially used for mining external compound libraries to identify novel 
putative binders providing a potential alternative to structure based virtual screening methods. 
12, 111
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The goal of this study was to develop robust binary classification QSAR models that 
would have high predictive power to differentiating binders vs. non-binding ‘decoys’ for 
AmpC beta-lactamase. We have employed a rigorous validated QSAR modeling workflow 
that has been developed in our laboratory in recent years. This workflow that incorporates a 
virtual screening module was applied successfully to several ligand datasets leading to the 
identification of experimentally confirmed novel hits for different biological targets 112-116 
(see recent review 117 ). Herein, we report on classification QSAR models that are capable of 
discriminating binders from decoys with the external classification accuracy exceeding 90%. 
Furthermore, we have used these models to screen the compound library tested earlier in the 
AmpC assay and available from PubChem 118. We have identified 15 molecules as putative 
AmpC ligands and demonstrated in subsequent experimental studies that five compounds 
chosen from these hits were millimolar binders. It worth emphasizing that in all studies 
reported in this paper we did not use any information on the crystallographic structure of 
AmpC-ligand complexes and moreover, chemical descriptors were generated from two-
dimensional rendering of molecular structures. 
2.1b.2  Methods 
2.1b.2.1 Data Sets 
Compounds used for QSAR model building.  
The AmpC beta-lactamase inhibitors and binding decoys were downloaded from Dr. 
Brian Shoichet’s laboratory web site 119. This dataset contains 21 confirmed inhibitors (cf. 
Appendix I) and 80 decoys. The inhibitors were shown to be non-covalent, reversible AmpC 
beta-lactamase inhibitors.103, 120, 121 All decoys were shown to have no binding to AmpC at 
1mM concentration but falsely predicted to bind by multiple scoring functions 120, 122. 
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Library used for virtual screening.  
We used the dataset of 69653 compounds that was screened in the HTS assays for 
AmpC beta-lactamase inhibition by the National Center for Chemical Genomics (NCGC). 
The screening results are reported in PubChem as Bioassays AID584 123 and AID585 124. The 
experimental protocols are described in 125 as well as in the PubChem database. AID584 and 
AID585 were designed for screening of specific and promiscuous AmpC beta-lactamase 
inhibitors, respectively. Compounds are classified as having full titration curves, partial 
modulation, partial curve (weaker actives), single point activity (at highest concentration 
only), or inactive. Compounds that showed activity in both AID584 and AID585 assays were 
considered ‘true’ positives. However, if compounds were only found active in AID585 but 
inactive in AID584, they were categorized as ‘aggregators’.  Thus, 64 compounds were 
identified as ‘true inhibitors of’ the AmpC beta-lactamase that could be used to test the 
ability of QSAR model based virtual screening to recover known hits.  
2.1b.2.2 AmpC β-lactamase Competitive Inhibitor Assay  
The details of enzymatic assays to measure the efficiency of AmpC beta-Lactamase 
inhibitors were described in detail elsewhere (26, 40). Briefly, the change in initial rate of 
substrate hydrolysis at increasing concentrations of the inhibitor was monitored and the IC50 
was obtained using the resulting dose-response curve. The inhibition constant, Ki, was 
derived from the IC50 value using the Cheng-Prusoff equation. 
2.1b.2.3 Training, Test, and External Validation Set Selection 
We have followed the rigorous QSAR workflow for model building, validation and 
database mining (Figure 2.1b.1) established in our laboratory (see 117 for recent overview). 
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For classification QSAR modeling, it would be ideal to have the balanced ratio between 
different compound classes in the modeling dataset. However, the AmpC beta-lactamase 
binding dataset included 21 inhibitors and 80 decoys, i.e., it is imbalanced with the inhibitors 
to non-binders ratio of 1:4. In the absence of special statistical treatment, such ratio would 
skew the prediction accuracy of the classification models. Thus, the distance matrix was 
calculated in the multidimensional descriptor space for all 101 compounds and similarity 
search was carried out using 21 inhibitors as queries against the remaining 80 non-binders. 
30 compounds were selected from the original 80 non-binders as most similar to 21 inhibitors 
using Euclidean distance as similarity metric (we note that this treatment makes the task of 
building the discriminatory binary QSAR models even more challenging. Consequently, 
these 30 non-binders combined with 21 true inhibitors formed a new balanced dataset for 
QSAR model building. The remaining 50 “dissimilar” non-binders were retained as an 
external validation set. Furthermore, 10 compounds (five binders and five decoys) were 
randomly excluded from the balanced dataset of 51 compounds and formed a second external 
validation set.  The remaining 41 compounds were considered a modeling dataset that was 
divided into multiple diverse and representative training and test sets using the Sphere 
Exclusion approach developed in our laboratory earlier 20, 126. 
2.1b.2.4 Generation of 2D Molecular Descriptors 
The SMILES 127 strings of each compound in AmpC beta-lactamase dataset were 
converted to 2D chemical structures using the Unity module of the SYBYL software package 
128
. The MolConnZ 129 software (version 4.09) was used to calculate a wide range of 
topological indices of molecular structure. These indices include (but are not limited to) the 
following descriptors: simple and valence path, cluster, path/cluster and chain molecular 
  
35 
 
connectivity indices 130-132, kappa molecular shape indices 133, 134, topological and 
electrotopological state indices 135-137, differential connectivity indices, graph’s radius and 
diameter 138, Wiener and Platt indices, Shannon and Bonchev-Trinajstić information indices, 
counts of different vertices, counts of paths and edges between different kinds of vertices. 
Overall, MolConnZ produced over 770 different descriptors. Most of these descriptors 
characterize chemical structure, but several depend upon the arbitrary numbering of atoms in a 
molecule and are introduced solely for bookkeeping purposes. In our study, only 644 chemically 
relevant descriptors were initially calculated and 340 descriptors were eventually used for AmpC 
beta-lactamase binding dataset after deleting descriptors with zero value or zero variance. MolConnZ 
descriptors were range-scaled prior to distance calculations since the absolute scales for MolConnZ 
descriptors can differ by orders of magnitude139. Accordingly, our use of range-scaling avoided giving 
descriptors with significantly higher ranges a disproportional weight upon distance calculations in 
multidimensional MolConnZ descriptor space. 
2.1b.2.5 k-Nearest Neighbors (k-NN) Classification Method 
The kNN classification QSAR method 139, 140 is based on the idea that the class that a 
compound belongs to can be defined by the class membership of its nearest neighbors (i.e., 
most similar compounds) taking into account weighted similarities between a compound and 
its nearest neighbors. Since our implementation of kNN approach includes variable selection, 
the similarity is evaluated using only a subset of all descriptors (nvar). The similarity is 
characterized by weighted Euclidean distance between compounds in multidimensional 
descriptor space. Thus, the class membership of compound i can be predicted from the 
following equation: 
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where k is the number of nearest neighbors (k = 1 to 5) of compound i, yj is the class 
membership of compound j and dij is the Euclidean distance between compound i and its jth 
nearest neighbors. In practice, the value of iyˆ  is rounded to determine the class membership 
of compound i: 
iy 'ˆ  = round ( iyˆ )                             (2) 
The model is internally validated by leave-one-out cross-validation (LOO-CV) where 
each compound is eliminated from the training set and its class membership is predicted as 
the class the majority of its k nearest neighbors belongs to. The descriptor set is optimized by 
simulated annealing approach with the Metropolis-like acceptance criterion to achieve the 
best CCR value. The CCR is defined as113: 
CCR = 0.5(TP/N1+TN/N0)                      (3) 
where N1 and N0 are the number of inhibitors and non-binders in the dataset, TP and 
TN are the number of known inhibitors predicted as inhibitors (true positives) and the 
number of non-binders predicted as non-binders (true negatives). The statistical significance 
of the training and test set models is characterized by the LOO-CV CCRtrain and predictive 
CCRtest, respectively. In summary, the variable selection kNN classification method generates 
a model with the highest value of CCR that is characterized by the optimal k value, the 
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number of nearest neighbors, and a subset of selected descriptors. Additional details of this 
approach can be found elsewhere139, 141. 
2.1b.2.6 Applicability Domain of k-NN Models 
When developing kNN QSAR models, each compound is represented as a point in M-
dimensional descriptor space (where M is the total number of selected descriptors); thus, the 
molecular similarity between any two molecules can be characterized by the Euclidean 
distance between their representative points. The Euclidean distance di,j between two points i 
and j (which correspond to compounds i and j) in M-dimensional space can be calculated as 
follows: 
∑
=
−=
M
k
jkikij XXd
1
2)(                        (4) 
Compounds with the smallest distance between one another are considered to have the 
highest similarity. 
Theoretically, for any compound that can be represented by its MZ descriptors one 
should be able to predict its class membership using classification kNN approach. However, 
if the distance between the query compound and its k nearest neighbors in the training set is 
large, then the query compound is too dissimilar to the training set compounds, and the 
prediction of its activity using kNN approach appears meaningless. Therefore, a similarity 
threshold (or model applicability domain) should be introduced to avoid making predictions 
for compounds, which differ substantially from the training set molecules 19. The similarity 
threshold is defined as follows: 
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DT =  + Zσ                               (5) 
Here,  is the average Euclidean distance of the k nearest neighbors of each compound 
within the training set (where the value of k is the same as in predictive kNN QSAR models), 
σ is the standard deviation of these Euclidean distances, and Z is an arbitrary parameter to 
control the significance level. Typically, we set Z to 0.5, which places the boundary for 
deciding whether a compound is within or outside of the applicability domain at one-half of 
the standard deviation. It is important to notice that increasing the value of Z would increase 
the number of compounds in the external set that are considered within the applicability 
domain but could decrease the accuracy of prediction due to inclusion of dissimilar nearest 
neighbors. 
2.1b.2.7 Y-randomization Test 
Y-randomization test is widely used to ensure model robustness 142. It includes 
rebuilding the training set models using randomized activities (Y-vector) of the training set 
and comparing the resulting model statistics with that for the original test set. It is expected 
that models built with randomized activities should have significantly lower CCR value for 
both the training and test sets. In the model building process, it is possible that sometimes, 
though infrequently, high CCR values may be obtained due to a chance correlation or 
structural redundancy of the training set. If QSAR models obtained in the Y-randomization 
test have relatively high LOO-CV CCRtrain as well as predictive CCRtest, it implies that 
acceptable QSAR models cannot be obtained for the given dataset by the current modeling 
method. In this study, the Y-randomization test was performed twice for each training/test set 
splits. 
y
y
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2.1b.2.8 Virtual Screening using k-NN Models 
As mentioned above, the screening database included 69653 compounds tested by the 
NCGC against AmpC beta lactamase. The primary HTS screening assay identified 64 “true” 
hits.  Thus, we chose to screen the same database in silico using QSAR models as predictors. 
Only QSAR models that passed both internal and external validation tests were used. For 
each model we retained its parameters established in the process of external validation, i.e., 
the number of nearest neighbors k, selected descriptors, and Zcutoff value for the applicability 
domain. 
2.1b.3  Results and Discussions 
2.1b.3.1 k-NN Binary Classification Models 
As shown in Figure 2.1b.2, the kNN QSAR method with variable selection afforded 
multiple models with optimal accuracy characterized as CCR for both training and test sets. 
In total, there were 3305 models with both CCRtrain and CCRtest equal or higher than 0.70. 
Most models with CCRtest  ≥ 0.70 also had corresponding CCRtrain ≥ 0.70, but the opposite 
was not always true. The models with high values of both CCRtrain and CCRtest (≥ 0.70) were 
considered acceptable. 342 predictive models with the highest values of CCR (CCRtrain and 
CCRtest >= 0.90, red dots in Figure 2.1b.2) were selected for consensus prediction. Table 
2.1b.1 summarizes the detailed confusion matrix and statistical parameters for the best kNN 
binary classification models. The CCRtrain and CCRtest were found to be as high as 0.91 and 
1.00, respectively, which implies that the models could identify correctly all 18 nonbinders 
and 9 out of 11 inhibitors (SE = 0.82, SP = 1.00, EN(1) = 2.00, and EN(0) = 1.69) in the 
training set and all binders and non-binders in the test set. This remarkably high internal 
accuracy and the large number of acceptable models imply that the kNN classification 
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method was generally successful in correctly distinguishing binders vs. decoys using 
MolConnZ chemical descriptors of compounds only. 
2.1b.3.2 QSAR Model Validations 
In addition to the internal validation of kNN models using test sets, Y-randomization 
and external validation are the critical steps of the entire QSAR workflow (Figure 2.1b.1). 
Only models that have been validated by these two steps can be utilized for external 
prediction and database mining 19. 
Y-randomization Test  
In Y-randomization test, the binary annotations of AmpC beta-lactamase as inhibitors 
or non-binders were randomly shuffled and kNN classification models were built with the 
same parameter setting. The test was performed twice and both runs of Y-randomization tests 
showed that there were relatively small numbers of 330 and 429 models having both CCRtrain 
and CCRtest higher than 0.70. However, there were no models with both CCR value higher 
than 0.90. It implied that the kNN models obtained with real binding affinities and CCR 
greater than 0.90 are robust. 
External Validation  
Two datasets were employed for external validation, i.e. the 10 compounds randomly 
excluded from modeling sets and 50 non-binders, which were relatively dissimilar in their 
structure from the 21 inhibitors in the original dataset. Consensus predictions were carried 
out using 342 predictive models with CCRtrain and CCRtest greater than 0.9 under different Z 
value cutoffs (Z = 0.5 ~ 3.0, Table 2.1b.2). The prediction accuracy for the 10-compound 
external validation set was 100% for both 5 inhibitors and 5 non-binders under Zcutoff = 0.5, 
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leading to CCR = 1.00, SE = 1.00, SP = 1.00, EN(1) = 2.00, and EN(0) = 2.00. The accuracy 
of prediction for 50 non-binders was also high, ranging from CCR = 0.87 under Zcutoff = 0.5 
to CCR = 0.86 under Zcutoff = 3.0 (Table 2.1b.2). Because of the applicability domain 
inherent to individual kNN QSAR models, the consensus prediction usually can not cover the 
whole dataset. By increasing the Zcutoff from 0.5 to 3.0, the prediction coverage for 50 non-
binders increased from 94% to 98% whereas the prediction accuracy decreased. Figure 
2.1b.3 shows the consensus scores and the coverage of predictive models for each of the 50 
non-binders. The consensus score, in terms of the average class number in classification 
QSAR, was calculated by the fraction of models that predicted a compound as non-binder 
over the total number of models used for prediction plus 1. Under Zcutoff = 0.5, six falsely 
predicted inhibitors (average class number < 1.5) were within the applicability domain of 
only 70 models (i.e., approximately 20% of all models), i.e., the model coverage was as low 
as 20%. In general, the prediction with such a low coverage is viewed as of low confidence 
level. The higher Zcutoff significantly raised the model coverage for both inhibitor and non-
binder prediction because of the extended applicability domain for individual models. In 
Figures 2.1b.3B and 2.1b.3C, the model coverage for predicting inhibitors jumped up to 
53% for Zcutoff = 1.5 and up to 94% for Zcutoff = 3.0. However, the prediction with extended 
applicability domain for consensus models also comes with lower confidence level. 
Generally speaking, in order to have the reliable and accurate prediction, one has to have the 
broader model coverage and a smaller Zcutoff value. 
In summary, 342 models with both CCRtrain and CCRtest equal to or greater than 0.90 
could be applied for consensus prediction and database mining. The models chosen for the 
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prediction had relatively small Zcutoff (= 0.5) and relatively broad coverage for compounds in 
external datasets (>= 50%). 
2.1b.3.3 External Prediction 
We used models built from 41 AmpC inhibitor/nonbinder dataset to verify the 64 
"actives" from AID 584 and AID 585 screening. Under Zcutoff = 0.5, we could only generate 
predictions for 25 compounds out of 64 "actives" whereas the remaining compounds were 
found to be outside of the applicability domain. As shown in Table 2.1b.2, five out of these 
25 compounds were predicted as true inhibitors. However, the predictions were based on 
only two models (out of 342 models with both CCRtrain and CCRtest higher than 0.90, cf. 
Figure 2.1b.4A). Thus, the coverage for both compounds and consensus models was 
extremely low and as a result these predictions should not be viewed as reliable. Even under 
higher Zcutoff = 3.0, the model coverage was still low such that "actives" were predicted by 
only 110 models (32% of all models, cf. Figure 2.1b.4C). Furthermore, the formal prediction 
accuracy (assuming that the 64 hits were true inhibitors) was extremely low, e.g. CCR = 0.20 
(Zcutoff = 0.5), CCR = 0.10 (Zcutoff = 1.5) and CCR = 0.15 (Zcutoff = 3.0) (Table 2.1b.2). Thus, 
based on our modeling results none of the 64 compounds in the NCGC set was predicted 
reliably as a non-covalent and reversible inhibitor. 
Notably, the independent experimental verification of those 64 "actives" hits appears 
to confirm the results of our consensus prediction based on recent results obtained in Dr. B. 
Shoichet’s lab. These studies 122 have shown that 25 of these active compounds are beta-
lactam-based irreversible inhibitors of beta-lactamase. Five to ten additional actives are 
believed to be aggregators. The data on the remaining 35 compounds have not been 
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confirmed yet but preliminary data indicate that none of them act as true reversible inhibitors 
of beta-lactamase (Dr. Shoichet, personal communications). These recent results confirm that 
our models are both accurate and robust. 
2.1b.3.4 Descriptor Interpretation 
A summary of descriptors ranked as top 20 based on their frequency of occurrences in 
342 consensus models are given in Table 2.1b.3. The frequency of occurrence is defined as 
percentage of models where a descriptor is present. For instance, the highest frequency of 
32.2% means that a particular descriptor type occurs in about 110 out of the total of 342 
models. The descriptor class and the structural illustration of individual descriptor types are 
shown in this Table as well. It should be noted that molecular connectivity descriptors are 
predominant in all models, i.e., over 50% of descriptors in 20 top-ranked most frequent 
descriptor types belong to this class. The remaining descriptor types are mostly related to 
class of electrotopological state (E-state) indices which reflect the electronic environment of 
each atom due to its intrinsic electronic properties and the influence of other atoms in the 
molecule. By mapping the frequent descriptors to the inhibitors and non-binders in the 
dataset, the sulfonamide group was found to be a common feature in both inhibitors and non-
binders. Importantly, all the nitrile groups could only be found in the structure of non-binders. 
Thus, conventional structure based scoring functions appear to be insensitive to (the presence 
or absence of) this group in chemical structures. This result illustrates a potential power of 
QSAR models in informing conventional scoring functions of their possible deficiencies that 
probably could be corrected with ease. 
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2.1b.3.5 Virtual Screening Using Predictive QSAR Models 
Instead of using only one single and best model for virtual screening, the consensus 
prediction approach was applied that relies on averaging predictions from all qualified 
models, i.e. 342 models with both CCRtrain and CCRtest equal to or greater than 0.90. The 
complete modeling set (i.e., including training and test sets) was used for the prediction using 
each model as opposed to using only the corresponding training set. Initially, as many as 
4565 compounds in the NCGC dataset of 69653 compounds were predicted as inhibitors by 
at least one of 342 models. To narrow the hit list and obtain the higher confidence level for 
each prediction, we took both the consensus score (average class number) and model 
coverage into account. In particular, only the hits with average class number between 1.0 and 
1.2 and the model coverage over 50% (171 out of 342 models) were selected (Figure 2.1b.5). 
Furthermore, we restricted ourselves to the most conservative applicability domain for each 
model using Zcutoff = 0.5. We found that there were only 15 compounds that satisfied both 
criteria (Table 2.1b.4). 
We have clustered these 15 compounds together with 16 competitive inhibitors from 
the training set using tools available in PubChem 143. Each compound was represented by a 
fingerprint of 881 substructure keys, indicating the presence or absence of a particular 
chemical substructure. The pairwise similarity between compounds was measured by the 
Tanimoto coefficients (TC), which were used for hierarchical clustering of hits. The most 
chemically different pair of structures had TC = 0.522 (Figure 2.1b.6). Several structural 
classes were observed depending on the TC thresholds, e.g. there were four clusters at TC = 
0.70. Notably, many of the 15 computational hits were found to be structurally similar to 
inhibitors used in model building. There were five hits that were highly similar (TC >= 0.90; 
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CID: 39854, 665205, 699751, 793725 and 699907) to the competitive inhibitor 11771345. 
More often than not, hit compound 647810 was in close proximity to inhibitor 11347033 
with the Tanimoto coefficients over 0.90. Several computational hits were selected for the 
experimental validation in Dr. Shoichet’s laboratory as potential AmpC beta-lactamase 
inhibitors. 
We should emphasize that our model validation is a critical inherent feature of our 
QSAR modeling workflow. This issue of model validation has been given a lot of attention 
by the QSAR research community 144. Until recently, most practitioners merely presumed 
that internally cross-validated models built from available training set data should be 
externally predictive. We and others have demonstrated that internal validation techniques 
such as leave-one-out (LOO) or even leave-many-out (LMO) cross-validation applied to the 
training set is insufficient to ensure the external predictive power of QSAR models 18, 19. 
Thus, we used two external validation sets in this study as well as the Y-randomization test to 
ensure the robustness and predictive power of kNN models. Needless to say, the use of 
externally validated models and applicability domains is especially critical when the models 
are employed in virtual screening. 
Another important feature of many current biomolecular datasets, especially 
generated as a results of HTS campaigns is the imbalance between “actives” and “inactives”, 
obviously in favor of inactives. For example, the hit rates in assays deposited in PubChem by 
the NIH screening centers forming the Molecular Library Screening Center Network 
(MLSCN) are very low, in most cases not exceeding 0.5% 145. The imbalanced datasets pose 
a significant problem for classification QSAR modeling because models that predict 
correctly the same fraction of objects in each class will have different objective function 
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values. To circumvent this problem in this study, we conducted the similarity search between 
the members of the underrepresented class (inhibitors) vs. another one (non-binders). A 
subset of the original dataset that was relatively balanced (2:3) was formed and utilized for 
model building. The 50 non-binders that were less similar to binders were retained as one of 
the external validation datasets. The classification models built for the balanced subset were 
shown to predict compounds in this external dataset as non-binders with very high accuracy. 
Among the 47 non-binders (3 were outside of the applicability domain), 41 were accurately 
annotated by consensus prediction (CCR = 0.87, cf. Table 2.1b.2). The success of this 
strategy suggests that it could be applied to the analysis of many imbalanced datasets. 
2.1b.3.6 Experimental Validation 
Of the 15 computational hits from mining the NCGC AmpC screening library, five 
compounds were selected based on their chemical similarity (measured by Euclidean 
distance in the MZ descriptor space) to the 21 inhibitors and commercial availability. We 
should stress that binary QSAR models were used for prediction so no quantitative estimate 
of binding affinity could be made. All five hits (CID: 647810, 665205, 699751, 699907 and 
2980565; Table 2.1b.4) did show the inhibitory activities at millimolar level at the single 
concentration. Among them, compound 699751 had the highest inhibitory activity at 0.7 mM. 
For this compound, a full dose-response curve was obtained and the inhibition constant, Ki, 
was calculated by the Cheng-Prusoff equation using the IC50 and Kd, the dissociation 
constant of AmpC for the substrate measured in a separate assay. Thus, compound 699751 
yielded the Ki and Kd value of 135 and 18 M, respectively (Figure 2.1b.7). In summary, 
the above results did prove the predictive power of our binary kNN classification QSAR 
models built for AmpC beta-lactamase inhibitors. These studies illustrate that the validated 
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QSAR workflow, as employed in this paper, could be used as a general tool for identifying 
promising hits by the means of virtual screening of chemical libraries. 
2.1b.4  Conclusions 
Our studies demonstrate that binary kNN classification QSAR models built with 
MolconnZ descriptors can accurately differentiate true AmpC beta-lactamase inhibitors from 
non-binding decoys. A special QSAR modeling scheme was employed for this imbalanced 
dataset and the models were rigorously validated using both internal (multiple training/test 
set divisions and Y-randomization) as well as external (two external validation sets) 
validation approaches. We have demonstrated that this strategy afforded multiple QSAR 
models with high internal and external predictive power. As part of our QSAR modeling 
workflow, the predictors were further utilized for mining the NCGC dataset (69653 
compounds tested for AmpC beta-lactamase binding). We found that our validated models 
disagreed with the experimental annotation of 64 compounds as AmpC binders as reported in 
PubChem BioAssays AID584 123 and AID585 124. Interestingly, our negative predictions for 
these compounds appear to be in agreement with the preliminary results of the confirmatory 
secondary assays conducted in B. Shoichet’s lab (B. Shoichet, personal communications). On 
the other hand, our models used in the most conservative way (i.e., in consensus fashion and 
with the strictest applicability domain criteria) did identify 15 putative AmpC inhibitors 
among compounds annotated as experimental non-binders in the NCGC assays reported in 
PubChem. Five of them showed inhibition activities at the millimolar concentration, and one 
compound (compound 699751) was found to have the highest Ki of 135M. The results of 
our studies suggest that at least in some cases when a sufficient amount of data on true 
binders vs. nonbinding compounds is available simple QSAR modeling approaches could be 
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used successfully to complement (and possibly educate based on QSAR model interpretation) 
the conventional scoring functions used in three-dimensional docking studies. Furthermore, 
as we have demonstrated in this paper, QSAR models can be successfully used not only to 
discriminate binders vs. binding decoys but most importantly, for finding promising hits by 
the means of virtual screening of chemical libraries. 
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Figures for Chapter 2.1b  
 
Figure 2.1b.1: The workflow of QSAR model building, validation, and virtual screening as 
applied to the AmpC beta-lactamase dataset of 21 inhibitors and 80 non-binding decoys. 
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Figure 2.1b.2: The plot of kNN classification QSAR model accuracy for test (CCRtest) vs. 
training (CCRtrain) sets for AmpC beta-lactamase dataset. 
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Figure 2.1b.3: The consensus scores and the coverage of predictive models for the 50 non-
binding decoys dissimilar to the modeling dataset.  
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Three Z cutoff values were used: A. Zcutoff = 0.5; B. Zcutoff = 1.5; C. Zcutoff = 3.0. 
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Figure 2.1b.4: The consensus scores and the coverage of predictive models for the 64 HTS 
hits identified from the primary HTS screening assays reported in PubChem.  
Three Z cutoff values were used: A. Zcutoff = 0.5; B. Zcutoff = 1.5; C. Zcutoff = 3.0. 
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Figure 2.1b.5: The consensus scores and the coverage of predictive models for the mining 
hits in the NCGC database (Zcutoff = 0.5). 
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Figure 2.1b.6: The structural clustering of 15 mining hits from NCGC database combined 
with 16 AmpC beta-lactamase competitive inhibitors (underlined) based on the Tanimoto 
score.  
The computations were carried out at the PubChem server. 
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Figure 2.1b.7: The full dose response curve for compound 699751.  
The experimental studies were conducted in B. Shoichet’s laboratory. 
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Tables for Chapter 2.1b 
Table 2.1b.1: Ten best kNN QSAR classification models with highest CCR values for all test 
sets using Molconnz descriptors. 
Model 
No. 
Nearest 
Neighbors 
No. 
 
CCRtrain 
Confusion Matrix  Statistics for the Models 
N(1) N(2) TP TN FP FN  SE SP EN(1) EN(2) CCRtest 
1 5 0.91 11 18 9 18 0 2  0.82 1.00 2.00 1.69 1.00 
2 5 0.90 10 18 8 18 0 2  0.80 1.00 2.00 1.67 1.00 
3 1 0.97 11 18 11 17 1 0  1.00 0.94 1.89 2.00 1.00 
4 5 0.91 11 16 9 16 0 2  0.82 1.00 2.00 1.69 0.94 
5 4 0.92 11 16 10 15 1 1  0.91 0.94 1.87 1.82 0.94 
6 4 0.92 9 19 8 18 1 1  0.89 0.95 1.89 1.79 0.93 
7 1 0.94 10 18 10 16 2 0  1.00 0.89 1.80 2.00 0.93 
8 5 0.92 10 19 9 17 1 1  0.90 0.89 1.89 1.80 0.92 
9 5 0.92 9 19 8 18 1 1  0.89 0.95 1.89 1.79 0.92 
10 5 0.90 10 17 8 17 0 2  0.80 1.00 2.00 1.67 0.92 
               
N(1) = number of inhibitors, N(2) = number of non-binders, TP = true positive (inhibitors 
predicted as inhibitors), FP = false positives (non-binders predicted as inhibitors), FN = false 
negatives (inhibitors predicted as non-binders), TN = true negative (non-binders predicted as 
non-binders), SE = sensitivity = TP/N(1), SP = specificity = TN/N(2), EN - the normalized 
enrichment, EN(1) = (2TP * N(2))/(TP * N(2) + FP * N(1)), EN(2) = (2TN * N(1))/(TN * 
N(1) + FN * N(2)), and CCR = correct classification rate. 
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Table 2.1b.2: Consensus predictions under different Z value cutoffs for two external 
validation sets, the randomly-excluded 10 compounds from modeling sets and 50 non-
binders which were dissimilar in structure to 21 inhibitors in the original dataset. 
 
External 
Validation 
Sets 
Zcutoff 
Prediction 
CCR 
Confusion Matrix  Statistics 
N(1)a N(2)a TP TN FP FN  SE SP EN(1) EN(2) 
10 randomly-excluded 
 compounds 0.5 1.00 5 5 5 5 0 0  1.00 1.00 2.00 2.00 
 0.5 0.87 0 47 0 41 6 0  N/A 0.87 N/A N/A 
50 non-binders 1.5 0.87 0 47 0 41 6 0  N/A 0.87 N/A N/A 
 3.0 0.86 0 49 0 42 7 0  N/A 0.86 N/A N/A 
 0.5 0.20 25 0 5 0 0 20  0.20 N/A N/A N/A 
64 HTS ‘hits’ 1.5 0.10 41 0 4 0 0 37  0.10 N/A N/A N/A 
 3.0 0.15 55 0 8 0 0 47  0.15 N/A N/A N/A 
              
N(1) = number of inhibitors, N(2) = number of non-binders, TP = true positive (inhibitors 
predicted as inhibitors), FP = false positives (non-binders predicted as inhibitors), FN = false 
negatives (inhibitors predicted as non-binders), TN = true negative (non-binders predicted as 
non-binders), SE = sensitivity = TP/N(1), SP = specificity = TN/N(2), EN - the normalized 
enrichment, EN(1) = (2TP * N(2))/(TP * N(2) + FP * N(1)), EN(2) = (2TN * N(1))/(TN * 
N(1) + FN * N(2)), and CCR = correct classification rate. 
aMany N(1) inhibitors of 64 HTS ‘hits’ and N(2) non-binders of 50 non-binders were out of 
application domain of all consensus models, thus having no prediction. Only data for 
compounds found within the AD were used for statistical summaries. 
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Table 2.1b.3: The 20 most frequent MolConnZ descriptors found in acceptable kNN QSAR 
models. 
Ran
ka 
Descriptor 
ID 
Frequenc
yb Descriptor Class Illustration 
1 nHCsatu 32.2 atom-type counts CHn (unsaturated) 
2 Hsulfonami
de 
28.4 group-type Hydrogen E-State values S
O
O N
 
3 nnitrile 27.5 group-type counts C N
 
4 Hmin 27.2 minimum H E-State  
5 naaO 26.3 atom-type counts :O: (aromatic) 
6 naaS 26.3 atom-type counts aSa (aromatic) 
7 SaaCH 26.0 atom-type EState sums :CH: 
8 n3Pad24 26.0 vertex alpha-delta counts  
9 SssCH2 26.0 atom-type EState sums -CH2- 
10 SHBint5 25.4 internal H-Bond counts and EStates  
11 Xvch5 24.3 valence cluster/chain Chi indices  
12 n2Pag23 24.3 vertex alpha-gamma counts  
13 IDW 24.0 Bonchev-Trinajstic information indices  
14 htets2 23.7 total topological state indices based on H E-State indices  
15 nimine 23.7 group-type counts C
N
 
16 ndsCH 23.4 atom-type counts =CH- 
17 IDC 23.4 Bonchev-Trinajstic information indices  
18 tets3 23.1 total topological state indices based on E-State indices  
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19 n3Pad13 23.1 vertex alpha-delta counts  
20 nhydrazine 22.8 group-type counts N N
 
a
 kNN rank is based on the frequency of each descriptor occurred. 
b
 Frequency is the number of times each descriptor occurred in 342 validated models. 
 
 
 
 
Table 2.1b.4: The fifteen computational hits predicted as AmpC beta-lactamase inhibitors as 
a result of mining the NCGC AmpC screening library. 
Structure Serial No. 
PubCh
em 
CID 
No. of 
models  
predicted 
as 
inhibitor 
No. of 
models  
predicte
d as 
non-
binder 
No. of 
models 
in 
predicti
on 
Avera
ge  
class 
num. 
Exp. 
IC50 
 
(mM)a 
 
1 5315 213 2 215 1.01 Unknow
n 
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2 39854 186 20 206 1.10 Unknow
n 
 
3 573009 190 40 230 1.17 Unknow
n 
 
4 647810 193 43 236 1.18 3.0 
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5 661093 172 22 194 1.11 Unknow
n 
 
6 665205 171 8 179 1.04 9.0 
 
7 699751 189 29 218 1.13 0.7b 
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8 699907 184 6 190 1.03 1.8 
 
9 713179 169 16 185 1.09 Unknow
n 
 
10 793725 168 25 193 1.13 Unknow
n 
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11 843845 152 31 183 1.17 Unknow
n 
 
12 970871 183 25 208 1.12 Unknow
n 
 
13 2980565 190 28 218 1.13 7.0 
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14 2998088 160 22 182 1.12 
Unknow
n 
 
15 3240498 148 35 183 1.19 
Unknow
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Chapter 3 Development of Quantitative Structure-Binding Affinity Relationship 
Models (QSBAR) Using Protein-Ligand Interface Descriptors Based on Conceptual 
Density Function Theory (DFT) and the Application to Community Structural-
Activity Resources (CSAR) Data Sets  
3.1 Introduction 
Predicting binding affinity of protein-ligand complexes, either relative or absolute, 
plays an essential role in structure-based drug design/discovery. In all structure-based 
drug design methods, if the experimental protein-ligand structural information is 
unknown, docking and scoring functions are applied jointly to generate putative poses for 
binding affinity prediction. Since 1980s, many scoring functions have been developed 
and been critically assessed recently.60, 146, 147 These studies demonstrate that correctly 
predicting binding affinity of compounds by traditional docking/scoring functions is still 
fairly challenging. The squared correlation coefficient (R2) between experimental and 
predicted binding affinities of several popular scoring functions is in the range of 0.3 to 
0.4 when predicting binding affinity of static x-ray structures,60 not even to mention the 
R2 value when conducting cross-docking calculations where protein induced-fit effects 
are encountered. The result suggests that, for other than some computationally intensive 
approaches (e.g., free energy perturbation148 or linear interaction energy58) recently being 
developed for target-specific lead optimization in structure-based drug design,58, 59 the 
improvement of current scoring functions for generic high-throughput molecular docking 
is also needed.  
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In general, scoring functions can be divided into three major classes:27 force-field-
based, empirical, and knowledge-based methods. The force-field-based scoring function 
relies on explicitly computed electrostatic and van der Waals interaction energies (i.e., 
enthalpic effects) between the ligand and the protein based on a molecular force field. 
The empirical scoring function is defined as the sum of individual uncorrelated energy 
terms whose coefficients are optimized from regression analysis by fitting the 
experimental data such as binding energies/affinities. The knowledge-based scoring 
function is designed based on various statistical parameters derived from x-ray crystal 
structures that could reflect the interactions between a ligand and its receptor depending 
on their molecular environment. Compared with force-field-based and empirical scoring 
functions, knowledge-based scoring functions could implicitly capture the binding effects 
that are difficult to model and specify (e.g., entropy and solvation) by analyzing the 
statistics of atomic contacts based on a large number of experimentally determined 
protein-ligand structures.  However, the score from knowledge-based scoring functions 
usually corresponds to the sums of pair interactions or other binding effects, which are 
indirectly associated with the absolute binding affinity.   
The tuning of above scoring functions relies on the availability of structural 
information of protein-ligand complexes. In contrast, typical cheminformatics approaches 
(e.g., QSAR modeling) usually do not require the protein-ligand structural information 
and absolute binding affinity of ligands can be predicted as a function of their chemical 
descriptors. Recently, a hybrid scoring function incorporating cheminformatics concepts 
into conventional scoring functions was developed in our lab.16 This scoring function 
consists of quantitative structure-binding affinity relationship (QSBAR) models derived 
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from 264 x-ray protein-ligand complexes (the old ENTess data set) with known binding 
affinity using novel protein-ligand interfacial geometrical properties, called ENTess 
descriptors. The ENTess descriptors are generated based on the tetrahedra resulting from 
Delaunay tessellation (Tess), characterizing the protein-ligand interface by means of 
Pauling electronegativity (EN) values. The output of ENTess scoring function can be 
directly related to absolute binding affinities and can implicitly take into account binding 
effects that are difficult to specify, combining the merit of both empirical and knowledge-
based scoring function. However, the performance of ENTess scoring function in 
practical virtual screening is limited (data not shown). One of the possible reasons could 
be the limitation in applicability domain of ENTess models. In the following study, we 
report the study managing to improve the ENTess scoring function.  
Taking the advantage of rapidly increasing number of x-ray protein-ligand 
complexes with experimentally determined binding affinity, firstly we extend the 
previous study by including large number of structurally diverse protein-ligand 
complexes into model building and validation. Those high-quality complexes for 
modeling are acquired from PDBbind database149, 150 and Community Structural-Activity 
Resources (CSAR),151 both of which are public available. Secondly, we also incorporate 
theoretically more rigorous values (i.e., conceptual DFT atomic properties152) as well as 
protein-ligand pairwise distances within interfacial tetrahedra into descriptor generation. 
Finally, in addition to the applicability domain of respective eligible models, i.e., model 
applicability domain, we only predict the protein-ligand complexes which are similar to 
the complexes of the modeling set in the entire descriptor space (i.e., those within global 
applicability domain).   
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With above strategies, we predict the binding affinity of x-ray protein-ligand 
complexes from two data sets (Set1 and Set2) provided in the 2010 CSAR exercise. 
CSAR 2010 exercise has involved researchers developing their various scoring 
methodologies in the hope of improving current scoring methods. We achieve 
comparable prediction accuracy (R2: 0.57) to the best in the CSAR exercise (R2: 0.58 by 
July 2010) using the updated QSBAR models.  
3.2 Methods 
3.2.1 Data Sets 
PDBbind version 2007 
We employ the x-ray protein-ligand complexes as well as their ligands’ binding 
affinity (BA) data collected from PDBbind (version 2007) database in our QSBAR study. 
PDBbind database149, 150 is a collection of x-ray protein-ligand complexes with 
experimentally measured binding affinity data (IC50, Ki, or Kd). In total, there are 3124 
complexes (a.k.a. the “general” set) included in the version 2007 of PDBbind database. 
From the complexes of the general set, 1300 complexes are culled to form the “refined” 
set considered as high-quality (e.g., resolution ≥ 2.5Å, non-covalent protein-ligand 
binding, and experimentally determined Ki or Kd values). The BLAST sequence 
clustering using 90% similarity threshold is conducted on 1300 protein sequences of 
refined set, resulting in 70 clusters (families). Three representative complexes with 
highest, medium, and lowest BA from each of the 70 clusters are collected to form the 
“core” set. The core set is designed to provide a diverse and non-redundant sampling of 
the refined set. The relationships between general set, refined set, and core set are 
presented in Figure 3.1. 
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The proteins in the core set are employed as probes to search for the structurally 
similar proteins in the refined set in order to construct a new QSBAR modeling set with 
increased size and diversity (compared with the old data set of 264 protein-ligand 
complexes, see Introduction). For each protein binding site in the refined set, the protein 
descriptors153 are calculated and the similarity threshold is defined using Euclidean 
distance in the protein descriptor space (i.e., threshold = <d> + 0.5σ, where σ is the 
standard deviation and <d> is the average of distances between each data point in the 
core set and its nearest data point in the refined set). In total, 455 complexes with protein 
binding sites similar to those of query proteins are selected, along with 210 complexes in 
the core set, forming our new data set for QSBAR modeling (665 complexes). The BA 
range of these 665 complexes is from 1.36 (1qpb.pdb) to 13.96 (7cpa.pdb) and the 
number of protein families based on 90% sequence similarity clustering is 101 clusters. 
The new data set is almost three fold larger than the old data set and has more families 
(101 versus 83). The comparison between old and new data set is shown in Table 3.1. 
In the 2010 CSAR exercise, the researchers are asked to predict the binding 
affinity of protein-ligand complexes in Set1 and Set2 using their own scoring methods 
which are trained without CSAR data sets or can be tuned based on either of Set1 or Set2 
data set.  
3.2.2  Protein-ligand Interfacial Descriptors 
ENTess descriptors 
The ENTess chemical geometrical descriptors are obtained by combining Pauling 
electronegativity (EN) as atomic property and Delaunay Tessellation (Tess) to 
characterize the protein-ligand interface as follows.  When applied to protein-ligand 
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complexes represented at the atomic resolution level, Delaunay tessellation partitions the 
protein ligand interface into an aggregate of space-filling, irregular tetrahedra, with both 
protein and ligand atoms as vertices (see also Figure 3.3).  Each Delaunay quadruplet is 
characterized by its unique four-atom composition, which defines the descriptor type 
(certainly, the same four-body compositions may occur in different, or even the same, 
protein/ligand interfaces).   Furthermore, for each quadruplet we calculate the sum of EN 
values of the composing atom-vertices, which produces the descriptor value. 
PL/MCT descriptors 
The PL/MCT descriptors are methodologically similar to ENTess descriptors but 
are theoretically more rigorous.154 This is because these new descriptors employ pairwise 
atomic potentials for the protein-ligand (PL) complexes based on maximal charge 
transfer (MCT) derived from conceptual Density Function Theory (DFT)152 in place of 
Pauling EN, called here PL/MCT.  Compared to Pauling EN empirical scales, the 
conceptual DFT can evaluate chemical properties of different chemical species (e.g., 
atoms, functional groups, and molecules) systematically.154 The PL/MCT value is 
calculated from the following equation (Equation 3.1): 
kpll
n
1k
3~1
p
3~1
l
pm )MCT*(MCTPL/MCT d∑∑∑
=
=
          (3.1) 
where PL/MCTm is the potential of the m-th tetrahedron type (i.e. individual descriptor 
type); n is the number of occurrences of this tetrahedron type in a given pose; p is the 
vertex index of a protein atom, l is the vertex index of a ligand atom, and dpl is the 
distance between a pair of protein and ligand atoms found in the same Delaunay 
tetrahedron. (Note that Delaunay tetrahedra at the protein-ligand interface can be 
classified based on the relative content of protein and ligand atoms, i.e., three protein and 
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one ligand atoms, two from each, or one protein and three ligand atoms; this explains the 
tetrahedral type counts in the second and third sum in Eq. 3.1). 
The MCT characterizes the maximal electron flow between the donor and 
acceptor atoms at the protein-ligand interface. It is derived from the conceptual DFT,152, 
155
 which provides a theoretical basis for calculating the PL/MCT descriptors. The MCT 
is calculated as follows, assuming that the total energy of the system is perturbed by the 
charge transfer up to the second order: 
∆E = µ∆N + 1/2η∆N2                                                     (3.2) 
where ∆E and ∆N represent energy change and charge transfer, respectively. When the 
total energy is minimized with respect to the charge transfer, d∆E/d∆N = 0, we have 
∆Nmax = - µ/η  ≡ MCT                                                           (3.3) 
where µ and η are the chemical potential (negative of electronegativity) and the chemical 
hardness respectively, defined by µ = (∂E/∂N)ν and η = (∂2E/∂2N)ν with ν representing the 
external potential formed by the framework of atomic nuclei. 
Occurrence Descriptors  
The occurrences of tetrahedral descriptor types at the interface, which are 
fundamental for calculation of ENTess and PL/MCT descriptors, can be also 
independently employed as descriptor values in QSBAR modeling.  
Combination of ENTess and PL/MCT descriptors 
Since the Pauling EN and MCT values represent chemical properties based on 
distinctive theories, it is sensible to test the modeling performance using the combined 
descriptor set. The combined descriptor set is constructed by concatenating the ENTess 
and the PL/MCT descriptor set.  We remove the descriptors in the combined descriptor 
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set which are with low variance (all, or all but one value is constant) and high correlation 
(if pair-wise square correlation coefficient is greater than 0.99, one of the pair, chosen 
randomly, is removed).  The remaining descriptors are range scaled (0 to 1). 
3.2.3  k-Nearest Neighbors (k-NN) QSBAR Modeling 
Phase I 
The five-fold external validation technique is applied in the QSBAR modeling. 
The 665 QSBAR modeling data set is divided, by random selection, into five nearly equal 
subsets (133 complexes). By turns, one out of five subsets is used solely as the external 
validation set and the remainder (4/5, 532 complexes) is used for training by the kNN 
algorithm with different descriptor sets. Moreover, the previously excluded complexes of 
the refined set (635 complexes), whose protein binding sites are dissimilar to the ones in 
the core set, are retained as an additional external validation set (Figure 3.4A).  
In addition, the CSAR data sets are utilized as another external validation set for 
those models that perform best in five-fold external validation. Since many complexes in 
CSAR data sets have been included in the PDBbind modeling set, their predictions are 
removed when calculating the prediction statistics.  
Phase II 
In the second stage of model building, we build models using either Set1 or Set2 
data set with the descriptor set, which performs best in the five-fold external validation of 
Phase I. Then we use the respective models to predict either Set2 or Set1 data set.  N-fold 
external validation technique is also applied except that instead of five-fold validation, 
ten-fold (Set1) and nine-fold (Set2) are used due to the smaller size of data sets (Figure 
3.4B).  
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Phase III 
Finally, the PDBbind modeling set is combined with either Set1 or Set2 data set 
to have a composite modeling set. The resulting models validated by the five-fold 
external validation technique are employed to predict Set2 or Set1 data set respectively 
(Figure 3.4C).  
 
3.2.4  k-NN Modeling Algorithm 
Initially, a subset of nvar (number of selected variables) descriptors is selected 
randomly.  The model developed with this set of descriptors is validated by leave-one-out 
(LOO) cross-validation, where each compound is eliminated from the training set and its 
biological activity is predicted as the weighted average activity of its k (k= 1 to 9) nearest 
neighbors in the subspace of nvar descriptors (Equation 3.4).  The weights of neighbors, 
wi, decrease with distance, thus closer neighbors contribute to the calculated activity 
more: 
∑
∑
=
== k
i
i
k
i
ii
pred
w
yw
y
1
1 ;   wi = exp(-di)         
(3.4) 
Here ypred is predicted activity; di , wi and yi are, respectively: Euclidean distance, weight 
and actual activity for the nearest neighbor i.  A genetic algorithm was used to optimize 
the variable selection (with population size of 500 solutions of nvar size from 5 to 50 
descriptors). 
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3.2.5 Validation of QSBAR Models  
As emphasized in the previous study, training-set-only modeling is insufficient to 
achieve models with validated predictive power. Thus, prior to kNN, the modeling set 
(532 complexes) is further subdivided into 20 training/test subsets using the sphere 
exclusion algorithm20, maximizing the diversity of both training and test sets.  The kNN 
QSBAR models are developed solely based on these training sets and the resulting 
models are validated through predicting the binding affinity of complexes in the 
respective test sets.  The statistical significance of QSBAR models is characterized by the 
following parameters: a) LOO cross-validated q2; b) square of the correlation coefficient 
R (R2) between the predicted and observed activities; c) coefficients of determination 
(predicted vs. observed activities R02, and observed vs. predicted activities R′02; d) slopes 
k and k′ of regression lines (predicted vs. observed activities, and observed vs. predicted 
activities) through the origin. 
The detailed discussion of these parameters has been provided in previous studies.20, 126  
Individual models are considered to have acceptable predictive power if  
q2 ≥ 0.5 and R2 ≥ 0.6 
otherwise they are discarded.  The ensemble of all models that pass the above criteria is 
then used for consensus prediction of compounds in an external validation set.  
Besides, the Mean Absolute Error (MAE) and Root Mean Square Error (RMSE) values 
are also used in evaluating the prediction results of five-fold external cross validation. 
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3.2.6 Applicability Domain 
Because kNN models interpolate activities from the nearest neighbor compounds 
in the relevant training sets, a similarity threshold (i.e., model applicability domain) 
should be introduced to avoid making predictions for compounds that differ substantially 
from the training set molecules. The similarity threshold is defined as follows:  
DT =  + Zσ      (3.5) 
Here,  is the average over Euclidean distances to k nearest neighbors of all 
compounds in the training set (where the value of k is the same as in predictive kNN 
QSBAR models), σ is the corresponding standard deviation of these Euclidean distances, 
and Z is an arbitrary parameter to control the significance level. Typically, we set Z to 0.5, 
which places the boundary for deciding whether a compound is within or outside of the 
applicability domain at one-half of the standard deviation.  It is important to notice that 
increasing the value of Z would increase the number of compounds in the external set 
that are considered within the applicability domain but could decrease the accuracy of 
prediction due to inclusion of dissimilar nearest neighbors.  Previous studies have 
demonstrated that model applicability domain is important in model building and should 
be universally applied during the prediction.18  
Moreover, we further introduce another similarity threshold to avoid making 
predictions for compounds that differ substantially from the modeling set compounds (i.e., 
global applicability domain). The definition of this similarity threshold is analogous to 
the one of model applicability domain except the average Euclidean distance ( ) and 
standard deviation (σ) are calculated by using one nearest neighbor of each compound 
within the modeling set in the entire descriptor space. 
y
y
y
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3.2.7 Stochastic Proximity Embedding  
The stochastic proximity embedding (SPE) algorithm intends to embed high-
dimensional data points into a low-dimensional space yet preserves the geodesic 
distances between the embedded data.156, 157 The classical algorithm for this task is 
principle component analysis (PCA). However, PCA can fail to provide accurate 
projection if its first few components do not cover enough of data variation, which is 
common when handling data sets with diverse chemical structures.  
For the SPE calculation, initial 2D coordinates are randomly assigned to each data 
point and then are refined by iteratively selecting pairs of data points and adjusting their 
coordinates based on their respective proximities in the original descriptor space. The 
calculation is carried out using the entire set of descriptors computed for the modeling set 
(e.g., Set1) and its respective external validation set (e.g., Set2). The SPE calculations are 
conducted by in-house Matlab (version 7.7.0)158 scripts.  
3.3  Results and Discussions 
3.3.1 Assessment of Protein-ligand Interfacial Descriptors Performance 
 The statistics of five-fold external validation results of PDBbind data set are 
presented in Table 3.2. These predictions are made by qualified models (q2 ≥ 0.5 and R2 
≥ 0.6) based on different sets of descriptors. Generally, the predictions of five-fold 
external sets using models built by ENTess or PL/MCT descriptors show only marginal 
improvement when compared with occurrence descriptors. In contrast, significant 
improvement of five-fold external predictions in all statistical metrics is observed using 
the models built with the combined descriptor set (ENTess + PL/MCT), demonstrating 
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the synergetic effect of ENTess and PL/MCT descriptors in model building. Then we 
apply all the models generated from five splits by different descriptor sets to predict 
binding affinity of complexes in the additional external validation set, whose protein 
binding sites are dissimilar to the core set. The prediction accuracy of this external set 
drops drastically yet the predictions from models built with the combined descriptor set 
are still slightly better than for other descriptor sets (Table 3.3). This result suggests that 
it should be possible to improve external prediction accuracy by removing complexes 
whose binding sites are dissimilar to the PDBbind modeling set. Since the models built 
by the combined descriptor set show better performances in predicting both five-fold 
external validation sets and the additional validation set, the combined descriptor set is 
employed in further Phase II and Phase III model building.  
3.3.2  Model Validation Using CSAR Data Sets  
The phase I models built with the combined descriptor set are also used to predict 
the CSAR data sets. However, since part of the CSAR data sets originates from the 
PDBbind database, many predictions cannot be considered as rigorous (i.e., the overlaps 
between the modeling set and the validation set) and are removed when calculating the 
prediction statistics. The results are shown in Table 3.5. The R2 for Set1 is somewhat 
better than for Set2 (0.48 versus 0.42) despite the fact that Set1 data set is more diverse in 
nature. Nevertheless, both sets’ predictions are much worse than the results of five-fold 
external validation using PDBbind modeling set.  
Since the CSAR exercise requires participants to submit valid predictions of all 
CSAR complexes for analysis, the Set1 and Set2 data set are re-predicted by models built 
from either Set2 or Set1 data set respectively (phase II in Figure 3.5). The results of 
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external n-fold cross validation from CSAR data set modeling are reported in Figure 
3.5A and Table 3.4. The average R2 is 0.45 for Set1 data set modeling and 0.53 for Set2 
data set modeling in external n-fold cross validation, in agreement with the fact that the 
number of activity outliers (usually called “activity cliffs”) in Set1 data set is larger than 
in Set2 data set (Figure 3.6). Then the validated Set1 or Set2 models are applied to 
predict Set2 and Set1 data set respectively (Table 3.5). Interestingly, the R2 of Set2 
prediction using Set1 models is significantly better than the one using PDBbind models 
(0.51 versus 0.42) even though there are more complexes employed in PDBbind model 
building. On the other hand, the R2 of Set1 data set prediction using Set2 models is much 
worse than the one using PDBbind models (0.40 versus 0.48).  
Neither PDBbind models nor CSAR models can have desirable prediction 
reliability for the CSAR data sets. Therefore, we manage to build the QSBAR models 
using the data set by combining the PDBbind data set with either Set1 or Set2 data set 
(phase III). The external cross validation results are reported in Figure 3.5B and Table 
3.4. The average R2 is 0.56 for PDBbind plus Set1 data set modeling and 0.59 for 
PDBbind plus Set2 data set modeling in external five-fold cross validation.  Then the 
validated models built on PDBbind plus Set1 and on PDBbind plus Set2 are applied to 
predict Set2 and Set1 respectively. The prediction of both Set1 and Set2 data sets shows 
improved statistics compared to previous results using PDBbind Phase I models or CSAR 
Phase II models (Table 3.5). The prediction accuracy (R2) can be as high as 0.50 for Set1 
(versus 0.48 by PDBbind models and 0.40 by Set2 models) and 0.53 for Set2 (versus 0.42 
by PDBbind models and 0.51 by Set1 models). We suspect the improvement might be 
due to including into the modeling set more complexes that are structurally similar to the 
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complexes in the external set as well as due to the decreased number of activity outliers 
in the modeling set (vide infra).  
3.3.3  Analysis of Nearest Neighbor Distribution of CSAR Data Sets 
We compare nearest neighbor (NN) distribution within Set1 (Set2) as an external 
set to the distribution of NNs between external and modeling sets, where modeling set 
can be Set2 (Set1) or PDBbind + Set2 (Set1). The results are shown in Figure 3.6, where 
we plot the pairwise nearest neighbor distances, adjusted based on the number of 
descriptors in the modeling set, versus pairwise binding affinity difference. The mean and 
standard deviation of nearest neighbor distances are calculated (mean.NN.dist and 
std.NN.dist.) and reported in Table 3.6.   
We have tried to analyze if the improvement of external prediction accuracy using 
models built from PDBbind plus Set2 (Set1) data set is due to the decreased number of 
activity outliers. We define activity outliers as the data points whose distance to the 
nearest neighbors is small while binding affinity difference is large (for example, see the 
green shaded area in Figure 3.6). An overview of Figure 3.6 shows that the nearest 
neighbor distribution of Set1 external validation set from the PDBbind plus Set2 
modeling set is more compact in comparison with the one from the Set2 modeling set, 
tending to include more structurally similar complexes and have fewer activity outliers. 
This agrees with the results that the external prediction R2 of Set1 data set by models 
built from PDBbind plus Set2 is better than by models built from Set2 alone (0.50 versus 
0.40). Regarding the nearest neighbor distribution of Set2 external validation set from the 
PDBbind plus Set1 modeling set, and from the Set1 modeling set, the difference in 
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number of activity outliers from two distributions is less obvious, which is in line with 
the smaller difference between external prediction accuracy (R2: 0.53 versus 0.51) 
3.3.4 The Effect of Applicability Domain  
The Applicability Domain (AD) defines the area of the descriptor space in which 
QSBAR models can predict the binding affinity of complexes more reliably. If a protein-
ligand complex has interfacial chemical geometry that is “too dissimilar” to that of all 
complexes in the modeling set (i.e., greater than the predefined similarity threshold, Z-
cutoff=0.5), we assume that we cannot predict its activity reliably. The model AD is 
universally applied, but the application of global AD is switched on and off during the 
prediction in order to study its impact. 
In Phase I modeling, after applying the global AD, no matter which descriptor set 
is used for constructing models, we observe consistent improvement of prediction 
accuracy in five-fold external validation (Table 3.2). However, the number of complexes 
that can be predicted (i.e., coverage) decreases after the application of global AD. The 
best average R2 across five folds is 0.68 (with global AD) in comparison with 0.63 (w/o 
global AD) by using models built with the combined descriptor set. Similarly, the 
prediction of those complexes with pockets dissimilar to the core set improves (e.g., from 
0.28 to 0.40) after applying the global AD (Table 3.3). 
When predicting the CSAR data sets, we also apply the global AD which is 
defined based on PDBbind data set, Set1/Set2 data set, or PDBbind plus Set1/Set2 data 
set (cf. Table 3.5).  A tangible improvement of R2 is observed for prediction of both sets 
using models built from either PDBbind data set (Set1: 0.48 to 0.53 and Set2: 0.42 to 
0.47) or PDBbind plus Set1/Set2 data set (Set1: 0.50 to 0.56 and Set2: 0.53 to 0.58). The 
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overall prediction accuracy is comparable (despite the lower coverage rate) to the best in 
CSAR exercise reported in July 2010. However, the global AD fails to improve the 
results when the predictions are made by using models built from either Set1 or Set2 data 
set.  
Since the global AD is defined using the average and standard deviation of 
nearest neighbor distances based on the entire descriptor space of the modeling set and is 
then applied to the external set to exclude complexes which are dissimilar to the 
modeling set, we would like to examine the relative distribution of external set and 
modeling set data points. Initially we applied the PCA analysis since it is the most 
popular approach to visualize relative distribution of data points in 3D space. However, 
only less than 30% of variance within the data set can be explained by the first three 
principle components (PC). Thus, PCA’s visualization is not representative. Instead, we 
employed the SPE method, which can preserve the intrinsic relationships of high-
dimensional data.  
As shown in the SPE plots (Figure 3.7), the data distribution of Set1 external set 
is much sparser in the Set2 descriptor space compared with the one in the PDBbind 
descriptor space or in the PDBbind plus Set2 descriptor space. Similarly, the data 
distribution of Set2 modeling set is sparser than the one of PDBbind or PDBbind plus 
Set2 modeling set (Figure 3.7A). Incidentally, the R2 of Set1 prediction using models 
built from Set2 drops from 0.4 to 0.3 after applying global AD. At the same time, there is 
significant R2 improvement of Set1 prediction, after applying global AD, using models 
built either from PDBbind data set (R2 from 0.48 to 0.53) or from PDBbind plus Set2 
(from 0.50 to 0.56). On the other hand, data distribution of Set2 in the Set1 descriptor 
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space is relatively sparse and applying global AD did not help improve the Set2 
prediction accuracy by models built on Set1 data set (from 0.51 to 0.50). However, a 
significant R2 improvement is seen after applying global AD when models built from 
PDBbind dataset (from 0.42 to 0.47) or from PDBbind plus Set1 (from 0.53 to 0.58) are 
used in prediction. This analysis might indicate the limitation of the current global AD 
definition as it seems to be sensitive to changes in data set distribution. 
3.4 Conclusions 
We have modified previous ENTess descriptors by incorporating theoretically 
more rigorous values (i.e., conceptual DFT atomic properties) as well as protein-ligand 
pairwise distances within tetrahedra into descriptor generation. We named the new 
descriptors as PL/MCT descriptors. Employing models built by PL/MCT descriptors in 
combination with ENTess descriptors, the prediction accuracy in five-fold external 
validation of PDBbind data set is much better than using models built by any single 
descriptor set. Furthermore, we applied this combined descriptor set to construct 
models to predict CSAR data sets. When predicting the CSAR data sets (Set1 or Set2), 
we got better prediction accuracy by using models built by data set including both 
PDBbind data set and CSAR data set (Set2 or Set1) than by using models built by 
either PDBbind data set or CSAR data set (Set1 or Set2) alone, indicating the model 
quality and applicability are improved. This improvement seems to be due to the 
inclusion of more complexes structurally similar to the prediction set as well as due to 
the decreased number of activity outliers. Moreover, although applying global 
applicability domain decreases the prediction coverage, it also can help to significantly 
improve the prediction accuracy in some cases. The overall R2 of external sets in CSAR 
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exercise can be as high as 0.57, which is comparable to the best in the CSAR exercise 
(R2 = 0.58, July 2010). However, we also demonstrate that applying global applicability 
domain (as it is defined in Methods) does not help or even deteriorate the prediction 
accuracy when the data distribution of external sets and/or modeling set is very sparse.
  
Figures for Chapter 3 
 
Figure 3.1: A brief introduction to the PDBbind v. 2007. 
(The graph was modified from
http://sw16.im.med.umich.edu/databases/pdbbind/pdfs/pdbbind_2007_intro.pdf
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Figure 3.2: The pKd distribution of CSAR data sets (A. Set1; B. Set2).  
The x-axis is the pKd value binned by 0.5 log value and the y-axis is the frequency of data 
points in the corresponding bin. 
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Figure 3.3: Illustration of the method to derive PL/MCT 
protein-ligand complex (3ER
The atom types for protein and ligand 
tetrahedron at the left corner, 
Ol and Nl are oxygen and nitrogen
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descriptors using 
T, the ER/antagonists benchmarking dataset).  
 are treated differently. For instance, for the 
Cp and Op are carbon and oxygen atoms from the protein while 
 atoms from the ligand. 
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Figure 3.4: The workflow of model building and validation using A) PDBbind data set; B) 
Set1 (solid line) or Set2 (dash-dotted line); C) PDBbind plus Set1 (solid line) or PDBbind 
plus Set2 (dash-dotted line). 
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PDBbind+CSAR 5-fold external prediction
+s
et1
_
de
fau
lt
+s
et1
_
w
_
glo
ba
lA
D
+s
et2
_
de
fau
lt
+s
et2
_
w
_
glo
ba
lA
D
0.45
0.50
0.55
0.60
0.65
0.70
0.75
R
2
PDBbind+CSAR 5-fold external prediction
+s
et1
_
de
fau
lt
+s
et1
_
w
_
glo
ba
lAD
+s
et2
_
de
fau
lt
+s
et2
_
w
_
glo
ba
lAD
0.8
0.9
1.0
1.1
1.2
1.3
M
AE
PDBbind+CSAR 5-fold external prediction
+s
et1
_
de
fau
lt
+s
et1
_
w
_
glo
ba
lAD
+s
et2
_
de
fau
lt
+s
et2
_
w
_
glo
ba
lAD
1.0
1.2
1.4
1.6
1.8
RM
SE
PDBbind+CSAR 5-fold external prediction
+s
et1
_
de
fau
lt
+s
et1
_
w
_
glo
ba
lA
D
+s
et2
_
de
fau
lt
+s
et2
_
w
_
glo
ba
lA
D
0.5
0.6
0.7
0.8
0.9
1.0
Co
ve
ra
ge
 
 
Figure 3.5: The statistics (R2, MAE, coverage, and RMSE; clockwise) of external n-fold 
validation sets using models built with A) Set1 (or Set2); B) PDBbind plus Set1 (or PDBbind 
plus Set2).  
The mean and  standard deviation of data points are shown as horizontal lines on each 
plot. The improvement of average prediction accuracy is negligible when applying global 
AD to models built with Set1 (or Set2) alone.  
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Figure 3.6: Nearest neighbor distribution of Set1 as external set: A1) within itself; A2) based 
on neighbors taken from Set2 modeling set; A3) based on neighbors taken from PDBbind + 
Set2 modeling set. Likewise, nearest neighbor distribution of Set2 external set: B1) 
itself; B2) based on neighbors from Set1 modeling set; A3) based on neighbors from 
PDBbind + Set1 modeling set.
The x-axis is adjusted nearest neighbor distance and the y
difference between each complex in the external s
marks the standard deviation of binding affinities in the external set (cf. 
shade covers the region of “activity cliff”; the number in the green shade is the number of 
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Figure 3.7: The 2D SPE plots. The black dots are data points of the external set and the red 
dots are data points of the modeling set. 
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 Set1 is the external set in A plots; Set2 is the external set in B plots. Plots 1-3 represent the 
data distribution in the descriptor space of different modeling sets: 1, Set2 (Set1); 2, 
PDBbind set; 3, PDBbind plus Set2 (Set1). The absolute coordinates of data points are 
generated randomly then iteratively optimized. Only relative positions of data points are 
meaningful.  
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Tables for Chapter 3 
Table 3.1: The discriminant analysis of data sets based on protein-ligand binding pKd values 
and protein sequences 
 data set 
parameter Set1 Set2 PDBbind 
Old  
ENTess 
 Count 176 169 665 264 
 Mean 6.23 6.10 6.69 6.42 
pKd Median 6.25 6.24 6.77 6.57 
values Standard deviation 2.31 2.17 2.22 2.39 
 
Range/Lowest/Highe
st 
13.15/-
0.15/1
3 
10.7/1.4/12.
1 
12.6/1.36/13.9
6 
12.48/1.48/13.9
6 
sequenc
e 
# of families/ 
# of singletons  
(90% sequence 
similarity) 
121/80 107/68 101/26 83/43 
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Table 3.2: The statistics (R2, coverage, MAE, and RMSE) of five-fold external validation 
sets using models built with PDBbind data set using occurrence, ENTess, PL/MCT, or 
combined descriptor set (ENTess + PL/MCT). 
 
R2:  
                          Fold 
Descriptor #1 #2 #3 #4 #5 
Occurrence 0.55/0.63* 0.57/0.59 0.56/0.60 0.57/0.61 0.55/0.57 
ENTess (1) 0.56/0.66 0.59/0.61 0.54/0.62 0.63/0.69 0.53/0.56 
PL/MCT (2) 0.54/0.62 0.58/0.58 0.56/0.59 0.62/0.68 0.54/0.55 
(1) + (2) 0.63/0.70 0.64/0.67 0.62/0.69 0.68/0.72 0.56/0.61 
coverage 
                          Fold 
Descriptor #1 #2 #3 #4 #5 
Occurrence 1/0.64 0.99/0.72 0.99/0.78 0.99/0.71 0.95/0.73 
ENTess (1) 1/0.64 0.99/0.73 0.99/0.79 0.99/0.70 0.98/0.71 
PL/MCT (2) 1/0.66 0.99/0.74 0.98/0.77 0.99/0.70 0.99/0.72 
(1) + (2) 1/0.64 1/0.67 1/0.75 1/0.73 1/0.68 
MAE 
                       
Fold 
Descriptor 
#1 #2 #3 #4 #5 
Occurrence 1.09/0.98 1.09/1.08 1.21/1.22 0.98/0.99 1.14/1.11 
ENTess (1) 1.12/0.98 1.08/1.07 1.26/1.20 0.92/0.89 1.19/1.10 
PL/MCT (2) 1.11/1.00 1.09/1.04 1.22/1.21 0.93/0.89 1.19/1.16 
(1) + (2) 0.99/1 1.04/1.02 1.15/1.02 0.84/0.79 1.12/1.17 
RMSE 
                       
Fold 
Descriptor 
#1 #2 #3 #4 #5 
Occurrence 1.44/1.35 1.47/1.51 1.57/1.55 1.29/1.28 1.51/1.44 
ENTess (1) 1.41/1.26 1.42/1.46 1.61/1.51 1.18/1.15 1.56/1.45 
PL/MCT (2) 1.46/1.36 1.45/1.44 1.57/1.59 1.20/1.16 1.53/1.49 
(1) + (2) 1.30/1.26 1.36/1.39 1.46/1.28 1.12/1.08 1.50/1.62 
*default/with global AD, Z = 0.5; bold type: the best statistics in folds and global AD helps 
improve the results 
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Table 3.3: The statistics (R2, coverage, MAE, and RMSE) of external validation set 
(complexes which have pockets dissimilar to the core set) using models built with PDBbind 
data set using occurrence, ENTess, PL/MCT, or combined descriptor set (ENTess + PL/MCT) 
 
               
Parameter 
Descriptor 
R2 Coverage MAE RMSE 
Occurrence 0.24/0.32* 1/0.30 1.39/1.31 1.84/1.78 
ENTess (1) 0.24/0.35 1/0.29 1.37/1.29 1.83/1.71 
PL/MCT (2) 0.26/0.34 1/0.32 1.35/1.3 1.81/1.76 
(1) + (2) 0.28/0.40 1/0.39 1.34/1.23 1.77/1.57 
*default/ with AD, Z = 0.5; bold type: the best statistics 
 
Table 3.4: The statistics (R2, MAE, coverage, RMSE, and coverage) of external n-fold 
validation sets using models built from Set1, Set2, PDBbind plus Set1, or PDBbind plus Set2. 
“Set1” data set modeling 
Fold 
 
 
Param
eter 
#1 #2 #3 #4 #5 #6 #7 #8 #9 #10 
R2 0.38/0
.47 
0.17/0
.22 
0.50/0
.53 
0.49/0
.74 
0.45/0
.07 
0.57/0
.60 
0.26/0
.36 
0.70/0
.70 
0.61/0
.72 
0.35/0
.11 
MAE 1.00/1
.04 
1.27/1
.41 
1.72/1
.72 
1.45/1
.18 
1.45/1
.76 
1.24/1
.21 
1.42/1
.33 
1.08/1
.21 
1.17/1
.09 
1.36/1
.3 
RMSE 1.28/1
.27 
1.56/1
.73 
2.16/2
.19 
1.94/1
.63 
1.75/2
.08 
1.76/1
.73 
1.82/1
.59 
1.26/1
.36 
1.48/1
.51 
1.70/1
.89 
Cover
age 
1.00/0
.70 
1.00/0
.65 
1.00/0
.88 
1.00/0
.65 
1.00/0
.50 
1.00/0
.83 
1.00/0
.61 
1.00/0
.78 
1.00/0
.67 
1.00/0
.50 
“Set2” data set modeling 
Fold 
 
 
Param
eter 
#1 #2 #3 #4 #5 #6 #7 #8 #9 NA 
R2 0.54/0
.51 
0.35/0
.40 
0.65/0
.65 
0.70/0
.71 
0.80/0
.80 
0.21/0
.18 
0.52/0
.43 
0.71/0
.62 
0.27/0
.29 NA 
MAE 1.10/1
.14 
1.16/1
.31 
1.24/1
.41 
0.83/0
.86 
1.06/1
.19 
1.6/1.
07 
1.11/1
.23 
1.25/1
.27 
1.29/1
.44 NA 
RMSE 1.30/1
.35 
1.42/1
.56 
1.52/1
.66 
0.99/1
.07 
1.29/1
.42 
2.27/1
.46 
1.41/1
.52 
1.67/1
.68 
1.69/1
.81 NA 
Cover 1.00/0 1.00/0 1.00/0 1.00/0 1.00/0 1.00/0 1.00/0 1.00/0 1.00/0 NA 
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age .72 .61 .79 .63 .79 .63 .84 .74 .63 
*default/ with global AD, Z = 0.5 
“PDBbind plus Set1” data set modeling 
                Fold 
 
Parameter 
#1 #2 #3 #4 #5 
R2 0.54/0.56* 0.59/0.66 0.55/0.62 0.57/0.63 0.56/0.63 
MAE 1.03/1.02 1.13/1.07 1.21/1.22 1.04/1.03 1.16/1.06 
RMSE 1.35/1.35 1.45/1.41 1.67/1.63 1.33/1.33 1.53/1.36 
Coverage 1.00/0.69 1.00/0.70 1.00/0.71 1.00/0.66 0.99/0.70 
“PDBbind plus Set2” data set modeling 
               Fold 
 
Parameter 
#1 #2 #3 #4 #5 
R2 0.52/0.59 0.66/0.70 0.60/0.66 0.55/0.64 0.64/0.66 
MAE 1.07/1.04 0.98/1.00 1.12/1.07 1.01/0.92 1.06/1.13 
RMSE 1.42/1.41 1.25/1.25 1.52/1.39 1.36/1.22 1.37/1.46 
Coverage 1.00/0.70 1.00/0.75 1.00/0.69 1.00/0.65 1.00/0.62 
*default/ with global AD, Z = 0.5 
 
Table 3.5: The statistics (R2, R02, coverage, MAE, and RMSE) of Set1 and Set2 prediction 
using models built from Set2 (or Set1), PDBbind data set, and PDBbind plus Set2 (or Set1) 
with combined descriptor set (ENTess + PL/MCT) 
 
Parameters R2 R02 RMSE MAE Coverage 
Models Set1 prediction 
Set2 0.40/0.30* 0.40/0.29 1.82/1.93 1.36/1.46 1/0.47 
PDBbind 0.48/0.53 0.48/0.53 1.68/1.75 1.32/1.44 1+/0.49 
PDBbind + Set2 0.50/0.56 0.50/0.55 1.62/1.67 1.26/1.30 1/0.49 
Models Set2 prediction 
Set1 0.51/0.50 0.50/0.50 1.53/1.55 1.18/1.23 1/0.73 
PDBbind 0.42/0.47 0.41/0.47 1.59/1.54 1.22/1.22 1+/0.64 
PDBbind + Set1 0.53/0.58 0.53/0.57 1.49/1.46 1.14/1.15 1/0.67 
*default/ with AD, Z = 0.5; bold type: the best statistics and 
global AD helps improve the results 
+ only 169 out of 176 in Set1 and only 122 out of 169 in Set2 are not overlapped with 
PDBbind modeling set 
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Table 3.6: Analysis of nearest neighbors of Set1 (Set2), as external validation set, taken from 
itself, from Set2 (Set1), or from PDBbind plus Set2 (Set1) and the prediction accuracy of 
Set1 (Set2) external validation set using models built from Set2 (Set1) modeling set and 
PDBbind plus Set2 (Set1) modeling set 
Nearest neighbors (NN) of Set1 external set 
  Data sets→ Set1 Set2 PDBbind+Set2 
Mean NN dist. 1.97 3 1.98 
Std. NN dist. 0.79 1.34 0.81 
R2 (RMSE) - 0.40 (1.82) 0.50 (1.62) 
Nearest neighbors (NN) of Set2 external set 
Data sets→ Set 2 Set 1 PDBbind+Set1 
Mean NN dist. 1.72 2.32 1.68 
Std. NN dist. 0.68 0.97 0.66 
    R2 (RMSE) - 0.51 (1.53) 0.53 (1.49) 
Std.: standard deviation; dist.: distance
   
Chapter 4 Cheminformatics Meets Molecular Mechanics: A Combined Application 
of Knowledge-based Pose Scoring and Physical Force Field-based Hit Scoring 
Functions Improves the Accuracy of Structure-based Virtual Screening 
4.1  Introduction 
In recent years, virtual screening (VS) has become an increasingly popular strategy 
for computer-aided drug design.28, 159 VS approaches explore available or synthetically 
feasible chemical databases to identify a relatively small number of high-scoring hits that can 
be validated experimentally. A successful VS method can be applied to large data sets of 
compounds, resulting in significant enrichment of true binders among the top ranking hits. 
Two types of methodologies are employed in virtual screening: structure-based160, 161 
and ligand-based.9 Structure-based approaches require knowledge of the 3D structure of the 
target, and employ docking methods to generate binding poses. Then, scoring functions are 
used to identify the putative native-like pose(s), for which binding affinities can be predicted. 
Conversely, most ligand-based VS methods search chemical compound databases to identify 
molecules that are chemically similar to known active ligands or are predicted to be active 
against the respective targets. Such methods do not require knowledge of 3D structures of the 
targets and are computationally efficient.9 However, ligand-based VS approaches require 
knowledge of active ligands and have inherently lower potential to identify novel chemical 
scaffolds than do structure-based methods. Nevertheless, recent studies have shown that 
ligand-based methods have often outperformed structure-based approaches in terms of VS 
efficacy.162 
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Rigorous scoring functions are a critical component of structure-based VS approaches. 
Most scoring functions predict binding affinity using physical force fields that account for 
intermolecular interactions such as electrostatic, van der Waals and hydrophobic interactions, 
and hydrogen bonding. Due to the static nature of the underlying molecular models many 
important effects influencing the binding free energy are often not taken into account; 
examples include entropy, micro-environment dependent polarization, π-stacking, and 
solvent effects.  
Recent studies have shown that inaccuracy of scoring functions is the major 
bottleneck of structure-based VS.47 It has been demonstrated that scoring functions often fail 
to recognize pose decoys, i.e., ligand poses that are geometrically different from the native 
binding orientation of a ligand in the experimentally determined crystallographic structure of 
the protein-ligand complex, but score better than the native pose.  In addition, known non-
binders may also score better than true binders the former compounds are then designated as 
binding decoys.103 Obviously, the presence of both binding and geometrical pose decoys in 
an ensemble of compound poses resulting from computational docking studies will decrease 
the accuracy of structure based VS. Moreover, structure-based scoring functions are well-
known for having inconsistent VS performances across diverse targets.47  
Several recent studies have shown that inclusion of pose decoys in the training sets of 
native structures helps in tuning the scoring functions against decoys, which enhances the 
accuracy of virtual screening.63-69 Besides, some other studies have demonstrated that target-
specific customized scoring functions61, 62 are effective methods for improving the 
discrimination between true ligands and binding decoys in VS for the aimed target. In the 
present study, we devise a target-specific pose (-scoring) filter that is trained to distinguish 
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native-like poses from pose decoys. The pose filter is developed by applying novel chemical 
descriptors of the protein/ligand interface and a machine learning classifier to discriminate 
native-like poses from pose decoys in an ensemble of poses. The training set is generated by 
multiple rounds of docking of a single cognate ligand to its binding target. Furthermore, we 
develop a two-step protocol for target-specific virtual screening based on pose filter and 
MeduaScore. In the first step our pose filter is used to eliminate/penalize putative pose 
decoys for every ligand, and in the second step the remaining putative native-like poses are 
scored with physical force field based MedusaScore.163 
We test the performance of this novel, two-step VS protocol on several benchmark 
sets available from the Directory of Useful Decoys (DUD).164 DUD is a specially designed 
data set including multiple targets, their known ligands, and binding decoys, i.e., compounds 
that are chemically dissimilar to known ligands but score as well as (or better than) native 
ligands by the majority of current scoring functions. The recently refined DUD data sets 
include only lead-like compounds and have the true ligands clustered, making it a ideal 
benchmark set for testing scaffold hopping capability of VS methods. We use Fred (OpenEye 
Scientific Software)36 to dock ligands to target structures and generate poses of each 
compounds. We find that for most targets eliminating/penalizing pose decoys with the pose 
filter leads to significant improvement in the enrichment of virtual screening hits, as 
compared with using the MedusaScore scoring function alone. We compare the VS 
performance of several popular structure-based scoring functions (XSCORE::HMSCORE50, 
Fred::ChemScore51, Fred::PLP165, and Fred::Chemgauss3166) and several novel VS methods 
(FieldScreen167, FLAP::LBX168, and FLAP::RBLB168) that have been recently reported to 
achieve good performances on the same DUD data sets. We find that our combined scoring 
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function outperforms other structure-based scoring functions for majority of the targets. 
Furthermore, the retrieved ligands are less similar to the cognate ligand in comparison with 
ligand-based approaches (FieldScreen and FLAP::LBX), and are complementary to the 
ligands retrieved using the structure-based method (FLAP::RBLB).  
Our approach employs protocols that are routinely used in cheminformatics research, 
e.g., binary quantitative structure activity relationship (QSAR) modeling, with the caveat that 
we use unconventional descriptors of the protein/ligand interface for pose scoring as opposed 
to using standard chemical descriptors of compounds. An interesting and unique feature of 
our approach is that the pose classifier is formally trained to recognize geometrical decoys of 
each ligand; yet it succeeds in correctly recognizing (and eliminating) most of the binding 
decoys because they are predicted as geometrical decoys.  We then employ the MedusaScore 
physical force field potential for final ranking of poses that remain after filtering. 
Methods employing structure-based and ligand-based VS strategies concurrently are 
only beginning to emerge in the literature (e.g., refs.168-171). However, most studies focus on 
finding consensus hits between the two approaches. In contrast, the method described in this 
paper, combines for the first time cheminformatics and physical force field based approaches 
(as reflected in the title of the paper) to structure-based pose scoring into a two-step 
hierarchical workflow leading to an improved general protocol for virtual screening that can 
be applied to a large variety of targets. 
4.2  Methods 
4.2.1 Selection of Targets and Data Sets  
The data sets of true ligands and presumed binding decoys for each target in this 
study are collected from the publicly available Directory of Useful Decoys (DUD).164 The 
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DUD data sets were designed to minimize the physical biases inherent in the benchmarking 
of virtual screening schemes against different biological targets. Each ligand was matched 
with 36 binding decoy molecules that resemble the native ligand in physical properties, such 
as molecular weight, LogP, number of hydrogen bonding groups, and number of rotatable 
bonds but are distinct from the ligand topologically. In total, the DUD database consists of 40 
data sets and each ligand has around 36 binding decoys. Further refinement of the DUD data 
sets is done recently by applying a lead-like filter (MW < 450, AlogP < 4.5) on both ligands 
and binding decoys35 as well as the reduced graph cluster filter on ligands172. These two 
filters are intended to mimic the real-life virtual screening campaign and to reduce the 
analogue bias inflating enrichment in virtual screening. We employ the entire 13 data sets, 
each of which includes at least 15 ligand clusters, for our method validation. The detailed 
information of data sets is shown in Table 4.1. Six of the 13 targets belong to the kinase 
family (CDK2, EGFR, p38, PDGFrb, Src, and VEGFr2), where the majority of known 
ligands occupy ATP binding region. The remaining targets include the class of 
metalloenzymes (ACE, PDE5), serine protease (FXa), and several other enzymes (AChe, 
COX-2, HIVRT, and InhA). In order to compare strictly with other VS methods, we use the 
protein-ligand complexes provided in the original DUD for pose filter training. For VEGFr2 
and PDGFrb targets, the complex structures provided in the DUD data sets are generated by 
docking ligands to apo protein structures. 
4.2.2 Docking Methods for Pose Generation 
For each target, we prepare the x-ray structure using utilities on Molprobity173 server 
to add and optimize hydrogen atoms while correcting potential misinterpretations of amino 
acid (asparagine, glutamine, or histidine) terminal flips. The crystallographic water 
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molecules located inside the binding pocket are removed in order to avoid biases when 
generating poses of molecules but cofactors (e.g., NAD in 1p44 protein model) or metal 
atoms (e.g., Zinc in the 1o86 protein model) are preserved if they are important for enzyme 
to function or are involved in interactions with the cognate ligand.  
We employ the docking software, Fred (version 2.2.5) from OpenEye Scientific36 to 
generate an ensemble of poses for each compound. The ensemble of poses is generated by 
enumerating rigid rotations and translations of each conformer within the binding site. The 
conformers of each compound are generated by Omega (version 2.2.1)36 based on default 
parameters and the binding site is defined by a 5 Å grid box centered on the cognate ligand. 
For kinase targets, it is well-known that a hydrogen bond interaction to the protein hinge 
residues is necessary for both Type I and Type II kinase inhibitors.174 Thus, this constraint is 
applied during pose generation to improve docking accuracy.  
We apply default parameters provided by Fred during docking except for the number 
of output poses. For pose filter construction, we retain up to 1000 top-scoring poses 
generated by docking a single cognate ligand in order to ascertain the conformational 
diversity of poses. For virtual screening, the top 30 poses (ranked by the Fred’s default 
scoring function, Chemgauss3) of each molecule are preserved for re-scoring by other 
scoring functions (e.g., MedusaScore). 
4.2.3 Ligands vs. Binding Decoys and Native-like Poses vs. Pose Decoys. 
“Binding decoys” are defined as ligands that do not bind to a specific target 
experimentally (non-binders) but score as high as (or better than) true ligands. Similarly, we 
use the terms “pose decoys” to describe the poses generated by docking the cognate ligand 
against the protein target but score better than native-like poses. In our study, native-like 
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poses are defined as poses generated from docking process with binding mode similar to the 
native pose. The similarity between poses and the native pose is often measured using Root 
Mean Square Deviation (RMSD). For the purpose of pose-filter training, we artificially 
define a RMSD threshold of 4Å to classify poses into native-like poses and pose decoys. The 
4Å threshold is consistent with the observation that there is a gap on the distribution plot 
(MedusaScore vs. RMSD) of poses generated by re-docking the cognate ligand for most 
targets (Figure 4.1, Figure S1). 
4.2.4 Novel Descriptors of the Protein-Ligand Interface Based on Conceptual DFT 
Earlier, we developed the so called ENTess chemical geometrical descriptors16 of the 
protein-ligand interface. These descriptors are obtained by using Pauling electronegativity 
(EN) as an atomic property and Delaunay Tessellation (Tess) to characterize the protein 
ligand interface as follows. When applied to protein-ligand complexes represented at the 
atomic resolution level, Delaunay tessellation partitions the protein ligand interface into an 
aggregate of space-filling, irregular tetrahedra, with both protein and ligand atoms as vertices. 
Each Delaunay quadruplet is characterized by its unique four-atom composition, which 
defines the descriptor type (certainly, the same four-body compositions may occur in 
different, or even the same, protein/ligand interfaces). Furthermore, for each quadruplet we 
calculate the sum of En values of the composing atom-vertices, which produces the 
descriptor value. In the previous study,16 we used the ENTess descriptors to build successful 
quantitative structure-binding affinity relationship (QSBR) models for 264 x-ray 
characterized protein-ligand complexes with known binding affinity; the modeling approach 
followed our standard model development and validation workflow.117  
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In this study, we have developed and employed novel descriptors that are 
methodologically similar to ENTess descriptors but are theoretically more rigorous.154 These 
new descriptors employ pairwise atomic potentials for the protein-ligand complexes (PL) 
based on maximal charge transfer (MCT)152 in place of Pauling electronegativities, called 
here PL/MCT. The PL/MCT is calculated from the following equation (see also Figure 4.2): 
 
          (1) 
where PL/MCTm is the potential of the m-th tetrahedron type (i.e. individual descriptor type); 
n is the number of occurrences of this tetrahedron type in a given pose; p is the vertex index 
of a protein atom, l is the vertex index of a ligand atom, and dpl is the distance between a pair 
of protein and ligand atoms found in the same Delaunay tetrahedron. (Note that Delaunay 
tetrahedra at the protein-ligand interface can be classified based on the relative content of 
protein and ligand atoms, i.e., three protein and one ligand atoms, two from each, or one 
protein and three ligand atoms; this explains the tetrahedral type counts in the second and 
third sum in Equation 1). 
The MCT characterizes the maximal electron flow between the donor and acceptor 
atoms at the protein-ligand interface. It is derived from the conceptual DFT,152, 155 which 
provides a theoretical basis for calculating the PL/MCT descriptors. The MCT is calculated 
as follows, assuming that the total energy of the system is perturbed by the charge transfer up 
to the second order: 
∆E = µ∆N + 1/2η∆N2      (2) 
where ∆E and ∆N represent energy change and charge transfer, respectively. When the total 
energy is minimized with respect to the charge transfer, d∆E/d∆N = 0, we have 
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∆Nmax = - µ/η  ≡ MCT    (3) 
where µ and η are the chemical potential (negative of electronegativity) and the chemical 
hardness respectively, defined by µ = (∂E/∂N)ν and η = (∂2E/∂2N)ν with ν representing the 
external potential formed by the framework of atomic nuclei. 
4.2.5 Knowledge-based Pose Scoring Filter  
As described in the previous session, we classify the poses generated by docking the 
cognate ligand against the protein target into native-like poses and pose decoys based on the 
RMSD threshold. The problem of separating native-like poses vs. pose decoys for a molecule 
can be treated as a binary classification problem where poses are characterized by their 
protein-ligand interfacial descriptors (e.g., PL/MCT descriptors in this study); this is a 
standard classification problem addressed in many conventional cheminformatics 
investigations using QSAR modeling. Accordingly, we apply the models (i.e., pose filter) to 
poses generated in virtual screening, assuming that “bad” poses are similar (based on 
structural descriptors) to pose decoys in the modeling set and that the filter predicts them as 
such. “Bad” poses should include both poses of binding decoys and non-native poses of 
ligands. 
To train this knowledge-based pose scoring function for each target, we retain up to 
1000 poses generated by re-docking a single cognate ligand against its respective target 
(Figure 4.3). For the VEGFr2 and PDGFrb target, where the native pose is unavailable (an 
apo structure and a model structure respectively), the pose with lowest MedusaScore is 
considered as a native pose for RMSD calculation. This is a reasonable assumption since 
MedusaScore performs well at the benchmarking exercise in native pose prediction.163 We 
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classify the poses based on the 4 Å threshold as either native-like (RMSD ≤ 4Å) or pose 
decoys (RMSD > 4Å) except for the PDE5 pose set where the gap is observed at 3 Å and 3 Å 
threshold is therefore used. For the poses from re-docking the cognate ligand of 1ckp 
(CDK2), we do not observe a characteristic distribution (as, for example, in Figure 4.1). 
Therefore, we regenerate the poses using MedusaDock175 instead of Fred.  
For each pose, we generate PL/MCT descriptors to characterize its interfacial 
interactions. The degree of similarity of each pose to the native pose is quantified by the 
Euclidean distance in the PL/MCT descriptor space. Therefore, the pose distribution of each 
target’s modeling set can be characterized by three parameters: the distance to the native pose 
in the PL/MCT descriptor space (x-axis), the RMSD value (y-axis), and the MedusaScore 
(colorbar). It is desirable that poses with lower RMSD value correspond to smaller distances 
to the native pose in the PL/MCT descriptor space (e.g., Figure 4.1). 
If this binary data set with native-like poses and pose decoys is quite balanced (their 
ratio being less than 2-fold), we randomly exclude 20% poses as the test set and construct 
models based on the remaining 80% poses. In the case of imbalanced distribution, we 
downsize the major class by retaining only those poses that are similar to poses in the minor 
class, where the degree of similarity is assessed by Euclidean distance in the PL/MCT 
descriptor space. For example, the ACE target has 48 native-like poses and 952 pose decoys, 
after down-sampling, only 49 pose decoys most similar to the native-like poses are retained 
for model building and validation (Table 4.2 and Figure S4.1).  
In the modeling process we employ the Support Vector Machines (SVM) software 
implemented in the open-source LibSVM88 package to build binary classification models (i.e., 
pose filters). We use all models built from SVM with eligible CV accuracy (i.e., pose filter) 
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for predicting the poses in the test set and poses generated in virtual screening. For each pose, 
we calculate a FilterScore, which is the fraction of models that predict it as native-like. 
It should be emphasized again that only one cognate ligand is used for each target to 
develop a pose scoring function. However, due to the generic nature of the PL/MCT 
chemical descriptors this scoring function can be applied to score poses for all diverse 
ligands used in docking and VS studies. 
4.2.6 Physical Force Field-based MedusaScore Scoring Function 
MedusaScore163 is a physical force field-based scoring function that describes the 
major physical interactions between proteins and ligands, including van der Waals interaction, 
salt bridge, hydrogen bonding and solvation. MedusaScore is an extension of the Medusa 
force field,176 which was developed originally to describe physical interactions within 
proteins. The original parameters of the Medusa force field were trained on 34 high-
resolution protein crystal structures with diverse sequences. Thus, by default MedusaScore is 
expected to be transferable and applicable to virtual screening of a variety of chemical 
compounds. Notably there were no protein-ligand data used in the development of 
MedusaScore, but it still exhibits remarkable accuracy in both docking pose discrimination 
and binding affinity prediction.163 During the pose rescoring by MedusaScore, we turn off 
van der Waals repulsion because this term has been shown to be sensitive to small deviation 
in ligand poses.163 It is safe to remove the term in this case because all steric clashes have 
already been considered during the generation of docking poses. 
4.2.7 Data Fusion of MedusaScore and FilterScore 
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In order to combine the FilterScore and the MedusaScore, which are of different 
scales, we utilize normalized Z-scores based on their statistical distributions. We firstly apply 
the pose filter to the poses in VS, and discard poses that are predicted as pose decoy by all 
eligible models (i.e., FilterScore = 0). Based on the mean (µ) and standard deviation (σ) of 
each scoring function, the Z-score is calculated from the raw score (X) using Equation 4.  
Z   X 	 µ
 σ⁄      (4) 
If the filter is constructed based on the entire sampling space of poses from re-
docking the cognate ligand, we apply the same weight for FilterScore and MedusaScore, and 
the Z-score for each pose is derived as: 
 Zcombined = ZMedusaScore – ZFilterScore           (5) 
We add a minus sign for ZFilterScore so that lower Z-score will correspond to better 
ranked pose, in consistent with MedusaScore convention. If the filter is constructed based on 
the poses after the down-sampling procedure, we employ a modified scoring strategy based 
on the concept of applicability domain.18 We predict the poses within applicability domain 
using Equation 5 and predict the poses out of applicability domain by adjusting the weight 
of FilterScore by DistScore (Equation 6).  
   Zcombined = ZMedusaScore – 0.5*(ZFilterScore  – ZDistScore)                   (6) 
 The ZDistScore is the Z-score of each pose based on the its distance to the native pose, 
the mean, and the standard deviation derived from the distribution of PL/MCT-tess Euclidean 
distance to native pose of all VS poses. Assuming a normal distribution of VS poses 
comparable with that of poses from re-docking the cognate ligand, we define VS poses that 
occupy the space of modeling set are within the applicability domain (ZDistScore < -1). This 
threshold is defined by inspecting the covering space of modeling set for five targets (ACE, 
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CDK2, COX-2, HIVRT, and VEGFr2 in Figure S4.1). The final score for each compound in 
the combined VS scheme is based on the pose with the lowest sum of Z-scores among all the 
poses retained for that compound. 
4.2.8 Evaluation of Virtual Screening Performance 
To examine the overall performance of a method for a target data set in virtual 
screening, we plot the Receiver Operator Characteristic (ROC) curve. And we calculate the 
Area Under the Curve (AUC) value at each ROC curve to estimate the average performance 
of a method throughout the ranked list. On the other hand, to quantify the performance of 
each method at the early stage for a target data set in virtual screening, we employ the ROC 
enrichment (ROCE) value. Unlike the conventional enrichment factor (EF) metric, ROCE 
values are independent of the ratio of binding decoys to ligands in a target data set, making 
them ideal metrics for comparing different methods.177 The ROCE value is defined as the 
ratio of true positive rates to the false positive rates, for a given percentage of binding decoys 
has been observed (i.e., the slope at each point on the ROC plot). We report ROCE values at 
0.5%, 1%, 2%, 5% as suggested177-179 and adopted in previous publications167, 168, 180. The 
meaning of ROCE value at 1% represents the fold enrichment over random performance. In 
order to emphasize the retrieval of diverse scaffolds, the above metrics (ROCE and AUC) are 
modified by applying an arithmetic weight to each ligand (awROCE and awAUC)181, which 
is inversely proportional to the size of the cluster it belongs to.   
We estimate the uncertainty of awROCE/awAUC values using the statistical 
bootstrapping procedure.167 For each ranked list, we randomly exclude 20% of data points 
and recalculate the awROCE values. This is repeated 10000 times and the standard deviation 
of awROCE values is used to estimate the error of awROCE. Due to the nature of pose filter, 
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many true negatives (presumed binding decoys) and some false negatives (ligands) are 
eliminated in several data sets (e.g., ACE, p38, and etc). For these data sets, we calculate the 
awROCE values based on the reduced list, resulting in a larger estimated error at the low 
percentages. 
4.2.9 Comparison against Structure-based Scoring Functions, FieldScreen, and FLAP 
Several popular structure-based scoring functions, which show good docking pose 
discrimination and binding affinity prediction in publications60, 163, 182, are selected to 
compare against our combined approach. It is intriguing to test the performance of these 
scoring functions in virtual screening since it has been suggested that scoring functions 
should be tailored for virtual screening.64, 105 In total, we have tested five scoring functions 
including MedusaScore, HMSCORE, Chemgauss3, ChemScore51, and PLP165. HMSCORE 
belongs to the XSCORE146 scoring utility. Chemgauss3, ChemScore, and PLP are scoring 
functions implemented in Fred. All of them belong to the class of empirical scoring function 
except MedusaScore. Moreover, we also compare our approach with some methods that have 
been published using the same data set including FieldScreen167 and FLAP (both LBX and 
RBLB protocols)168, FieldScreen167 and FLAP::LBX168 are two novel ligand-based virtual 
screening approaches using grid points derived from the cognate ligand as query; 
FLAP::RBLB approach168 utilize grid points generated from protein target biased to the 
cognate ligand. It should be noted that the binding decoys in DUD are designed to be 
physically similar to, yet topologically distinct from the true ligands. Any ligand-based 
approaches applied to this data set might generate optimistic results. 
4.2.10 2D Chemical Similarity to the Cognate Ligand 
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We generate the MACCS structural keys for each compound using MOE software 
(version 2007.09)183 under standard protocols, and calculate the Tanimoto coefficient (Tc) as 
the similarity metric between the cognate ligand and compounds in the screening library. 
4.3  Results 
4.3.1 Native-like vs. Pose Decoys Classifier 
The number of poses used in the construction of the pose filter, along with the model 
statistics for each target, is shown in Table 4.2. We also present the distribution of poses of 
modeling set for each target set in Figure S4.1. Depending on the target, the distribution of 
the native-like poses and pose decoys are either balanced (AChE, EGFR, FXa, InhA, p38, 
PDE5, PDGFrb, and Src), or biased towards pose decoys (ACE, CDK2, COX-2, HIVRT, and 
VEGFr2). The details of modeling techniques to address the imbalanced classes have been 
described in the Methods. The results show that the overall accuracy for both the training set 
(internal five-fold CV) and the external test set (external five-fold CV) exceeds 90% for all 
data sets except ACE, HIVRT, and p38 data sets. We predict the VS poses generated from 
each data set using the models which have CV accuracy greater than 90% except for the 
HIVRT data set which has no models with CV accuracy above 90%. In the latter case, a 
threshold of 80% is applied. 
It should be emphasized again that for each target-specific filter, we use only one 
cognate ligand to generate multiple docking poses for further model building. Nevertheless, 
the filter is applicable to diverse compounds during VS due to the generality of the chemical 
descriptors we use to characterize the protein-ligand interface. As demonstrated below, these 
single-ligand based pose filters can significantly improve the accuracy of virtual screening 
and true hit selection in combination with the MedusaScore force field. 
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 4.3.2 MedusaScore plus Pose Filter Approach Consistently Improve MedusaScore VS 
Performance 
We compare the VS performance of MedusaScore and MedusaScore plus pose filter. 
We apply the protocols to all the 13 targets in the DUD clustered data set. We measure the 
VS performance of the two scoring protocols using the awROC curves (Figure S4.2). More 
specifically, we use awAUC values to measure the overall ligand retrieval of the protocols, 
and use awROCE values at 1% to measure the ligand retrieval at the early stage of the VS 
(Figure 4a).  
We find remarkably improved VS performance over the benchmark set by applying 
the MedusaScore plus pose filter (i.e., the combined scoring function). For all the 13 targets 
from the DUD set, the awAUC values from using the combined scoring function are 
consistently higher than from using MedusaScore alone. The improvements are least 
significant for target EGFR and VEGFr2, where the awAUC value is improved by about 0.02 
in both cases. This is probably due to the fact that using MedusaScore alone already results in 
high awAUC values for these two targets (0.83 and 0.65, respectively). For the other targets, 
the average degree of awAUC improvement is 0.15, and we find the most improvements are 
for target AChE and FXa.  
When comparing the awROCE values at 1%, we find the combined scoring function 
is better than using MedusaScore alone for all targets except Src (Figure 4.4b). The 
improvement of awROCE at 1% is most significant for target PDE5 and PDGFrb. For PDE5, 
we are not able to retrieve any active ligand using MedusaScore alone (awROCE@1% = 0), 
but the value is improved to approximately 26.5 fold over the random at 1% after combining 
MedusaScore with pose filter. The pose filter also improves the ligand retrieval for target 
PDGFrb (awROCE@1% = 43.18), even though the original awROCE value is already high 
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(23.49) using MedusaScore alone. In addition, for the two targets (EGFR and VEGFr2) 
where the least improvement of awAUC is observed, the awROCE values at 1% are also 
improved significantly.  
Therefore, by combining MedusaScore with pose filter, we not only improve the 
overall VS performance (as measured by awAUC), but also improve the early enrichment (as 
measured by awROCE values at 1%). The improvement seems to be more pronounced at the 
early stage, which is a desirable feature because practically often only a small fraction of VS 
hits will be experimentally tested.   
4.3.3 MedusaScore plus Pose Filter Approach vs. Other Structure-based Scoring 
Functions 
We also compare the VS performance of our combined scoring function with four 
popular pose scoring functions, including XSCORE::HMSCORE, Fred::ChemScore, 
Fred::PLP, and Fred::Chemgauss3. We apply those scoring function on the same docking 
poses and compare their VS performance at the early screening stage (Figure 4.5).  
We find that our combined pose scoring function outperforms others for most of the 
targets. At a false positive rate of 0.5%, the combine scoring function has the highest 
enrichment for seven out of the 13 targets. In addition, the awROCE values for those targets 
vary from 21.66 to 86.46. In contrast, other scoring functions have the best performance at no 
more than 3 targets, with awROCE values vary from 12.07 to 43. We find a similar trend at 
the 1% level. In this case, our combined scoring function has the highest enrichment for six 
targets, with awROCE values vary from 22.88 to 43.18, while other scoring functions 
perform best for at most 3 targets, with awROCE values in the range of 9.67 to 26.56. This 
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comparison demonstrates that our combined scoring functions have better and more 
consistent VS performance than conventional scoring functions. 
The combine scoring function has the worst performance for target Src. We will 
analyze the reason of Src failure in Discussion. For this target, using MedusaScore alone 
gives reasonably good enrichment factor of 24.77, close to that from using ChemScore 
(25.97). With Src as an exception, the combined scoring function tends to have the best 
performance on targets where using MedusaScore alone also gives fairly good enrichment. 
4.3.4 MedusaScore plus Pose Filter Approach vs. Other Novel VS Methods 
We select a few recently developed VS methods, for which the benchmark results 
have been reported on the same DUD Cluster data set. One of the methods available for 
comparison is FieldScreen167, which is a ligand-based scoring VS method that utilizes 
molecular fields derived from the cognate ligand as query. Excellent VS performance has 
also been reported using FLAP168 molecular field-derived pharmacophores. For FLAP, we 
compare with two different VS protocols: FLAP::LBX, similar to FieldScreen, which uses 
ligand-based molecular field, and FLAP::RBLB, which uses both receptor and co-
crystallized ligand structure to derive the pharmacophore query. These methods represent the 
state-of-art VS methods that has been fully tested the entire DUD clustered set. 
The awROC curves of scoring methods for each target are shown in Figure 4.6 and 
the awROCE values at each stage are tabulated in Table S4.6-S4.10. Out of expectation, we 
find that the VS performance of each scoring method is target-dependent. Our method has 
the best retrieval for target HIVRT, p38, and PDGFrb. RBLB has clearly the best 
performance for target PDE5, Src, and VEGFr2. On the other hand, ligand-based VS 
methods unquestionably outperform other structure-based methods for target COX-2. A close 
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examination of the COX-2 data set reveals that around 47% of true ligands belong to the 
same cluster as the cognate ligand used as query. To further investigate the chemical 
similarity of retrieved ligands to the cognate ligand from different scoring approaches, we 
compare the average Tanimoto coefficient (Tc) values of true ligands from top 20 ranking 
lists (Table 4.3). Not surprisingly, we find that ligands retrieved by ligand-based VS methods 
are chemically more similar to the cognate ligands, as measured by the average Tc values. 
And the average Tc value of the retrieved COX-2 ligands is 0.88 (e.g., FieldScreen), much 
higher than the average of those for other 12 targets (0.66). The high degree similarity of 
COX-2 ligands to the query will definitely bias toward the better performance of any ligand-
based VS methods such as FieldScreen and FLAP::LBX methods. 
We further compare the early enrichment for our combined scoring function and 
FLAP::RBLB approach because these two methods seem to have the best VS performance at 
the early stage (in the 0.5% to 5% range). In addition, both methods take advantage of the 3D 
structures of the receptor and co-crystallized ligands, albeit using different approaches for VS. 
We want to identify if the different approaches might result in retrieving different ligands. In 
fact, we find the two methods seem to be complementary to each other. Among the top 20 
hits retrieved by the two methods, we find little overlap of the ligand types (Figure 4.7).  For 
example, FLAP::RBLB approach is able to retrieve only one cluster for target p38 and 
PDGFrb, and two clusters for target ACE. In contrast, the MedusaScore with filter approach 
can retrieve 4, 5, and 7 clusters, for these three targets ACE, p38 and PDGFrb, respectively. 
Interestingly, the additionally retrieved ligand clusters do not overlap with those obtained 
using FLAP::RBLB approach. This is also the case for target VEGFr2, where MedusaScore 
with filter approach retrieved additional five clusters with no overlap with ligands retrieved 
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by FLAP::RBLB method. For other targets such as AChE, CDK2, EGFR, HIVRT, and InhA, 
only a small fraction of the newly retrieved clusters overlaps with the ones from 
FLAP::RBLB approach. Hence, although both methods used receptor and cognate ligand 
structures for VS, the resulting performance of FLAP::RBLB approach and our approach 
seem quite complementary on different targets. Combining the two methods shall result in 
most diverse ligands among the top hits for VS application. 
4.4 Discussions 
Ligand dependency. The atom types in PL/MCT descriptors are defined based on 
their exact chemical names. This implementation makes PL/MCT descriptors fairly sensitive 
to special interactions (e.g., a tri-fluoro functional group). However, using poses with such 
interactions to construct pose filter makes it too specific. For example, in the Src data set, the 
cognate ligand we apply to construct pose filter is ANP, which has a long phospho-
aminophosphoric chain uncommon to any lead-like ligands.  Unsurprisingly, the pose filter 
predicts almost everything as pose decoys and the combined scoring function deteriorates the 
VS performance of MedusaScore against the Src data set. Accordingly, we employ another 
cognate ligand obtained from 1yol protein-ligand complex to construct pose filter and apply 
it to virtual screening. The combined scoring function slightly improves the VS performance 
of MedusaScore against the Src data set (awROCE@1% = 27.6 vs. 25.5; awAUC = 0.66 
vs.0.62).  
 Similarly, the combined scoring approach only marginally improves the VS 
performance of MedusaScore against the COX-2 data set, where the pose filter is constructed 
based on the cognate ligand with a tri-fluoro functional group. For this case, combining 
MedusaScore with pure DistScore can easier fish out ligands having the distinctive features 
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of the query compound than using MedusaScore plus pose filter approach (awROCE@1% = 
8.7 vs. 4.1; awAUC = 0.67 vs. 0.39). 
Parent scoring function dependency. Theoretically, the target-specific pose scoring 
filter can be used in combination with any other structure-based scoring function since the 
definition of pose decoys is based on the RMSD threshold, independent from scoring 
functions’ output. This combined scoring approach can improve the VS performance by a) 
eliminating binding decoys recognized by pose filter; b) increasing weight for the ligands 
favored by pose filter. If the ligands favored by pose filter have relatively poorer scores 
predicted by the parent scoring function and the high-scoring binding decoys are not 
completely eliminated, then combining the pose filter and the parent scoring function gives 
limited improvement. For example, in the CDK2 data set, the Cluster #1, #2, #3, #7, and #8 
are favored by both the pose filter and Chemgauss3 but are relatively disfavored by 
MedusaScore, resulting in better performance of combining pose filter with Chemgauss3 
(awROCE@1% = 26.0 vs. 14.4; awAUC = 0.84 vs. 0.71).  Another example is the FXa data 
set, where combining pose filter with Chemgauss3 has better VS performance (awROCE@1% 
= 15.4 vs. 4.8; awAUC = 0.80 vs. 0.72). However, docking programs/scoring functions are 
well-known for having inconsistent VS performances across diverse targets.47 Therefore, 
from the practical point of view, it is more important to improve scoring function 
performance consistently rather than to achieve ideal results for a few targets. The proposed 
pose filter is designed to this end.   
The judgment of threshold to classify native-like poses and pose decoys. We find that 
the 4 Å-threshold seems optimal considering the distribution of RMSD values of poses and 
the pose filter performance in virtual screening. Lowering the threshold results in fewer 
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native-like poses included, which occupy a smaller portion of descriptor space; this 
ultimately leads to a smaller applicability domain of the pose filter. As a result, using this 
pose filter in VS leads to poorer performance compared with using the pose filter built based 
on the 4 Å-threshold. The PDE5 data set is an exception, where a clear gap around 3 Å 
RMSD can be observed on the pose distribution plot. In virtual screening against the PDE5 
data set, the performance of the combined scoring approach with 3 Å-threshold filter is better 
than with the filter based on the 4 Å-threshold (awROCE@1% = 26.5 vs 17.2; awAUC = 
0.75 vs. 0.72). Moreover, it should be interesting to include the output of a scoring function 
into the definition of native-like poses and pose decoys (e.g., to train filter only on those 
native-like poses and pose decoys that are ranked high by the given scoring function), thus, 
building filters specifically adjusted for each scoring function.  
Virtual screening using MedusaScore in combination with DistScore. As shown in 
Figure 4.1, poses with lower RMSD value correspond to having smaller distances to the 
native pose in the PL/MCT descriptor space. It can be assumed that, for a given molecule, its 
likelihood to be a true ligand is directly related to how close its poses to the native pose, 
which can be reflected by the DistScore. We have been applying DistScore in combination 
with FilterScore to virtual screening for the data sets, where down-sampling during filter 
construction is necessary. Therefore, for the proper comparison, we also perform virtual 
screening against all data sets using MedusaScore in combination with DistScore alone 
(Figure S2). We find that using pose filter to eliminate/penalize pose decoys in virtual 
screening can consistently improve MedusaScore VS performance and the MedusaScore plus 
pose filter approach has the best performance for all data sets except for the outliers 
mentioned above. 
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4.5 Conclusions 
We have developed an integrated knowledge-based pose (-scoring) filter using 
concepts frequently employed in cheminformatics research such as chemical descriptors of 
the protein-ligand interface and machine learning techniques for deriving binary pose 
classification (native-like vs. pose decoys) models. We have combined this novel pose 
filtering procedure with a recently developed physical force field-based scoring function 
(MedusaScore) to score the docking poses in virtual screening applications. We validated this 
combined scoring protocol using the refined subsets (13 targets) from the DUD database. The 
refined DUD sets consist of only lead-like compounds and ligands are clustered based on the 
reduce graph algorithm, making them suitable for testing scaffold hopping capability of VS 
methods. The validation results demonstrated that our method can consistently improve the 
VS performance of MedusaScore provided that the protein-ligand complex is suitable for 
filter training. Comparing with other conventional structure-based scoring functions, 
including XSCORE::HMSCORE, Fred::ChemScore, Fred::PLP, and Fred::Chemgauss3, the 
combined scoring protocol outperforms in six out of 13 data sets at early stage of VS (1% 
decoys been screened). Moreover, we found that the retrieved ligands by the combined 
scoring protocol are chemically more diverse than those by other two ligand-based VS 
methods (FieldScreen and FLAP::LBX) using the same DUD data sets. Interestingly, we 
observed that our method is complementary to FLAP::RBLB, which is a high-performance 
VS method that also utilizes both the receptor and the cognate ligand structures.  
Our method demonstrated its ability to achieve good enrichments and perform 
scaffold hopping, suggesting that it could be applied to virtual screening against novel 
pharmaceutically relevant protein targets to identify promising leads. In particular, this 
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method is suitable for protein targets with limited ligand binding data available. A single x-
ray protein-ligand complex or, as we have demonstrated for PDGFrb target, a homology 
protein model with a known binder is enough for constructing a successful target-specific 
pose filter. Additional improvements can be sought for both the pose (-scoring) filter (e.g., 
using more than one ligand for training, employing alternative atomic properties or potentials 
for ENTess-like scoring functions, or incorporating other tetrahedral geometric properties), 
as well as approaches for the integration of knowledge-based and physical force field-based 
scoringfunctions.
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Figures in Chapter 4 
 
 
Figure 4.1: The distribution of poses generated by re-docking the ligand structure obtained 
from the DUD website against the PDGFrb homology protein model.  
The pose with the lowest MedusaScore is served as the reference to calculate the RMSD 
value of poses (the lower MedusaScore values correspond to higher ranks). The left plot 
shows the pose distribution based on Z-score values of MedusaScore (x-axis) vs. RMSD 
values (y-axis). The right plot shows the pose distribution based on Z-score values of 
distance to the native pose in PL/MCT descriptor space (x-axis) vs. RMSD values (y-axis). 
The data points are colored corresponding to their Z-score values of MedusaScore.   
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Figure 4.2: Illustration of the method to derive PL/MCT 
protein-ligand interface (e.g., 3ER
The atom types for protein and ligand 
at the left corner, Cp and Op are 
are oxygen and nitrogen atoms from the ligand.
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descriptors using the tesselated 
T).  
are treated differently. For instance, for the 
carbon and oxygen atoms from the protein while 
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Figure 4.3: Flowchart of the 
pose filters, and their use in combination with MedusaScore for VS.
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approach described in this paper for developing target
  
 
 
-specific 
  
Figure 4.4: The awROCE values at 1% (a) and awAUC values (b) of MedusaScore (black) 
and MedusaScore + filter approach (dark green) for each target.
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Figure 4.5: The heat map of 
structure-based scoring functions (XSCORE::HMSCORE, ChemScore, PLP, Chemgauss3, 
and MedusaScore) as well as MedusaScore plus Filter approach for each target. 
We highlight the highest awROCE v
(purple box) 
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Figure 4.6: The awROC curves of VS experiments for 13 DUD data sets. For each target, 
the true positive (FP) rate is plotted against the logarithmic false positive (FP) rate.  
Gray dot dash lines correspond to the random VS performance, magenta lines are from 
FieldScreen, purple lines are from FLAP (LBX), blue lines are from FLAP (RBLB), and 
green lines are from the MedusaScore + pose filter approach
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Figure 4.7: The analysis of ligand cluster type retrieval of MedusaScore + filter approach 
and FLAP::RBLB approach from top 20 ranking list of each data set.  
We rearrange the retrieve clusters of each target based on a) the clusters only retrieved by 
MedusaScore + filter approach (green); b) the clusters only retrieved by FLAP::RBLB 
approach; c) the overlapping clusters of two approaches (cyan).
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Tables for Chapter 4 
Table 4.1: Summary of benchmark data sets used in studies described in this paper. The data 
sets are obtained from DUD website.  
Target  Function  PDB  # of ligands  # of decoys  # of clusters  
ace metallopeptidase 1o86 46 1726 19 
ache  acetylcholine esterase 1eve 99 3631 19 
cdk2  serine/threonine kinase 1ckp 47 1776 32 
cox2 cyclooxygenase 1cx2 212 11841 44 
egfr tyrosine kinase 1m17 365 14516 40 
fxa serine protease 1f0r 64 1888 19 
hivrt HIV reverse transcriptase 1rti 34 1415 17 
inha enoyl ACP reductase 1p44 57 2501 23 
p38 serine/threonine kinase 1kv2 137 6230 20 
pde5 phosphodiesterase 1xp0 26 1562 22 
pdgfrb tyrosine kinase modela 124 5265 22 
src tyrosine kinase 2src 98 5216 21 
vegfr2 tyrosine kinase 1vr2b 48 2479 31 
a: protein structure is homology model, the ligand structure is taken from the DUD website 
b: apo structure, the ligand structure is taken from DUD website 
HIV: Human Immunodeficiency Virus; ACP: Acyl Carrier Protein  
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Table 4.2: Statistics of target-specific pose filters. 
Targets 
Training set 
 
Test set 
Num. 
native-like 
poses 
Num. 
pose 
decoys 
CV 
accuracyα  
 
 Num. 
native-like 
poses 
Num. 
pose 
decoys 
Prediction 
accuracy 
ace 48 49 0.93  13 12 0.89 
ache  437 363 0.96  104 94 0.98 
cdk2  168 245 0.97  44 60 0.96 
cox2 125 96 0.96  36 20 0.99 
egfr 296 504 0.94  74 126 0.97 
fxa 384 416 0.94  100 100 0.94 
hivrt 168 121 0.84  44 29 0.84 
inha 296 504 0.96  78 122 0.96 
p38 20 24 0.91  6 5 0.82 
pde5 295 505 0.96  74 126 0.91 
pdgfrb 276 524 0.96  73 127 0.95 
src 444 356 0.94  112 88 0.94 
vegfr2 132 103 0.93  35 27 0.95 
αAverage CV accuracy is derived from all eligible models with CV accuracy greater than 90% 
except for the HIVRT data set which has no models with CV accuracy above 90%. Therefore, 
an 80% threshold is applied 
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Table 4.3: Average 2D Tc of the active ligands retrieved from the top 20 ranking list of 
scoring approaches (FieldScreen, FLAP::LBX, FLAP::RBLB, and MedusaScore + filter).  
Target 
2D similarity 
FieldScreen FLAP::LBX FLAP::RBLB MedusaScore + Filter 
ace 0.75 0.76 0.59 0.74 
ache  0.75 0.81 0.52 0.48 
cdk2  0.72 0.50 0.49 0.70 
cox2 0.88 0.88 0.68 NA 
egfr 0.58 0.50 0.45 0.64 
fxa 0.49 0.95 0.45 0.45 
hivrt 0.78 0.79 0.60 0.59 
inha 0.82 0.82 0.69 0.81 
p38 0.66 NA 0.45 0.57 
pde5 0.74 0.67 0.57 0.69 
pdgfrb 0.64 0.64 0.47 0.66 
src 0.44 NA 0.47 0.45 
vegfr2 0.59 0.67 0.48 0.47 
Aver. Similarity 0.68 0.73 0.53 0.60 
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Supplementary Figures in Chapter 4 
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Figure S4.1: The distribution of poses generated from re-docking cognate ligand against its 
respective target.  
The left plot shows the pose distribution based on z-score values of MedusaScore (x-axis) vs. 
RMSD values (y-axis).  
The middle plot shows the pose distribution based on the distance to the native pose (x-axis) 
vs. RMSD (y-axis).  
The right plot highlights the poses used for constructing filter.  
The data points are colored corresponding to their z-score values of MedusaScore (the 
smaller z-score values, the better the MedusaScore). 
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Figure S4.2: The awROC curves of VS experiments for the 13 DUD data sets. For each 
target, the true positive (FP) rate is plotted against the logarithmic false positive (FP) rate. 
Gray dot dash lines correspond to the random VS performance, red lines are from 
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MedusaScore, blue lines are from the MedusaScore +dist.Score approach, and green lines are 
from the MedusaScore + pose filter approach 
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Supplementary Tables in Chapter 4 
 
Table S4.1:  awROCE enrichment at 0.5% of structure-based scoring functions and the 
combined scoring approach 
target XSCORE::HMSCORE Fred::ChemScore Fred::PLP Fred::Chemgauss3 MedusaScore MedusaScore + filter 
ace 32.78  ±  8.06 25.45  ±  7.70 43.00  ±  9.06 28.11  ±  9.13 21.65  ±  5.53 36.95  ±  8.26 
ache 28.48  ±  6.55 0.00  ±  0.00 0.00  ±  0.00 1.12  ±  0.48 24.38  ±  6.74 44.97  ±  10.16 
cdk2 8.51  ±  4.13 27.71  ±  7.42 42.88  ±  6.83 27.90  ±  9.02 11.04  ±  3.19 26.73  ±  4.85 
cox2 5.89  ±  1.19 0.00  ±  0.00 4.45  ±  2.10 12.07  ±  2.49 4.16  ±  2.07 8.29  ±  2.87 
egfr 8.21  ±  1.98 18.38  ±  3.19 5.63  ±  1.70 12.80  ±  2.91 23.59  ±  4.27 41.61  ±  4.49 
fxa 8.18  ±  5.71 14.52  ±  4.79 6.70  ±  4.99 4.86  ±  4.04 0.00  ±  0.00 9.69  ±  4.87 
hivrt 23.77  ±  7.62 11.33  ±  5.73 0.01  ±  0.39 15.66  ±  5.91 23.92  ±  8.00 46.03  ±  9.60 
inha 8.79  ±  1.29 17.79  ±  5.89 15.70  ±  4.28 17.23  ±  4.25 5.92  ±  1.35 21.66  ±  6.24 
p38 0.00  ±  0.15 12.75  ±  6.45 13.03  ±  6.46 13.12  ±  6.39 28.69  ±  7.32 66.95  ±  17.33 
pde5 0.00  ±  0.00 1.11  ±  3.36 0.06  ±  0.84 9.59  ±  5.05 0.00  ±  0.00 59.08  ±  13.50 
pdgfrb 29.65  ±  5.32 15.16  ±  4.12 16.58  ±  4.07 16.26  ±  6.02 37.18  ±  6.51 86.46  ±  11.56 
src 0.50  ±  0.42 25.97  ±  7.23 0.00  ±  0.00 5.62  ±  1.26 24.77  ±  6.29 0.00  ±  0.00 
vegfr2 7.85  ±  4.38 34.53  ±  6.75 6.18  ±  3.11 14.18  ±  5.57 19.97  ±  5.94 30.00  ±  6.66 
       
 
Table S4.2:  awROCE enrichment at 1% of structure-based scoring functions and the 
combined scoring approach 
target XSCORE::HMSCORE Fred::ChemScore Fred::PLP Fred::Chemgauss3 MedusaScore MedusaScore + filter 
ace 23.71  ±  4.24 15.47  ±  4.77 24.56  ±  4.15 21.33  ±  4.50 10.91  ±  2.86 18.44  ±  4.13 
ache 14.64  ±  3.31 0.00  ±  0.00 0.02  ±  0.08 1.37  ±  0.38 18.37  ±  3.91 26.22  ±  4.95 
cdk2 8.99  ±  2.42 20.90  ±  4.84 26.56  ±  4.03 20.13  ±  4.57 9.47  ±  2.06 14.36  ±  2.33 
cox2 9.67  ±  1.85 0.83  ±  0.51 2.79  ±  1.07 8.79  ±  1.64 2.08  ±  1.03 4.14  ±  1.44 
egfr 6.46  ±  1.34 19.48  ±  2.33 4.75  ±  1.34 10.37  ±  1.78 17.22  ±  1.99 25.69  ±  2.13 
fxa 4.86  ±  2.42 11.26  ±  2.73 15.20  ±  3.76 13.82  ±  4.35 0.15  ±  0.95 4.85  ±  2.44 
hivrt 11.94  ±  3.90 9.12  ±  3.49 4.13  ±  3.35 18.13  ±  5.15 17.39  ±  4.45 22.88  ±  4.77 
inha 9.28  ±  2.15 16.46  ±  3.17 7.96  ±  2.15 10.33  ±  2.39 3.73  ±  0.63 11.26  ±  2.91 
p38 6.28  ±  3.31 6.52  ±  3.22 6.51  ±  3.23 6.56  ±  3.19 18.46  ±  4.71 35.65  ±  8.41 
pde5 0.00  ±  0.00 4.80  ±  2.39 4.23  ±  2.43 7.24  ±  2.86 0.00  ±  0.00 26.49  ±  6.07 
pdgfrb 14.82  ±  2.66 16.93  ±  3.20 12.28  ±  2.73 11.59  ±  2.74 23.49  ±  3.46 43.18  ±  5.77 
src 0.53  ±  0.21 21.37  ±  4.10 0.52  ±  0.31 7.27  ±  1.98 18.46  ±  3.93 0.00  ±  0.00 
vegfr2 6.47  ±  2.38 17.25  ±  3.37 3.09  ±  1.55 13.22  ±  3.34 12.30  ±  2.89 15.39  ±  3.23 
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Table S4.3:  awROCE enrichment at 2% of structure-based scoring functions and the 
combined scoring approach 
target XSCORE::HMSCORE Fred::ChemScore Fred::PLP Fred::Chemgauss3 MedusaScore MedusaScore + filter 
ace 15.47  ±  3.01 12.00  ±  2.54 12.72  ±  2.05 14.39  ±  2.60 7.84  ±  1.78 11.53  ±  2.56 
ache 7.72  ±  1.60 0.77  ±  0.38 0.82  ±  0.60 0.94  ±  0.23 10.47  ±  1.89 17.16  ±  2.60 
cdk2 7.71  ±  1.57 15.60  ±  1.91 14.42  ±  1.88 14.97  ±  1.76 8.30  ±  1.33 7.18  ±  1.16 
cox2 7.34  ±  1.21 2.07  ±  0.59 3.10  ±  0.79 8.23  ±  1.10 1.04  ±  0.52 2.07  ±  0.72 
egfr 4.92  ±  0.79 13.08  ±  1.39 4.63  ±  0.78 8.18  ±  0.98 12.46  ±  1.22 15.78  ±  1.25 
fxa 2.45  ±  1.22 10.63  ±  1.99 10.46  ±  1.99 7.72  ±  1.73 2.40  ±  1.23 4.91  ±  1.66 
hivrt 8.59  ±  2.20 6.53  ±  2.17 5.59  ±  2.30 10.76  ±  2.24 8.68  ±  2.22 12.76  ±  2.81 
inha 4.68  ±  1.05 8.75  ±  1.59 5.43  ±  1.24 5.47  ±  1.20 2.63  ±  0.31 5.65  ±  1.48 
p38 3.25  ±  1.62 3.27  ±  1.61 3.26  ±  1.61 3.28  ±  1.59 11.34  ±  2.21 20.63  ±  4.47 
pde5 0.00  ±  0.00 4.90  ±  1.72 2.58  ±  1.49 4.53  ±  1.57 1.91  ±  2.01 14.27  ±  3.61 
pdgfrb 7.56  ±  1.33 11.29  ±  1.98 6.30  ±  1.36 6.16  ±  1.36 16.32  ±  1.92 21.58  ±  2.89 
src 0.40  ±  0.23 18.72  ±  2.11 0.74  ±  0.21 5.30  ±  0.68 11.84  ±  1.93 0.00  ±  0.04 
vegfr2 4.96  ±  1.29 12.06  ±  2.06 2.49  ±  0.96 7.07  ±  1.55 6.85  ±  1.57 12.70  ±  1.90 
       
 
Table S4.4:  awROCE enrichment at 5% of structure-based scoring functions and the 
combined scoring approach 
target XSCORE::HMSCORE Fred::ChemScore Fred::PLP Fred::Chemgauss3 MedusaScore MedusaScore + filter 
ace 8.48  ±  1.00 5.84  ±  0.89 5.44  ±  0.96 9.18  ±  1.12 3.13  ±  0.71 7.04  ±  1.00 
ache 3.09  ±  0.64 0.64  ±  0.28 4.08  ±  0.72 1.94  ±  0.32 4.35  ±  0.75 8.39  ±  1.12 
cdk2 3.64  ±  0.62 6.92  ±  0.70 7.74  ±  0.82 7.40  ±  0.77 5.30  ±  0.69 5.14  ±  0.69 
cox2 4.94  ±  0.56 1.61  ±  0.32 2.40  ±  0.40 5.38  ±  0.56 1.24  ±  0.35 1.66  ±  0.39 
egfr 3.60  ±  0.37 9.56  ±  0.50 3.62  ±  0.40 4.36  ±  0.43 10.41  ±  0.49 9.25  ±  0.57 
fxa 1.97  ±  0.72 5.79  ±  0.93 6.13  ±  0.91 3.16  ±  0.69 1.54  ±  0.60 4.18  ±  0.91 
hivrt 4.32  ±  1.08 5.14  ±  1.03 3.07  ±  0.80 7.21  ±  1.05 4.56  ±  0.97 5.88  ±  1.01 
inha 2.69  ±  0.57 5.54  ±  0.76 3.10  ±  0.46 3.99  ±  0.69 1.97  ±  0.43 4.18  ±  0.75 
p38 1.30  ±  0.65 1.84  ±  0.65 2.64  ±  0.74 1.35  ±  0.64 5.85  ±  1.04 10.49  ±  1.49 
pde5 0.00  ±  0.00 2.95  ±  0.76 2.00  ±  0.77 3.15  ±  0.69 3.57  ±  0.84 6.90  ±  1.36 
pdgfrb 3.97  ±  0.62 6.68  ±  0.72 4.27  ±  0.75 4.57  ±  0.64 8.33  ±  0.77 8.63  ±  1.15 
src 0.72  ±  0.10 9.67  ±  0.77 0.49  ±  0.12 3.28  ±  0.76 5.49  ±  0.78 0.19  ±  0.11 
vegfr2 1.98  ±  0.52 6.65  ±  0.80 2.24  ±  0.58 2.92  ±  0.62 5.44  ±  0.75 6.27  ±  0.79 
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Table S4.5:  awAUC of structure-based scoring functions and the combined scoring 
approach 
target XSCORE::HMSCORE Fred::ChemScore Fred::PLP Fred::Chemgauss3 MedusaScore MedusaScore + filter 
ace 0.69  ±  0.04 0.68  ±  0.03 0.64  ±  0.03 0.66  ±  0.04 0.52  ±  0.04 0.63  ±  0.04 
ache 0.42  ±  0.03 0.47  ±  0.03 0.51  ±  0.03 0.47  ±  0.03 0.43  ±  0.04 0.73  ±  0.03 
cdk2 0.60  ±  0.03 0.78  ±  0.02 0.61  ±  0.03 0.78  ±  0.02 0.57  ±  0.03 0.71  ±  0.02 
cox2 0.68  ±  0.02 0.64  ±  0.01 0.61  ±  0.02 0.73  ±  0.02 0.27  ±  0.02 0.39  ±  0.02 
egfr 0.57  ±  0.01 0.92  ±  0.00 0.67  ±  0.02 0.66  ±  0.01 0.83  ±  0.01 0.85  ±  0.01 
fxa 0.57  ±  0.03 0.75  ±  0.02 0.76  ±  0.02 0.73  ±  0.02 0.52  ±  0.03 0.72  ±  0.02 
hivrt 0.53  ±  0.04 0.68  ±  0.04 0.54  ±  0.04 0.75  ±  0.03 0.55  ±  0.04 0.64  ±  0.04 
inha 0.29  ±  0.03 0.55  ±  0.03 0.45  ±  0.03 0.51  ±  0.03 0.44  ±  0.03 0.57  ±  0.03 
p38 0.39  ±  0.03 0.42  ±  0.03 0.40  ±  0.03 0.35  ±  0.03 0.64  ±  0.03 0.81  ±  0.03 
pde5 0.40  ±  0.03 0.70  ±  0.03 0.60  ±  0.03 0.61  ±  0.03 0.65  ±  0.03 0.75  ±  0.04 
pdgfrb 0.44  ±  0.03 0.74  ±  0.01 0.64  ±  0.02 0.63  ±  0.02 0.60  ±  0.03 0.69  ±  0.03 
src 0.44  ±  0.02 0.83  ±  0.01 0.45  ±  0.02 0.67  ±  0.02 0.50  ±  0.03 0.66  ±  0.05 
vegfr2 0.43  ±  0.03 0.83  ±  0.01 0.58  ±  0.03 0.74  ±  0.02 0.65  ±  0.03 0.67  ±  0.03 
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Table S4.6: awROCE enrichment at 0.5% of FieldScreen, FLAP (LBX), FLAP(RBLB), 
MedusaScore + filter 
target FieldScreen FLAP (LBX) FLAP (RBLB) MedusaScore + filter 
ace 13.76  ±  7.42 28.56  ±  8.92 6.53  ±  1.96 36.95  ±  8.26 
ache 15.88  ±  5.11 63.00  ±  8.16 48.39  ±  8.07 44.97  ±  10.16 
cdk2 8.56  ±  3.29 27.66  ±  6.17 41.61  ±  7.53 26.73  ±  4.85 
cox2 50.93  ±  4.67 57.33  ±  6.00 16.74  ±  5.59 8.29  ±  2.87 
egfr 48.57  ±  5.22 47.96  ±  5.40 19.80  ±  2.89 41.61  ±  4.49 
fxa 0.90  ±  2.54 9.57  ±  4.97 8.68  ±  1.81 9.69  ±  4.87 
hivrt 39.99  ±  8.18 33.47  ±  7.44 27.59  ±  4.46 46.03  ±  9.60 
inha 59.47  ±  7.05 70.23  ±  8.70 79.98  ±  8.20 21.66  ±  6.24 
p38 3.99  ±  0.74 0.00  ±  0.00 5.56  ±  2.00 66.95  ±  17.33 
pde5 8.19  ±  3.90 28.35  ±  5.61 73.64  ±  10.84 59.08  ±  13.50 
pdgfrb 25.91  ±  5.38 1.61  ±  0.96 2.36  ±  0.57 86.46  ±  11.56 
src 13.09  ±  4.78 0.00  ±  0.04 63.41  ±  8.08 0.00  ±  0.00 
vegfr2 13.58  ±  4.51 6.34  ±  3.32 48.22  ±  6.28 30.00  ±  6.66 
 
Table S4.7: awROCE enrichment at 1% of FieldScreen, FLAP (LBX), FLAP(RBLB), 
MedusaScore + filter 
target FieldScreen FLAP (LBX) FLAP (RBLB) MedusaScore + filter 
ace 12.23  ±  3.51 21.84  ±  5.58 11.15  ±  3.79 18.44  ±  4.13 
ache 19.69  ±  5.55 34.58  ±  3.99 28.66  ±  4.07 26.22  ±  4.95 
cdk2 4.27  ±  1.64 18.41  ±  3.28 22.11  ±  3.18 14.36  ±  2.33 
cox2 30.33  ±  2.54 30.70  ±  2.77 14.98  ±  2.00 4.14  ±  1.44 
egfr 28.04  ±  2.55 27.45  ±  2.75 14.66  ±  1.52 25.69  ±  2.13 
fxa 3.36  ±  2.32 8.27  ±  3.81 9.67  ±  2.48 4.85  ±  2.44 
hivrt 19.89  ±  4.07 16.64  ±  3.70 18.76  ±  3.59 22.88  ±  4.77 
inha 11.77  ±  2.31 36.51  ±  3.98 44.46  ±  4.25 11.26  ±  2.91 
p38 32.58  ±  3.81 0.00  ±  0.00 2.82  ±  1.00 35.65  ±  8.41 
pde5 2.04  ±  0.36 14.13  ±  2.79 36.76  ±  5.43 26.49  ±  6.07 
pdgfrb 5.70  ±  2.82 2.19  ±  0.67 1.19  ±  0.29 43.18  ±  5.77 
src 13.00  ±  2.66 0.33  ±  0.18 37.53  ±  4.42 0.00  ±  0.00 
vegfr2 6.77  ±  2.39 4.92  ±  1.96 24.12  ±  3.15 15.39  ±  3.23 
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Table S4.8: awROCE enrichment at 2% of FieldScreen, FLAP (LBX), FLAP(RBLB), 
MedusaScore + filter 
target FieldScreen FLAB (LBX) FLAP (RBLB) MedusaScore + filter 
ace 8.08  ±  2.84 17.00  ±  2.70 7.52  ±  1.74 11.53  ±  2.56 
ache 14.14  ±  1.78 20.30  ±  2.01 16.68  ±  1.94 17.16  ±  2.60 
cdk2 2.13  ±  0.82 10.23  ±  1.62 11.94  ±  1.68 7.18  ±  1.16 
cox2 18.71  ±  1.62 16.28  ±  1.39 9.64  ±  1.07 2.07  ±  0.72 
egfr 17.75  ±  1.40 15.49  ±  1.27 8.93  ±  0.90 15.78  ±  1.25 
fxa 5.42  ±  1.35 7.15  ±  2.29 5.14  ±  1.23 4.91  ±  1.66 
hivrt 11.77  ±  2.31 8.71  ±  2.14 9.57  ±  1.70 12.76  ±  2.81 
inha 16.29  ±  1.91 18.26  ±  1.99 24.51  ±  2.15 5.65  ±  1.48 
p38 1.14  ±  0.20 0.00  ±  0.00 4.41  ±  1.18 20.63  ±  4.47 
pde5 10.12  ±  2.07 7.05  ±  1.39 20.61  ±  2.76 14.27  ±  3.61 
pdgfrb 8.51  ±  1.55 3.20  ±  1.04 0.93  ±  0.18 21.58  ±  2.89 
src 3.55  ±  1.20 1.07  ±  0.64 19.91  ±  2.03 0.00  ±  0.04 
vegfr2 7.06  ±  1.56 3.38  ±  1.14 14.14  ±  1.69 12.70  ±  1.90 
 
 
Table S4.9: awROCE enrichment at 5% of FieldScreen, FLAP (LBX), FLAP(RBLB), 
MedusaScore + filter 
target FieldScreen FLAB (LBX) FLAP (RBLB) MedusaScore + filter 
ace 4.64  ±  0.96 7.59  ±  0.98 3.28  ±  0.70 7.04  ±  1.00 
ache 7.57  ±  0.80 8.71  ±  0.83 8.11  ±  0.82 8.39  ±  1.12 
cdk2 0.85  ±  0.33 5.02  ±  0.69 6.18  ±  0.75 5.14  ±  0.69 
cox2 10.49  ±  0.63 7.32  ±  0.59 5.72  ±  0.54 1.66  ±  0.39 
egfr 9.34  ±  0.54 8.38  ±  0.57 5.10  ±  0.40 9.25  ±  0.57 
fxa 5.14  ±  0.87 3.46  ±  0.84 4.29  ±  1.09 4.18  ±  0.91 
hivrt 5.14  ±  0.99 6.63  ±  0.96 4.95  ±  0.82 5.88  ±  1.01 
inha 6.85  ±  0.74 8.10  ±  0.82 10.21  ±  0.85 4.18  ±  0.75 
p38 0.53  ±  0.08 0.11  ±  0.02 2.61  ±  0.54 10.49  ±  1.49 
pde5 4.75  ±  0.96 5.49  ±  0.89 9.92  ±  1.06 6.90  ±  1.36 
pdgfrb 3.56  ±  0.62 1.35  ±  0.43 0.74  ±  0.14 8.63  ±  1.15 
src 2.40  ±  0.62 2.38  ±  0.69 9.67  ±  0.85 0.19  ±  0.11 
vegfr2 3.57  ±  0.63 1.89  ±  0.59 7.69  ±  0.82 6.27  ±  0.79 
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Table S4.10: awAUC of FieldScreen, FLAP (LBX), FLAP(RBLB), MedusaScore + filter 
target FieldScreen FLAP (LBX) FLAP (RBLB) MedusaScore + filter 
ace 0.64  ±  0.04 0.69  ±  0.03 0.53  ±  0.03 0.63  ±  0.04 
ache 0.63  ±  0.03 0.62  ±  0.04 0.74  ±  0.03 0.73  ±  0.03 
cdk2 0.44  ±  0.02 0.68  ±  0.02 0.50  ±  0.03 0.71  ±  0.02 
cox2 0.82  ±  0.02 0.69  ±  0.02 0.49  ±  0.02 0.39  ±  0.02 
egfr 0.82  ±  0.01 0.70  ±  0.02 0.55  ±  0.02 0.85  ±  0.01 
fxa 0.73  ±  0.02 0.61  ±  0.03 0.62  ±  0.03 0.72  ±  0.02 
hivrt 0.64  ±  0.04 0.56  ±  0.04 0.61  ±  0.04 0.64  ±  0.04 
inha 0.72  ±  0.02 0.66  ±  0.03 0.67  ±  0.03 0.57  ±  0.03 
p38 0.28  ±  0.02 0.31  ±  0.02 0.45  ±  0.03 0.81  ±  0.03 
pde5 0.62  ±  0.03 0.55  ±  0.04 0.64  ±  0.05 0.75  ±  0.04 
pdgfrb 0.40  ±  0.03 0.44  ±  0.02 0.34  ±  0.03 0.69  ±  0.03 
src 0.39  ±  0.03 0.44  ±  0.03 0.80  ±  0.02 0.66  ±  0.05 
vegfr2 0.53  ±  0.03 0.59  ±  0.03 0.61  ±  0.03 0.67  ±  0.03 
   
Chapter 5 Conclusions and Future Directions 
5.1  Applications of Cheminformatics Approaches to Complement Structure-based 
Drug Design 
In Chapter 2, I have discussed two case studies demonstrating that cheminformatics 
approaches can complement structure-based drug discovery/drug design and identify 
promising hits by virtually screening molecular libraries. The first case study is prediction of 
efflux properties (low vs. high) for Gram-negative bacteria, by the binary classification 
QSAR approach with pharmacophore fingerprint descriptors. Bacterial efflux properties are 
difficult to model by structure-based methods due to the structural complexity of the efflux 
pump. However, I have successfully constructed QSAR models which show high prediction 
accuracy in both internal and external validation. After applying the models to virtual 
screening, many compounds predicted as low-efflux were experimentally confirmed as such. 
In the future, I propose to conduct a comprehensive descriptor analysis of predictive models 
to identify discriminative 3D pharmacophoric features that might contribute to the low-efflux 
property. The identified 3D pharmacophoric features could provide useful information for the 
design of low-efflux compounds. The success of this project also suggests that the 
pharmacophore fingerprint-based SVM QSAR modeling protocol could be applied to predict 
observations arising from a complex mechanism of action, for example, the permeability of 
antibiotics.  
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The second case study is differentiation of AmpC β-lactamase binders vs. binding 
decoys using the binary classification QSAR approach. The binding decoys are false 
positives mispredicted by the conventional structure-based scoring function (the DOCK score 
in this case). To differentiate them, I have successfully constructed predictive QSAR models 
based on rigorous internal and external validations. Applying the models to predict false 
positives and false negatives from high throughput screening, I showed that the models can 
discard false positives and can rescue false negatives. Besides, the occurrence frequencies of 
the 2D chemical descriptors in those models were calculated and those 2D chemical 
descriptors were then ranked based on their respective frequencies. The top-ranked 
descriptors could provide the information of possible deficiencies of conventional structure-
based scoring functions. For example, the nitrile-group-counts descriptor (“nnitrile”) has a 
high rank (#3) in the frequent descriptor analysis and is only found in the structures of 
binding decoys, suggesting, it might play an important role in the misprediction by the 
DOCK score. Furthermore, it is possible to try to include the energetic terms from the 
structure-based scoring function as descriptors to construct binary classification QSAR 
models. In that way, the identified frequent descriptors might be found to be directly related 
to the flawed energetic terms that cause misprediction.  
The results of these two example studies suggest that at least in some cases, when a 
sufficient amount of data is available, QSAR modeling approaches could be used to 
complement structure-based drug discovery/drug design. 
5.2  Development of Single-family based QSBAR Models for Lead 
Optimization 
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In Chapter 3, I have demonstrated the development of a generic binding scoring 
function, which is a collection of QSBAR models. Compared with the previously reported 
ENTess scoring function, the new binding scoring function is constructed with a larger 
number of protein-ligand complexes, representing a more diverse set of protein families, and 
with novel, protein-ligand interfacial descriptors incorporating conceptual DFT atomic 
properties. Upon the application of global applicability domain, this new binding scoring 
function shows acceptable prediction accuracy towards the CSAR data set (n=199, R2: 0.57), 
which is much better than the prediction results from the ENTess scoring function (n=135, R2: 
0.30).  
It will be beneficial to include more protein-ligand complexes with diverse protein 
families to construct another new set of predictive QSBAR models based on the same 
protocol, which could bear larger applicability domain. In Chapter 3, I have shown that 
using the QSBAR models constructed based on the larger data set (PDBbind data set + Set2) 
significantly improves the external prediction accuracy of Set1 compared with using the 
models constructed from the smaller Set2 alone (R2: from 0.40 to 0.50). However, aside from 
the construction of diverse-family based QSBAR models for generic docking purpose, I 
would like to propose to construct single-family based QSBAR models in the hope of 
achieving better prediction accuracy. What is even more important is that the single-family 
based QSBAR models built with protein-ligand interfacial descriptors could address the 
selectivity issue of ligands between subfamilies, which is difficult to account for when using 
2D chemical descriptors alone (as is done in conventional QSAR modeling).  
The collection of protein-ligand complexes, where the protein belongs to the kinase 
family and the ligand is a Type I ATP competitive inhibitor,174 can be a good starting point 
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for constructing single-family based QSBAR models due to its relatively large size. The 
kinase family consists of many well-studied protein targets. Many marketed drugs act as 
inhibitors against protein targets in this family.184 Other than discovering novel chemical 
scaffolds for a new kinase target involved in a disease, researchers are also highly interested 
in accurately predicting binding affinity of leads (i.e., lead optimization) and the selectivity 
profile of compounds. Thus, in the future, I propose to construct the kinase-family based 
QSBAR models for lead optimization.   
5.3  Improvement of Pose (-scoring) Filter for Virtual Screening   
In Chapter 4, I have described the development of the target-specific pose (-scoring) 
filter with the aim to improve the hit enrichment in structure based virtual screening. The 
pose filter is developed for each target by building binary classification models that can 
discriminate native-like poses of ligands vs. pose decoys. The training set to develop the filter 
is generated by multiple rounds of docking a single cognate ligand against its binding target, 
which generates a large sample of docked poses for this ligand that differ in RMSD from the 
native pose in the x-ray characterized protein-ligand complex. The pose library is divided 
into native-like poses (typically, those with RMSD less than 4 Å from the native pose) and 
decoys (RMSD greater or equal to 4 Å).  Each pose is characterized by the chemical 
descriptors of the protein-ligand interface, which are used as independent variables for 
developing a binary classifier (i.e., the filter) that discriminates native-like from decoy poses. 
Furthermore, a two-step scoring protocol for target-specific virtual screening is developed. In 
the first step, the pose filter is used to remove/penalize putative pose decoys for every 
compound, and in the second step the remaining putative native-like poses are scored with 
MedusaScore, which is a conventional force-field-based scoring function.  
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The validation of this scoring protocol based on the DUD data sets, which are 
designed for benchmarking, has demonstrated that this method can consistently improve the 
VS performance of MedusaScore and outperforms many of the conventional structure-based 
scoring functions. The combined scoring protocol also showed its ability to perform scaffold 
hopping. In the future, this combined scoring protocol could be applied to virtual screening 
against several pharmaceutically relevant protein targets to identify promising leads. In 
particular, this method is suitable for protein targets with limited ligand binding data 
available. A single x-ray protein-ligand complex or, as I have demonstrated in Chapter 4, a 
homology protein model with a known binder is enough for constructing a target-specific 
pose filter. Moreover, the pose filter should be theoretically able to add upon any structure-
based scoring functions to consistently improve their VS performance.   
To further improve the pose filter, I propose to develop protein-ligand interfacial 
descriptors with pharmacophoric node types, e.g., hydrogen-bond donor nodes or 
hydrophobic nodes. As discussed in Chapter 4.4, the atom types in current implementation 
of PL/MCT-tess descriptors are defined based on their exact chemical names. This 
implementation makes PL/MCT-tess descriptors fairly sensitive to special interactions. 
However, using poses with such interactions to construct pose filter makes it too specific 
(e.g., the Src failure case analyzed in Chapter 4.4). Besides, chirality of tetrahedra (see 
tessellation, Chapter 2.2.2) can be also included as a descriptive property, which could 
significantly increase the amount of information for protein-ligand recognition. The new 
descriptors should be also useful to construct QSBAR models described in Chapter 3. 
Since the definition of pose decoys is based only on the RMSD threshold, 
independent from scoring functions’ output, theoretically, the pose filter can be used in 
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combination with any other structure-based scoring function. However, it should be 
interesting to include the output of a scoring function into the definition of native-like poses 
and pose decoys (e.g., to train the pose filter only on those native-like poses and pose decoys 
that are ranked high by the given scoring function), thus, building filters specifically adjusted 
for each scoring function. Although this implementation might limit the application of the 
pose filter to a specific scoring function, it might significantly improve the performance of 
the combined scoring protocol in virtual screening.   
It is a sensible assumption that adding more information should increase the 
applicability domain of the pose filter. Therefore, the idea of including poses from several 
protein-ligand complexes to construct a pose filter can be attractive. However, some initial 
trials suggest that constructing a multi-complex pose filter, by muddling all native-like poses 
and pose decoys generated from different protein-ligand complexes together, only decreases 
the discriminative ability of the pose filter when applying it to virtually screen poses 
generated from docking compounds against a particular protein. It seems that including poses 
generated from different protein-ligand complexes confuses the pose filter when predicting 
VS poses from a particular protein. Further investigation of combining poses from several 
protein-ligand complexes to construct a pose filter is needed. On the other hand, the merge of 
ranking lists produced by using several different single-complex pose filters is a viable 
alternative to the multiple-complex pose-filter strategy. Many data fusion techniques (and 
rank-merge algorithms in particular) can be applied. For example, the Pareto ranking 
approach generally shows better performance than the most common and simple consensus 
rank sum approach in the FLAP168 paper.   
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Appendices 
Appendix I: The AmpC β-lactamase modeling set (16 binders + 25 binding decoys) 
Name Structure Name Structure 
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Appendix II: The compiled 665 PDBbind data set 
PDB code pKd PDB code pKd PDB code pKd PDB code pKd PDB code pKd 
10gs.pdb 6.4 1b6k.pdb 8.74 1d09.pdb 7.57 1fkb.pdb 9.7 1ha2.pdb 5.54 
1a08.pdb 5.62 1b6m.pdb 8.4 1d3d.pdb 9.09 1fkh.pdb 8.15 1hbv.pdb 6.37 
1a0q.pdb 7.57 1b7h.pdb 8.02 1d3p.pdb 7.39 1fki.pdb 7 1heg.pdb 7.74 
1a1b.pdb 6.4 1b8n.pdb 10.52 1d4k.pdb 9.22 1fkn.pdb 8.8 1hfs.pdb 8.7 
1a1e.pdb 6 1b8o.pdb 10.64 1d4l.pdb 8.77 1fkw.pdb 5.05 1hi4.pdb 4.49 
1a30.pdb 4.3 1b9j.pdb 5.96 1d4p.pdb 6.3 1flr.pdb 10 1hih.pdb 8.05 
1a42.pdb 9.89 1bcd.pdb 8.7 1d6w.pdb 5.96 1fo0.pdb 5.59 1hk4.pdb 5.31 
1a4w.pdb 5.92 1bcu.pdb 3.28 1d7i.pdb 3.6 1fpc.pdb 7 1hpo.pdb 9.22 
1a69.pdb 5.3 1bdq.pdb 6.34 1d7j.pdb 3.3 1ftm.pdb 7.61 1hps.pdb 9.22 
1a9m.pdb 6.92 1bhx.pdb 6.84 1det.pdb 4.3 1fzj.pdb 8.1 1hvh.pdb 7.96 
1abf.pdb 5.42 1bma.pdb 4.59 1df8.pdb 9.7 1fzk.pdb 8.4 1hvi.pdb 10.92 
1af6.pdb 1.82 1bn1.pdb 9.34 1dhi.pdb 7.26 1fzm.pdb 7.7 1hvj.pdb 11.4 
1afl.pdb 6.28 1bn4.pdb 9.31 1dhj.pdb 6.55 1g2k.pdb 7.96 1hvl.pdb 9.95 
1ai4.pdb 2.5 1bnn.pdb 10 1dif.pdb 10.66 1g30.pdb 6.85 1hvr.pdb 9.51 
1ai5.pdb 3.72 1bnt.pdb 9.8 1dmp.pdb 9.55 1g35.pdb 8.14 1hwr.pdb 8.33 
1ajp.pdb 2.23 1bnu.pdb 9.7 1e1v.pdb 4.92 1g3d.pdb 5.55 1hxb.pdb 9.92 
1ajq.pdb 4.31 1bnv.pdb 8.77 1e1x.pdb 5.89 1g45.pdb 8.64 1hxw.pdb 10.82 
1ajv.pdb 7.72 1bra.pdb 1.82 1e5a.pdb 7.64 1g46.pdb 8.8 1i9l.pdb 8.48 
1ajx.pdb 7.91 1bxo.pdb 10 1e66.pdb 9.89 1g48.pdb 8.41 1i9m.pdb 8.48 
1alw.pdb 6.52 1bxq.pdb 7.38 1ejn.pdb 5.62 1g4o.pdb 8.25 1i9n.pdb 8.66 
1apw.pdb 8 1c1u.pdb 8.25 1ela.pdb 6.36 1g52.pdb 9.54 1i9o.pdb 8.42 
1avn.pdb 3.9 1c1v.pdb 7.64 1elb.pdb 7.15 1g53.pdb 9.04 1i9p.pdb 8.41 
1ax0.pdb 3.13 1c5c.pdb 6.96 1eld.pdb 6.7 1g54.pdb 8.82 1i9q.pdb 8.41 
1axz.pdb 3.2 1c5p.pdb 4.68 1ele.pdb 6.85 1g7q.pdb 6.06 1if7.pdb 10.52 
1b05.pdb 7.12 1c5q.pdb 6.36 1ent.pdb 6.96 1ghw.pdb 4.2 1if8.pdb 9.64 
1b11.pdb 7.39 1c5s.pdb 6 1ezq.pdb 9.05 1ghz.pdb 4.8 1iiq.pdb 7.48 
1b1h.pdb 7.03 1c5x.pdb 6.68 1f0s.pdb 7.74 1gi6.pdb 6.22 1is0.pdb 7 
1b32.pdb 7.1 1c5y.pdb 4.2 1f4e.pdb 2.96 1gi8.pdb 5.05 1iy7.pdb 6.19 
1b38.pdb 6.6 1c5z.pdb 4.01 1f4f.pdb 4.62 1gja.pdb 5.42 1j16.pdb 3.84 
1b39.pdb 6.92 1c83.pdb 4.85 1f4g.pdb 6.48 1gjb.pdb 6.35 1j17.pdb 5.22 
1b3h.pdb 6.21 1c84.pdb 5 1f57.pdb 5.64 1gni.pdb 8.07 1jaq.pdb 4.48 
1b46.pdb 5.28 1c86.pdb 4.7 1f5k.pdb 3.74 1gnm.pdb 6.25 1jmg.pdb 6.07 
1b4h.pdb 5.46 1c87.pdb 4.2 1fcx.pdb 7.19 1gno.pdb 7.7 1jq9.pdb 8.45 
1b51.pdb 7.37 1cbx.pdb 6.35 1fcy.pdb 8.52 1gpk.pdb 5.37 1jqd.pdb 5.16 
1b52.pdb 7.12 1ce5.pdb 4.74 1fcz.pdb 9.22 1gz9.pdb 3.51 1jqe.pdb 6.44 
1b5h.pdb 6.01 1cim.pdb 8.82 1fd0.pdb 8.4 1h1p.pdb 4.92 1jys.pdb 3.52 
1b5i.pdb 7.05 1cin.pdb 8.73 1fh7.pdb 5.24 1h1s.pdb 8.22 1k1i.pdb 6.58 
1b5j.pdb 7.43 1cnw.pdb 7.72 1fh8.pdb 6.89 1h22.pdb 9.1 1k21.pdb 8.38 
1b6h.pdb 7.82 1cnx.pdb 7.37 1fh9.pdb 6.43 1h23.pdb 8.35 1k22.pdb 8.4 
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1b6j.pdb 7.92 1cny.pdb 7.85 1fhd.pdb 6.82 1h9z.pdb 5.42 1k4g.pdb 5.85 
1k4h.pdb 5.11 1nfy.pdb 8.89 1pb9.pdb 3.62 1sqo.pdb 7.46 1v2j.pdb 3.25 
1k9s.pdb 6.52 1nh0.pdb 9.74 1pbq.pdb 6.27 1sqt.pdb 6.2 1v2o.pdb 4.73 
1kll.pdb 5.2 1nhu.pdb 5.66 1pph.pdb 5.92 1srg.pdb 5.3 1v2q.pdb 4.13 
1kv1.pdb 5.94 1nja.pdb 6.31 1ppk.pdb 7.66 1sri.pdb 6.08 1v2r.pdb 3.55 
1kv5.pdb 4.22 1njc.pdb 5.55 1ppm.pdb 5.8 1stc.pdb 8.1 1v2t.pdb 4.71 
1kzk.pdb 10.39 1nje.pdb 3.8 1pr5.pdb 3.92 1str.pdb 4.77 1v2w.pdb 4.01 
1l2s.pdb 4.59 1nny.pdb 7.66 1pro.pdb 11.3 1sv3.pdb 4.74 1v48.pdb 7.8 
1l6m.pdb 8.1 1nvq.pdb 8.25 1pxn.pdb 7.15 1swg.pdb 7.36 1vfn.pdb 5.6 
1l83.pdb 3.4 1nwl.pdb 2.39 1pxo.pdb 8.7 1syh.pdb 6.31 1vwl.pdb 5.63 
1li3.pdb 4.25 1o0h.pdb 5.92 1pxp.pdb 6.66 1t4v.pdb 7.68 1vwn.pdb 5.82 
1li6.pdb 3.8 1o0o.pdb 5.1 1pz5.pdb 5.4 1ta2.pdb 8.52 1vzq.pdb 7.44 
1lol.pdb 6.39 1o2h.pdb 7.17 1q63.pdb 5.85 1ta6.pdb 9.13 1w1g.pdb 7.68 
1loq.pdb 3.7 1o2j.pdb 6.92 1q7a.pdb 7.19 1tcx.pdb 6.95 1w3j.pdb 6.32 
1lor.pdb 11.06 1o2k.pdb 6.92 1q8t.pdb 4.76 1tlp.pdb 7.55 1w4o.pdb 5.22 
1lpg.pdb 7.09 1o2o.pdb 6.36 1q8u.pdb 5.96 1tmn.pdb 7.3 1w5v.pdb 8.15 
1lpz.pdb 7.6 1o2s.pdb 5.47 1q8w.pdb 5.24 1tnh.pdb 3.37 1w5w.pdb 8.8 
1m0n.pdb 2.22 1o2w.pdb 5.85 1qaw.pdb 5.12 1tni.pdb 4 1w5y.pdb 8.48 
1m0q.pdb 3.89 1o30.pdb 6.77 1qbu.pdb 10.24 1tnj.pdb 1.96 1ws4.pdb 3 
1m2q.pdb 6.1 1o33.pdb 5.74 1qf2.pdb 5.92 1tnk.pdb 1.49 1ws5.pdb 3.03 
1m2r.pdb 6.46 1o38.pdb 6.82 1qhc.pdb 7.57 1tnl.pdb 1.88 1wvj.pdb 6.73 
1m4h.pdb 9.52 1o3d.pdb 7.13 1qkb.pdb 7.35 1toi.pdb 4.05 1x1z.pdb 11.06 
1m7i.pdb 5.4 1o3f.pdb 7.96 1qpb.pdb 1.36 1toj.pdb 3.39 1xd1.pdb 7.92 
1mai.pdb 6.68 1o3i.pdb 7.3 1rdi.pdb 2.06 1tok.pdb 2.47 1xgj.pdb 6 
1mes.pdb 7.7 1o3j.pdb 6.77 1rdj.pdb 1.66 1trd.pdb 5.4 1xka.pdb 6.88 
1meu.pdb 6.1 1o3k.pdb 6.77 1rdl.pdb 2.24 1tsy.pdb 4.96 1xpz.pdb 7.08 
1mq6.pdb 11.15 1o3p.pdb 6.66 1re8.pdb 9.52 1ttm.pdb 7.35 1y1m.pdb 1.82 
1mrx.pdb 7.26 1obx.pdb 5.72 1rgl.pdb 4.43 1tx7.pdb 4.6 1y1z.pdb 3.08 
1msn.pdb 9.09 1ody.pdb 8.1 1rle.pdb 5.8 1tyr.pdb 7 1y3g.pdb 7.4 
1mtr.pdb 8.4 1ofz.pdb 4.62 1rnt.pdb 5.19 1u1b.pdb 7.8 1y6q.pdb 11.7 
1mu8.pdb 9 1ohr.pdb 8.7 1s38.pdb 5.15 1u2y.pdb 1.74 1yda.pdb 6.55 
1mue.pdb 8.64 1oif.pdb 7.72 1s39.pdb 7.7 1u33.pdb 4.6 1ydb.pdb 8.24 
1n2v.pdb 4.08 1okl.pdb 6.03 1sb1.pdb 6.89 1ulg.pdb 4.21 1ydd.pdb 7.07 
1n5r.pdb 5.66 1ols.pdb 5.82 1sbg.pdb 7.74 1uto.pdb 2.27 1ydr.pdb 5.52 
1nc1.pdb 6.12 1olu.pdb 4.41 1sdt.pdb 9.27 1utp.pdb 1.44 1yds.pdb 5.92 
1nc3.pdb 5 1om1.pdb 6.77 1sdu.pdb 10.07 1uwt.pdb 5.97 1ydt.pdb 7.32 
1ndw.pdb 5.23 1os5.pdb 6.85 1sgx.pdb 5.8 1uz1.pdb 6.89 1z1r.pdb 9.22 
1ndy.pdb 6.17 1owe.pdb 6.2 1sl3.pdb 11.85 1v0k.pdb 5.1 1z6e.pdb 9.72 
1ndz.pdb 8.11 1owh.pdb 7.4 1sle.pdb 6.17 1v11.pdb 3.98 1z71.pdb 9.18 
1nfw.pdb 8.96 1p1o.pdb 5.76 1slg.pdb 3.9 1v16.pdb 3.87 1z9g.pdb 5.64 
1nfx.pdb 8.52 1p1q.pdb 4.89 1sqa.pdb 9.21 1v1m.pdb 3.94 1zc9.pdb 3.22 
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1zdp.pdb 5.74 2cer.pdb 9.22 2j4i.pdb 9 6fiv.pdb 8.08 1g32.pdb 6.11 
1zky.pdb 6.25 2ces.pdb 7.25 2j77.pdb 4.89 6rnt.pdb 2.37 1g3b.pdb 5.74 
1zoe.pdb 7.4 2cet.pdb 8.02 2j78.pdb 6.42 6std.pdb 8.64 1g3e.pdb 5.38 
1zog.pdb 7.15 2cf8.pdb 8.1 2j7b.pdb 6.62 6tim.pdb 3.21 1g4j.pdb 8.7 
1zoh.pdb 7 2cgr.pdb 7.28 2j7d.pdb 7.13 7abp.pdb 6.46 1ghv.pdb 4.35 
1zp8.pdb 8.77 2ctc.pdb 3.89 2j7e.pdb 7.32 7cpa.pdb 13.96 1ghy.pdb 8.1 
1zpa.pdb 8.4 2d0k.pdb 5.02 2j7f.pdb 6.35 7hvp.pdb 9.62 1gi4.pdb 7.19 
1zs0.pdb 6.15 2d1o.pdb 7.7 2j7g.pdb 7 7std.pdb 10.72 1gi9.pdb 5.22 
1zsf.pdb 9.92 2d3u.pdb 6.92 2j7h.pdb 7.19 8abp.pdb 8 1gj6.pdb 7 
1zvx.pdb 9.22 2d3z.pdb 6.64 2qwb.pdb 2.74 8cpa.pdb 9.15 1gj8.pdb 6.96 
2aoc.pdb 4.89 2drc.pdb 9.89 2qwc.pdb 3.55 11gs.pdb 5.82 1gjc.pdb 6.35 
2aod.pdb 5.66 2er6.pdb 7.22 2qwd.pdb 4.85 1a1c.pdb 6.4 1gjd.pdb 5.22 
2aoe.pdb 7.62 2er9.pdb 7.4 2qwe.pdb 7.48 1a94.pdb 7.85 1gnn.pdb 5.68 
2aou.pdb 7.73 2erz.pdb 5.66 2rkm.pdb 3.9 1aaq.pdb 8.4 1gvw.pdb 6.96 
2aqu.pdb 9.32 2f01.pdb 13 2std.pdb 9.85 1afk.pdb 6.62 1gzc.pdb 3.49 
2avm.pdb 5.7 2f80.pdb 8.18 2tmn.pdb 5.89 1ai7.pdb 4.09 1hos.pdb 8.55 
2avo.pdb 8.85 2f81.pdb 10.52 2usn.pdb 6.51 1ajn.pdb 2.63 1hpv.pdb 9.22 
2avq.pdb 4.39 2f8g.pdb 8.7 3gss.pdb 5.82 1apv.pdb 9 1hpx.pdb 11.26 
2avv.pdb 9.26 2fai.pdb 6.24 3pcb.pdb 2.4 1b2h.pdb 4.54 1hvs.pdb 10.3 
2ayr.pdb 9.29 2fdp.pdb 7.59 3pcc.pdb 3.62 1b3f.pdb 6.89 1iih.pdb 2.89 
2azr.pdb 3.64 2flb.pdb 5.74 3pce.pdb 2 1b3g.pdb 6.7 1izh.pdb 7.7 
2b1v.pdb 5.74 2fvd.pdb 8.52 3pch.pdb 5.4 1b4z.pdb 5.23 1izi.pdb 6.59 
2b7d.pdb 8.7 2fx6.pdb 3.7 3pcj.pdb 7.22 1b6l.pdb 8.3 1j01.pdb 6.47 
2baj.pdb 8.4 2fzc.pdb 2.7 3pck.pdb 6.7 1bn3.pdb 9.89 1jmi.pdb 6.06 
2bak.pdb 7.43 2fzz.pdb 10.52 3pcn.pdb 3.66 1bnw.pdb 9.08 1kpm.pdb 5.8 
2boh.pdb 8.52 2g5u.pdb 8.49 3std.pdb 11.11 1bp0.pdb 5.4 1lgw.pdb 4 
2bok.pdb 6.55 2g8r.pdb 3.99 3tlh.pdb 8.82 1c4u.pdb 10.37 1li2.pdb 4.04 
2bpy.pdb 7.4 2g94.pdb 9.52 4er1.pdb 6.62 1c5n.pdb 4.7 1lpk.pdb 7.55 
2bq7.pdb 7.05 2gh7.pdb 13 4er2.pdb 9.3 1c5o.pdb 3.49 1m0o.pdb 2.31 
2br1.pdb 5.14 2gss.pdb 4.94 4fiv.pdb 6.52 1cps.pdb 6.66 1m2p.pdb 6.11 
2brb.pdb 4.86 2h3e.pdb 5.7 4std.pdb 10.33 1d4y.pdb 11.1 1met.pdb 9.4 
2brm.pdb 5.89 2h4n.pdb 8.7 4tim.pdb 2.16 1e4h.pdb 8.41 1mq5.pdb 9 
2bz6.pdb 7.09 2hdq.pdb 1.4 4tln.pdb 3.72 1elc.pdb 6.66 1mrw.pdb 9.7 
2bza.pdb 2.8 2hdr.pdb 1.72 4tmn.pdb 10.17 1epo.pdb 7.96 1msm.pdb 10.48 
2bzz.pdb 6.43 2hs1.pdb 8.48 5abp.pdb 6.64 1f0r.pdb 7.66 1mu6.pdb 8.38 
2c02.pdb 4.04 2hs2.pdb 8.31 5er1.pdb 6.02 1fao.pdb 7.37 1ndv.pdb 5.92 
2c3j.pdb 6.18 2i0a.pdb 11.4 5fiv.pdb 7.66 1fiv.pdb 6.59 1njd.pdb 5.57 
2cbu.pdb 5.68 2i0d.pdb 12.1 5std.pdb 10.49 1fkg.pdb 8 1nm6.pdb 10.05 
2cbv.pdb 5.48 2izl.pdb 6 5tmn.pdb 8.04 1g1d.pdb 9.44 1nt1.pdb 8.89 
2ceq.pdb 7.28 2j34.pdb 7.82 6cpa.pdb 11.52 1g2l.pdb 7.24 1nvr.pdb 8.11 
1nvs.pdb 7.82 1y20.pdb 5.32 1tng.pdb 2.93 1qbv.pdb 5.39 2f8i.pdb 7.26 
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1o0f.pdb 5.3 1y6r.pdb 10.11 1tog.pdb 3.22 1r5y.pdb 6.46 2fgu.pdb 9.18 
1o0m.pdb 5.15 1z1h.pdb 8.4 1tom.pdb 8.3 1rdn.pdb 1.84 2g00.pdb 9.74 
1o2n.pdb 6.09 1z6s.pdb 4.34 1ugx.pdb 5.91 1rej.pdb 8.3 2hb3.pdb 11.35 
1o2x.pdb 5.85 1zgi.pdb 5.34 1usn.pdb 7.74 1rgk.pdb 4.31 2j2u.pdb 7.33 
1o2z.pdb 6.11 1zsr.pdb 9.82 1utn.pdb 3.49 1sld.pdb 6.57 2j75.pdb 6.65 
1o36.pdb 5.96 220l.pdb 3.4 1uwu.pdb 5.98 1sts.pdb 5 2j79.pdb 5.96 
1o3h.pdb 7.3 2aog.pdb 6.28 1ux7.pdb 3 1swr.pdb 6.92 3aid.pdb 6.86 
1os0.pdb 6.03 2avs.pdb 7.57 1vjj.pdb 5.77 1syi.pdb 5.44 3pcf.pdb 6.05 
1owd.pdb 8.2 2bmz.pdb 3.7 1vot.pdb 6.6 1t7j.pdb 8.7 5tln.pdb 6.37 
1oyt.pdb 7.24 2bpv.pdb 7.67 1w1d.pdb 6.52 
    
1pb8.pdb 5.15 2bqv.pdb 8.05 1w7g.pdb 5.1 
    
1ppl.pdb 8.55 2bt9.pdb 6.19 1w7x.pdb 8.4 
    
1pzp.pdb 3.31 2c3l.pdb 5.07 1xgi.pdb 4.85 
    
1qbs.pdb 9.47 2cji.pdb 8.22 1xq0.pdb 6.34 
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